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ABSTRACT (English) 
Over 10 million tuberculosis (TB) cases are being reported annually and the World Health Organization 
(WHO) estimates that up to the 1/3 of the world population is infected with Mycobacterium tuberculosis (Mtb). 
Between 5 and 10% of the latently infected individuals develop TB during their lifetime. Yet, despite over 100 
years of research since Mtb has been identified, we are not able to define all the factors which are responsible for 
the different infection outcomes in the hosts.  
In this thesis I investigate the variability in the response to TB presented by different hosts. In one 
approach, I collect publicly available transcriptomic datasets from TB patients and healthy donors. Using Gene 
Set Enrichment Analysis (GSEA) I examine transcriptional profiles of individuals with TB. In particular, focus is 
brought to interferon (IFN) signaling which has been previously described as crucial for the disease outcome. I 
show that patients lacking IFN signature are present in the studied cohorts and investigate whether these patients 
present different phenotype than patients with strong regulation of IFN responses. Moreover, by focusing on 
patients lacking IFN response I try to unearth mechanisms present in all patient groups but dominated by the signal 
of IFN response. I show that strong regulation of IFN genes is related to severe pathology in the lungs of TB 
patients and that it is reflected by the levels of IFN-inducible cytokines in blood of healthy volunteers after 
vaccination with FLUAD® vaccine. Using Machine Learning (ML) methods, I identify and compare 
transcriptomic signatures of the patients presenting and lacking the IFN response. 
In the second approach I study the differences in the transcriptional responses to Mtb infection in human 
cohorts and two different mouse models. The immunity in infection, inflammation and malignancy differs 
markedly in man and mouse. Nevertheless, there are elements of immune system which have been conserved 
between the species. I propose a novel data integration approach which identifies concordant and discordant 
elements of gene expression regulation in heterologous datasets. The analysis is based on publicly available as 
well as novel experimental data acquired thanks to collaboration with my colleagues from the Department of 
Immunology and Microarray Core Facility of Max Planck Institute for Infection Biology (MPIIB). Additionally, 
I focus on the comparison of human and murine transcriptional responses to TB in whole blood (WB) and in 
macrophages. The results indicate profound differences between regulation of innate and adaptive immunity in 
man and mouse upon Mtb infection. I characterize differential regulation of T-cell related genes corresponding to 
the differences in phenotype between TB high and low susceptible mouse strains and identify the time point of 21 
days p.i. of mice as best reflection of transcriptional responses in the studied human cohorts.  
The implemented approaches facilitate the choice of an appropriate animal model for studies of the human 
immune response to a particular disease and provide the basis for better understanding of differences in the 
outcomes of Mtb infection in individual hosts.  
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ABSTRACT (German) 
Jedes Jahr treten weltweit über zehn Millionen Fälle von Tuberkulose (TB) auf. Die 
Weltgesundheitsorganisation (WHO) schätzt, dass ein Drittel der Weltbevölkerung mit dem Erreger 
Mycobacterium tuberculosis (Mtb) infiziert ist. Bei fünf bis zehn Prozent aller latent Infizierten bricht Tuberkulose 
im Laufe des Lebens aus. Dennoch sind bereits 100 Jahre seit der Entdeckung von Mtb vergangen, ohne dass die 
entscheidenden Faktoren für den unterschiedlichen Infektionsverlauf bekannt wären. 
In dieser Arbeit untersuche ich die unterschiedlichen Reaktionen auf eine Tuberkuloseinfektion in 
verschiedenen Wirten. In meinem ersten Ansatz habe ich öffentlich zugängliche Transkriptom-Datensätze von 
Tuberkulosepatienten und gesunden Probanden ausgewertet. Mit Hilfe der Gensatzanreicherungs-Analyse (eng. 
Gene Set Enrichment Analysis, GSEA) habe ich die Transkriptionsprofile von Tuberkulosepatienten betrachtet. 
Das besondere Augenmerk lag hierbei auf der Interferon (IFN)-Signalkaskade, die für den Krankheitsverlauf von 
besonderer Bedeutung ist. In dieser Arbeit zeige ich zunächst, dass Patienten ohne eine IFN-Signatur in der 
untersuchten Kohorte vorkommen und widme mich im Anschluss der Frage, ob diese Patienten einen anderen 
Phänotypus haben als jene mit einer starken IFN-Antwort. Indem ich nur Patienten ohne IFN-Antwort betrachte, 
werden Mechanismen deutlich, die allen Patientengruppen gemein sind, aber vorher von der starken IFN-Signatur 
überlagert wurden. Ich belege in dieser Arbeit, dass eine starke IFN-Regulation auch mit einer ausgeprägten 
Lungenpathologie in Tuberkulosepatienten einhergeht. Passend hierzu weisen auch gesunde Probanden nach 
Verabreichung des Impfstoffs FLUAD® einen erhöhten Blutwert IFN-induzierter Zytokine auf. Mit Hilfe 
maschinellen Lernens konnte ich Transkriptomsignaturen der Patienten mit bzw. ohne IFN-Antwort identifizieren 
und vergleichen. 
Im zweiten Ansatz widme ich mich den unterschiedlichen Transkriptionsantworten auf Mtb-Infektionen 
in humanen Kohorten und zwei verschiedenen Mausmodellen. Der humanen und der murinen Immunantwort auf 
Infektionen unterliegen gravierende Unterschiede. Trotzdem sind einige Elemente des Immunsystems in beiden 
Arten konserviert. In dieser Arbeit präsentiere ich einen neuen Ansatz der Datenintegration, der die Identifizierung 
von übereinstimmenden und nicht übereinstimmenden Regulationselementen der Genexpression in heterogenen 
Datensätzen ermöglicht. Die Analyse basiert auf öffentlich zugänglichen sowie de-novo-generierten Datensätzen, 
zu denen ich durch wissenschaftliche Kollaborationen meiner Kollegen in der Abteilung Immunologie sowie der 
zentralen Einheit Microarray des Max-Planck-Instituts für Infektionsbiologie, Zugang erhalten habe. Des 
Weiteren liegt ein Schwerpunkt auf der vergleichenden Analyse humaner und muriner Transkriptionsantworten 
auf Tuberkulose in Vollblut und Makrophagen. Die erhaltenen Ergebnisse weisen auf einen signifikanten 
Unterschied in der Regulierung der angeborenen sowie der erworbenen Immunität in Mensch und Maus als 
Reaktion auf eine Mtb-Infektion hin. In dieser Arbeit charakterisiere ich die unterschiedliche Regulierung von T-
Zell bezogenen Genen, die mit unterschiedlich ausgeprägten Phänotypen bei stark oder schwach TB-anfälligen 
Mausstämmen korrespondiert. Darüber hinaus habe ich den 21. Tag nach einer Tuberkuloseinfektion in Mäusen 
als Zeitpunkt ermittelt, der die Transkriptionsantworten in den untersuchten humanen Kohorten am besten 
widerspiegelt. 
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Die angewandten Ansätze erleichtern die Auswahl des am besten geeigneten Tiermodells für die 
Erforschung der humanen Immunantwort auf eine ausgewählte Krankheit und liefern die Basis für ein besseres 
Verständnis der unterschiedlichen Krankheitsverläufe in Mtb-infizierten Patienten.  
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1. CHAPTER 1: INTRODUCTION AND GOALS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tuberculosis is an airborne infectious disease caused by Mycobacteria, usually 
Mycobacterium tuberculosis. It typically affects the lungs and causes symptoms including fever, 
weight-loss, night sweats, and chronic cough containing blood-stained sputum (Hopewell, 2017). TB 
remains a threat to public health with an enormous disease burden of 10.4 million cases and 1.7 million 
deaths per year, as estimated for 2016 (WHO, 2017). One of the challenges in preventing TB results 
from the fact that only part (around 10%) of people infected with Mtb progress to clinical disease; 
however, so far there is no efficient way of predicting who of the infected individuals will develop 
active TB and therefore should start preventive treatment.  
The research presented in this thesis focuses on TB. Understanding of TB in humans and 
advancing the translation of TB research has been the main motivation behind the performed work. For 
this reason, in the first section of my thesis I introduce the reader to the topic of TB by reviewing the 
most important aspects of epidemiology, treatment, detection and prevention of TB as well as the 
current state of knowledge about immune response against TB focusing on the broadly discussed topic 
of the role of IFN responses. This is followed by a short discussion of variability of the events 
succeeding the Mtb infection which starts at the level of cellular events and finds its consequence in the 
ultimate disease outcome. Since our understanding of infectious disease mechanisms is to a major extent 
based on experimental murine models, my second point of focus is the description of the advances 
brought to the field of TB by investigating murine models and the need of finding a method to choose 
animal models which best approximate particular aspects of human disease. Lastly, I introduce the 
reader to the high-throughput experimental methods used to generate the transcriptomic datasets 
analyzed in this thesis as well as computational methods on which I base the presented results.  
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1.1. TUBERCULOSIS 
1.1.1. Epidemiology of TB 
TB leads the statistics of infectious diseases caused by a single infectious agent which have a 
worldwide impact. About 6.3 million new cases and 1.7 million deaths attributed to TB were reported 
in 2016, and an estimated 4.1 million remain undiagnosed (WHO, 2017). TB is more prevalent in the 
low-income areas and 56% of the cases reported in 2016 come from only five countries: China, India, 
Indonesia, Pakistan and the Philippines. The risk of TB is highly increased among the individuals 
infected with human immunodeficiency virus (HIV) which comprise 20% of the TB cases detected in 
the 2016. Other risk factors include poverty, smoking and undernutrition (WHO, 2013a). The disease 
is more frequent among men than among women and affects mostly adults which might be at least in 
part attributed to the fact that 80% of the newborns are vaccinated against TB (WHO, 2017). 
The spreading drug resistance of mycobacterial strains increases the gravity of TB threat. In 
2016 the resistance to rifampicin – a first line anti-TB drug – was detected in more than 500,000 patients. 
The treatment of drug-susceptible TB is costly and long, lasting at least 6 months and giving success 
rate of around 83%. In comparison, the shortest regimens for drug-resistant TB is twice as long and 
gives the success rate of around 54% (WHO, 2014, 2017) . Financing TB prevention and treatment is a 
major challenge and while the funds dedicated to fighting TB have been increasing during the last 10 
years, funding gaps still exist and require investments from the side of governments and organizations 
on both national and international levels (WHO, 2017).  
 
Figure 1 Vicious circle of TB  
Around 125,000 new Mtb infections occur each day through spreading of air droplets by the TB patients. This adds up to over 
2 million latent TB infections (LTBI) around the world according to the estimations of WHO (2017). 27,000 of the infected 
people daily develop TB, which gives rise to around 10 million new TB cases per year and results in 5,000 TB deaths daily. 
Adapted from (Kaufmann, 2010).  
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1.1.2. Transmission 
Mycobacterium tuberculosis was discovered and shown to be the causative agent of TB by 
Robert Koch in 1882. Thirty years later, Canadian physician William Osler noted that “all who mix with 
tuberculosis patients got infected, but remained well so long as they took care of themselves and kept 
the soil in a condition unfavorable for the growth of the seed” (after Dobbs & Kimmerling, 2008). In 
the following years the mechanism of airborne infection was partly elucidated by studies on droplet 
nuclei (Wells, 1934) and the deposition of airborne bacteria in lung was described (Riley & O’Grady, 
1961; Wells, 1934). Today, we know that the cascade of TB transmission starts with the source case, 
which is a TB patient generating infectious air droplets and expelling them by cough, laughter or any 
other forceful action of respiratory system (Churchyard et al., 2017). The bacteria survive in the air and 
are inhaled by an exposed individual, who in turn may become infected and can remain latent (LTBI - 
latent TB infection) or progress to active disease typically within a year after infection or when the 
organism is challenged, e.g. by undernutrition (Churchyard et al., 2017; Fox, Barry, Britton, & Marks, 
2013). Transmission can occur anywhere where an actively infected person meets other individuals and 
typically takes place in households or working environments affected by TB. Persons in close contact 
of the patients are particularly exposed to infection and interrupting this transmission way is a crucial 
step in counteracting the TB epidemic (Churchyard et al., 2017). 
1.1.3. Prevention of TB 
The most efficient way of reducing transmission as well as morbidity and mortality caused by 
infectious diseases is vaccination (Kaufmann, Hussey, & Lambert, 2010). So far, the only vaccine used 
against TB is Bacillus Calmette-Guérin (BCG) which is administered to around 80% of infants 
worldwide. BCG protects against severe forms of disseminated TB yet it fails to provide protection 
against pulmonary TB, which is the main disease form (Hatherill, 2011). BCG vaccine is based on 
attenuated Mycobacterium bovis, the pathogen responsible for TB in cattle. Currently more than a dozen 
vaccine candidates against TB are tested on different stages of clinical trials. Two of the vaccines, 
VPM1002 (Nieuwenhuizen & Kaufmann, 2018) and Mycobacterium vaccae (Kaufmann et al., 2010) 
are being tested for efficacy and are already on the third stage of the clinical trials. 
Prevention of TB relies primarily on early detection and vaccination. According to the WHO 
recommendations (WHO, 2015b), detection of TB requires active screening of individuals at high risk 
of TB, e.g. HIV positive (HIV+) individuals or close contacts of TB patients. Early diagnosis and 
treatment efficiently hinder TB transmission. In May 2014, the World Health Assembly passed a 
resolution called “End TB Strategy” which aims at reducing new TB cases by 80%, TB deaths by 90% 
and to protect 100% of the families affected by TB from the tremendous treatment costs by 2030 (WHO, 
2015a). This goal can only be achieved by dramatic reduction in TB transmission.  
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1.1.4. Symptoms and diagnosis of TB 
Pulmonary TB is the most frequent form of TB. However, in 15-20% of the cases the bacteria 
invade other sites, causing extrapulmonary forms of the disease. Bacteria can infect the pleurae causing 
tuberculous pleurisy, scrofula of the neck when they infect the lymphatic system, urogenital TB in the 
genital and urinary tract, TB meningitis in the central nervous system, or spinal TB (also known as 
Pott’s disease) when the bacteria infect bones and joints (Golden & Vikram, 2005). Extrapulmonary 
TB occurs more often in the immunosuppressed individuals, children and HIV+ people. The form of 
TB affecting multiple parts of the body is called miliary or disseminated TB and it consists of up to 
20% of extrapulmonary TB cases (Sharma, Mohan, & Sharma, 2016). If not indicated otherwise, in this 
thesis I focus on pulmonary TB cases. 
The main symptoms of TB are: severe cough lasting at least three weeks, chest pain, and blood 
or sputum presence in the cough. The accompanying symptoms can include weakness or fatigue, weight 
loss, lack of appetite, chills, fever, and night sweats (Hopewell, 2017). LTBI individuals do not present 
TB symptoms and do not spread TB.  
In 2016, approximately 40% of TB cases were not reported (WHO, 2017). Every year around 
one third of the global TB burden remains undiagnosed. Low-income countries, where the disease is 
particularly widespread, still rely on outdated diagnostic technologies which are ineffective and do not 
detect drug-resistance (Lawn, 2015). Currently, a wide spectrum of diagnostic tools exist and are being 
developed to become more cost effective, which will help those who are most in need. 
Light microscopy of sputum smears remains the most broadly used TB detection method. 
Every year, close to 90 million individuals undergo a sputum test (Perkins, 2009). This simple, 
inexpensive method can detect TB rapidly; however at the same time it is not sensitive enough and 
relies on the exact examination of the sample by a laboratory technician (Lawn, 2015). Only samples 
containing more than 10,000 bacilli per milliliter (ml) of sputum are recognized as TB positive, 
therefore the patients with lower bacterial content in sputum (typically HIV co-infected people) remain 
undiagnosed (Gupta et al., 2013). The specificity of smear microscopy-based TB detection is sufficient 
in the high TB burden areas but lower in the high-income countries where positive sputum smears are 
often caused by nontuberculous mycobacterial species. Nowadays the pre-processing of the sputum and 
fluorescent staining are used to increase the specificity of detection.  
The most sensitive way to detect TB is culture-based diagnosis. The processed sputum sample 
is cultured on the enriched media and the grown cultures are subsequently visualized. However, since 
Mtb is an extremely slowly growing bacterium, it requires up to 6-8 weeks for a colony to grow 
sufficiently. Recent developments of this method include the use of selective liquid media and growth 
indicator systems (Lawn, 2015). 
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Pathogens are often detected based on antigen presence in body secretions. In the case of Mtb, 
urine provides a source of Mycobacterial antigens which can be safely analyzed without risk of aerosol 
formation (Kashino, Pollock, Napolitano, Rodrigues Jr, & Campos-Neto, 2008). The cell wall 
lipopolysaccharide lipoarabinomannan (LAM), currently the best candidate antigen, can be detected by 
commercially available enzyme-linked immunosorbent assay (ELISA; Clearview-TB®-ELISA) and 
more recently as a point-of-care version. Despite the above mentioned advantages of the urinary TB 
detection, the LAM assay sensitivity is too low for regular clinical implementation (Minion et al., 2011). 
If the Mtb bacteria are present in the organism, their DNA can be rapidly detected in the human 
blood due to specific amplification reaction. Molecular detection of Mtb is possible thanks to the 
development of a range of methods based on nucleic acid amplification tests (NAATs): polymerase 
chain reaction (PCR), real-time PCR, isothermal amplification, and strain displacement (Lawn, 2015). 
NAAT can be accompanied by hybridization methods. These are highly specific, safe for the personnel 
and fast; moreover, they can also detect drug resistance in the identified bacterial DNA (Lawn, 2015). 
Their disadvantages include complexity and requirement for sophisticated equipment. The NAAT-
based line-probe assays and Xpert MTB/RIF assay have been already endorsed by WHO (WHO, 2008, 
2013b). The latter is a compact independent platform for Mtb detection, fully automated and integrated 
in a user-friendly, easily operated device (Lawn, 2015). Unprocessed clinical samples are purified and 
concentrated and the real-time PCR is conducted within the automated framework giving the results of 
Mtb detection and drug resistance within two hours after sample acquisition. The method detects 
approximately 9 out of 10 cases with a pooled specificity of 99% and is now widely implemented around 
the world; however the disadvantages include high cost, sophisticated hardware, necessity of computer 
connection and complicated service (Lawn, 2015). Hence, it is not attainable for poor areas and 
accessible mostly in laboratory rather than actual clinical settings.  
The aforementioned methods detect active TB. Other tests can be used to confirm Mtb 
infection. Mtb infection is often detected by the so called “tuberculin skin test” (TST) or Mantoux test. 
A mixture of mycobacterial antigens called purified protein derivative (PPD) which are not species 
specific is injected into the epidermis and the host previously exposed to Mtb develops a characteristic 
skin induration within 2-3 days. The reaction diameter is classified into one of the levels: 0-5mm, 5-
10mm, 10-15 mm or >15mm (Nayak & Acharjya, 2012). The medical risks of the tested person 
determine on which level the test result is considered positive. The drawbacks of the TST include 
relatively frequent false positive results (Starke, 1996). The false positive results are given by the 
vaccinated people as well as people with nontuberculous mycobacterial infections, and are estimated as 
20% of all positive test results (Rabinowitz & Conti, 2010). The false negative results may happen in 
recently infected patients, immunocompromised patients or malnourished children (Lloyd, 1968). 
Especially in children, touching and scratching the injected area also causes redness and swelling which 
can be interpreted as a positive test result. In some cases hypersensitivity to PPD occurs; therefore the 
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diagnostic centers using the test need to be equipped with epinephrine (Froeschle, Ruben, & Bloh, 
2002). 
Another molecule measured to detect previous Mtb exposure is interferon-γ (IFN-γ). IFN-γ-
release assays (IGRAs) detect the cytokine present in blood after ex-vivo stimulation with Mtb specific 
antigens: culture filtrate protein-10 (CFP-10) and early secretory antigen-6 (ESAT-6) (Lawn, 2015). 
Detection of a positive response indicates previous exposure to those antigens by Mtb infection. The 
results do not differentiate between TB and LTBI, and therefore the method is not used for the standard 
diagnosis but rather as complementary information (WHO, 2011). Moreover, old age, HIV coinfection 
and several other characteristics are associated with false negative IGRA results (Nguyen, Teeter, 
Graves, & Graviss, 2018). 
In the advanced disease phase when granulomas have already developed in lungs, they can be 
detected by X-Ray scan. The detected abnormalities on chest radiographs can be indicative of TB and 
support the diagnosis, but they do not serve as diagnosis on their own. However, pulmonary form of 
TB can be excluded by the lung radiography. 
All the above mentioned diagnostic tests are characterized by certain advantages and flaws. 
The ideal test to detect TB would be cost-efficient, rapid, available at the point of care and able to 
indicate an efficient treatment regime. The characteristics of such still unavailable tests - target products 
for TB diagnosis - are listed in Table 1. 
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Table 1. Target products for TB diagnostics  
The table has been adapted and modified from the website: “FIND. Because diagnostics matters.” (2018). 
Problem Target product 
Triage test 
Cough lasting for at least two weeks can indicate 
active TB disease; however, majority of individuals 
presenting this symptom do not have TB. A test 
excluding TB in such patients would reduce the 
population which needs to undergo further, more 
expensive testing. 
A point-of-care test to exclude TB, which should be a 
simple, inexpensive and available for first-contact 
health-care providers to identify those who need 
further testing. 
Point-of-care non-sputum biomarker test 
Sputum smear microscopy is currently used to detect 
most TB cases, even though it has suboptimal 
sensitivity and is difficult in case of children and HIV-
infected individuals. In the other hand, molecular 
detection of TB cannot be performed in most 
microscopy centers. 
A rapid, point-of-care, non-sputum-based test 
detecting all forms of TB by identifying characteristic 
biomarkers or bio-signatures. The test would be 
implemented at microscopy centers, easy to perform, 
robust with minimal sample preparation and 
operational requirements. 
Smear replacement test 
Sputum smear microscopy is currently used to detect 
most TB cases, even though it has suboptimal 
sensitivity and is difficult in case of children and HIV-
infected individuals. A more sensitive test at the 
microscopy center level has the potential to improve 
patient care by (i) reducing transmission by increasing 
TB diagnosis, linked to treatment and (ii) leveraging 
existing infrastructure in microscopy centers. 
A more sensitive point-of-care sputum-based test to 
replace smear microscopy for detecting pulmonary TB 
that is easy to perform and has minimal operational 
requirements. 
Next generation drug-susceptibility test to inform treatment 
Due to the spreading antibiotic resistance TB 
diagnosis should be supplemented with the indication 
of efficient treatment regimen. 
A rapid drug-susceptibility test that can be used at the 
microscopy-center level of the health-care system to 
select regimen-based therapy. Such a novel diagnostic 
test should ideally include testing for rifampicin, 
fluoroquinolones, and pyrazinamide and isoniazid 
resistance. 
Test for detection of disease progression 
Diagnosis and treatment of LTBI should be addressed. 
Around one third of the world population is infected 
with Mtb. While current diagnostic tests for infection 
show that an individual has been exposed to Mtb, they 
poorly predict whether an individual will progress to 
active TB in the future. 
An ideal test of TB disease progression would 
differentiate patients in the various stages from 
infection to active TB and may detect the presence or 
absence of incipient TB. 
 
Tools used to detect TB are imperfect and above all, do not allow prediction of whom of the 
infected individuals will develop active TB. Currently, significant hopes are being placed on the 
development of methods based on combinations of host-related markers which would detect or even 
predict the disease with superior performance (Maertzdorf, Kaufmann, & Weiner, 2014). Such an 
approach demands analysis of vast amounts of data and application of specialized bioinformatic tools 
for classification of healthy, infected, and sick individuals as well as for prognosis of risk and treatment 
outcomes. In the chapter 1.2, I introduce transcriptomic biomarkers as a candidate method for TB 
diagnostics.  
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1.2. TRANSCRIPTOME STUDIES IN TB 
1.2.1. RNA expression 
The genetic information carrying the instructions for growth, development, functions, and 
reproduction of every living organism is contained in DNA, which is shared across all cells of an 
organism. The ability of DNA to instruct development of appropriate cells or tissues is mediated through 
RNA, which is a functional carrier of genetic information. Fragments of DNA are being transcribed 
into RNA molecules and further instruct protein translation and expression in a manner dependent on 
the transcriptional regulation – a mechanism that ensures expression of different sets of transcripts 
according to the tissue, stimuli, and developmental stage (Adams, 2014). For this reason, the RNA 
expression levels vary between the cells of a particular organism and are responsible for structural and 
functional differences between tissues even though the DNA of each cell remains the same. The 
transcription of DNA into RNA is regulated by proteins called transcription factors (TFs), which can 
activate or suppress a given gene (Adams, 2014). They function through recruiting RNA polymerase to 
bind to particular gene’s promoter region or by blocking this binding. Once bound to the promoter, 
RNA polymerase enables production of primary RNA transcripts by pairing subsequent RNA bases 
with complementary DNA bases. In eukaryotic cells the initial transcripts encoding proteins, called 
mRNA (messenger RNA), are processed and edited after which they ultimately cooperate with a 
ribosome to produce the expected protein (Figure 2). Transcripts of other types, like tRNA (transfer 
RNA) and rRNA (ribosomal RNA) convey their functions without involvement of the translation 
process. The Human Genome Project estimated that the human genome contains about 20-25,000 genes 
(Human Genome Sequencing Consortium, 2004). Since thousands of transcripts are produced in every 
cell during every second, there are many mechanisms controlling this process on every stage – starting 
from initial transcription control, through RNA processing steps up to protein expression and 
degradation (Adams, 2014). Gene expression is dynamic, which means that the same gene may act 
differently depending on the circumstances. Therefore, the level of a transcript of a gene can be 
indicative of a state of the cell and can support information about what is happening with the host – for 
example, that the host is undergoing an infection or succumbing to a disease. For this reason, several 
methods of transcript detection and quantification have been developed. 
 
Figure 2 Overview of the gene expression in eukaryotes  
Adapted from Leung, Delong, Alipanahi, & Frey, 2016.  
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1.2.2. Methods of RNA detection and quantification 
Depending on the study type, there are two main categories of the RNA quantification 
methods. The first category encompasses methods directed to measure RNA of predefined transcripts, 
which is most useful when the investigation is based on a hypothesis involving an already predefined 
gene (or set of genes). For example, it tests how the level of particular cytokine involved in a disease 
changes upon infection. The expression of a particular gene can be directly measured using a technique 
called northern blotting. In this technology the RNA derived from a sample is separated on an agarose 
gel according to the size, hybridized to a labeled RNA fragment complementary to the gene of interest, 
exposed and analyzed (He & Green, 2013). mRNA of a particular gene can be also measured by reverse-
transcription quantitative PCR (RT-qPCR) (Bachman, 2013). The reverse transcription of an RNA 
fragment into DNA is followed by quantitative PCR with use of the generated cDNA template and 
fluorescently labeled nucleotides. The emitted fluorescence is measured, and the initial amount of RNA 
can be calculated based on the standard curve. 
Apart from detecting and quantifying single transcripts it is possible to investigate the 
transcriptional profile of a cell or tissue. Such profiling can be performed using the mentioned RT-
qPCR, tag-based technologies or microarray technology. The tag-based methods include serial analysis 
of gene expression (SAGE) and RNA-Seq. They are based on quantifying the amount of times with 
which each short sequence (tag) unique for a transcript is detected in a sample and therefore, provide a 
relative measure of transcript concentration. RNA-Seq technique generates simultaneously sequence 
data that can be matched to a reference genome. Additional information that can be gained using this 
approach is identification of single-nucleotide polymorphisms (SNPs), splice-variants or even novel 
genes (Stanton, 2001).  
In case of microarray, SAGE or RT-qPCR there is no clear-cut rule regarding their 
categorization - depending on the scientific approach, they can be used both to validate single genes in 
a hypothesis-driven approach and to screen hundreds of them in a hypothesis generating approach. 
The datasets analyzed in this study had been generated using microarray technology, which is 
a rapid, reliable, and reproducible technology to detect transcript abundance in a high-throughput 
manner. A microarray is a collection of microscopic spots of DNA fragments attached to a solid surface, 
e.g. silicon or glass (Simon, Korn, McShane, Wright, & Zhao, 2003). Two available array types, cDNA 
and oligonucleotide arrays, differ by the type of the immobilized molecules: up to 5,000 base pair (bp) 
long cDNA molecules in cDNA arrays versus (vs) typically 25-mer long oligonucleotides in high-
density oligonucleotide arrays (Schulze & Downward, 2001). The DNA fragments can be also 
imprinted on the arrays in two ways: by spotting of previously synthesized molecules on the glass 
(spotted microarrays) or by synthesizing oligonucleotide sequences directly onto the array (Simon et 
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al., 2003). Each spot (called probe) has defined coordinates and contains picomoles of a specific DNA 
sequence. This sequence corresponds to a single gene and under strictly defined conditions hybridizes 
with a complementary (target) cDNA fragment derived from the investigated sample and labeled with 
fluorophore, silver or chemiluminescence(Simon et al., 2003). After the hybridization the intensity of 
signal emitted by each spot is measured. From this measurement the relative transcript abundance in 
the target sample is calculated.  
The microarray technology can involve single- or double-color arrays (Duggan, Bittner, Chen, 
Meltzer, & Trent, 1999). In the first case, the microarray is hybridized with cDNA derived from two 
samples which will be later compared, and labeled with two different fluorophores. The most commonly 
used dyes are cyanine 3 (Cy3, green), emitting fluorescent signal at 570 nm wavelength, and cyanine 5 
(Cy5, red), with a fluorescent emission wavelength of 670 nm. The samples, each labeled with a 
different dye, are then mixed and hybridized to an array. The signals of each fluorophore are quantified 
and differentially expressed genes are identified using their ratios (Duggan et al., 1999; Simon et al., 
2003). 
Preparation of a sample for the hybridization consists of the following steps: extraction of 
RNA, isolation of mRNA, quality assurance and concentration measurement, reverse transcription to 
cDNA, amplification and labeling (Macgregor & Squire, 2002). The labeled cDNA is hybridized onto 
the array under specific conditions defined by the manufacturer in a hybridization oven, washed to 
eliminate non-specific binding, and then scanned. Subsequently, the image is transformed into a grid 
where each spot with measurable intensity occupies one field and the pixel intensity of the fields is 
quantified.  
The microarray technology is used for transcriptional profiling in large cohorts, enabling fast, 
reproducible high-throughput studies. In the last years the technology became cheaper and therefore 
also more broadly used in low-resource areas, frequently located in the developing countries which at 
the same time often have direct access to samples from certain diseases. In high-resource laboratories 
microarray technology has become partially substituted by RNA-Seq which allows transcript 
identification without prior knowledge and generates more versatile data. Nevertheless, the microarrays 
still remain a popular technology to investigate gene expression profiles and at the same time present 
an already standardized and commercialized field. It is nowadays expected to deposit the collected 
microarray data in one of the databases like Gene Expression Omnibus (GEO), ImmGen database, or 
ArrayExpress.  
Challenges of the analysis of microarray data which have been addressed in this study, include 
multiple levels of replication in experimental design, statistical treatment of the data, the number of 
platforms and independent data formats and mapping each probe to the mRNA transcript that it 
measures.  
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1.2.3. Whole blood transcriptomic biosignatures 
Blood provides an easily accessible source of information about the state of an organism and 
WB samples remain the primary source of biomarkers of pathology, including infection (Liew, Ma, 
Tang, Zheng, & Dempsey, 2006). WB cell transcriptome profiles are thought to illustrate a systemic 
immune response as blood contains cells and molecules of the immune system and is the carrier of 
metabolites between different tissues (Liew et al., 2006). WB cell composition in mouse and man is not 
directly comparable given that it varies in the ratio of neutrophils and lymphocytes – neutrophils 
comprise 50-70% of human and 10-25% of mouse WB cells, while lymphocytes comprise 30-50% of 
human and 75-90% of mouse WB cells (Mestas & Hughes, 2004). However, states of infection drive 
changes in blood composition in both types of host such as emergency granulopoiesis and neutrophilia 
(Berry et al., 2010; Dorhoi et al., 2013; Lowe, Redford, Wilkinson, O’Garra, & Martineau, 2012). 
As early as in 1980’s, the term ‘biomarker’ gained popularity in cancer research being used to 
describe molecules found in serum and potentially useful in the detection of cancerogenic processes 
(Paone, Waalkes, Baker, & Shaper, 1980). In 2001, the official definition of a biomarker was proposed 
by Biomarkers Definitions Working Group (Downing, 2000; Paone et al., 1980). According to the 
definition, a biomarker is “a characteristic that is objectively measured and evaluated as an indicator of 
a normal biological process, pathogenic process or pharmacologic response to a therapeutic 
intervention” (Biomarkers Definitions Working Group, 2001). Biomarkers help to identify different 
diseases and to define the disease or recovery stage of a patient.  
Transcriptomic biomarkers can be derived from any model or tissue affected by infection – 
e.g. from the mouse model of a certain disease or even more narrowly – from macrophages of an 
infected individual. Those biomarkers found in known and strictly controlled systems (with known 
infection time point, in a group of inbred mice living under standardized conditions) can be very precise 
and distinguish between sick and healthy individuals with nearly 100% sensitivity and specificity.  
In patients, acquisition of a specific affected tissue or isolation of particular cells is more 
challenging. Moreover, since biomarkers are meant to help clinical diagnosis they should be derived 
from a source that can be not only easily and quickly accessed, but also cheaply and efficiently analyzed. 
Such sources are body fluids and secretions: saliva, urine, and most importantly – blood. Blood accesses 
all organs and tissues to deliver oxygen and nutrients while collecting end products of cell metabolism 
and bringing them to the eliminating organs (lungs, kidneys, liver). It is also a carrier of circulating 
immune cells. The fraction of human blood used for immune system studies is obtained by removing 
red blood cells by density gradient centrifugation which separates WB into two fractions – above and 
below the density of 1.077g/ml in the most commonly used Ficoll gradient centrifugation (Miyahira, 
2012). The denser fraction is removed, containing erythrocytes and polymorphonuclear cells (PMNs). 
The remaining part of lower density contains lymphocytes (T cells, B cells and natural killer (NK) 
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cells), monocytes, and DCs and is referred to as peripheral blood mononuclear cells (PBMCs). In 
humans, the frequencies of different cell populations of PBMCs vary across individuals with 
lymphocytes comprising typically between 70 and 90%, monocytes between 10 and 30% and DCs 
between 1 and 2%. In a healthy organism T cells constitute between 45 and 70% of all lymphocytes, B 
cells between 5-20%, similarly as NK cells. Further, the T cell compartment is composed of roughly 
65% of CD4+ and 35% of CD8+ cells, among which naive and memory cells can be discriminated 
(Miyahira, 2012).  
Investigating WB transcriptomic profiles represents a new approach to diagnostics – looking 
at host transcriptomic regulation instead of isolating a pathogen or antibodies to identify the exposure. 
In cases of diseases like TB this capacity can bring significant advances, because the number of bacteria 
may be undetectable or the infected tissue inaccessible, and the antibody response may not be 
established at the moment of testing. 
1.2.4. Machine learning in biomarker discovery 
Considering vast amounts of multidimensional data provided by “-omics” experiments, ML 
approaches are currently considered the panacea for the identification of patterns in datasets from 
versatile areas (Jagga & Gupta, 2015). ML, a group of methods from the field of artificial intelligence, 
provides the potential to mine huge datasets with (supervised ML) or without (unsupervised ML) 
external information about which samples in a dataset belong to what class of input data (called a 
“label”) (Zhu & Goldberg, 2009). On the example of TB, supervised ML methods are used to analyze 
the samples labeled as “TB” or “healthy” and learn to classify new, unlabeled samples based on the 
variables from the training dataset. Unsupervised ML methods find clusters of unlabeled data which 
may correspond to the classification of donors as “TB” or “healthy”. Supervised ML algorithms can be 
used for classification (predicting a discrete class label output) or regression (predicting a continuous 
quantity output) problems. They also include a subgroup classified as “semi-supervised” which utilize 
both labeled and unlabeled datasets (Zhu & Goldberg, 2009). Unsupervised ML algorithms are 
implemented for clustering, density estimation or dimensionality reduction and class label information 
if patient sample is not available. The models or classifiers generated by ML can serve as standalone 
executable systems predicting clinical phenotype of the new patients in clinical decision support (Jagga 
& Gupta, 2015). 
A good ML study should be characterized by careful design which includes non-overlapping 
training, test datasets, and if possible, an independent validation dataset. An input dataset for ML is a 
matrix of samples vs attributes (features) (Jagga & Gupta, 2015). In case of the work presented here, 
the samples correspond to blood donors and the features correspond to transcripts measured on 
microarrays. Training dataset is the data subset used to train the learning algorithm to identify classifier 
(in the case of this study: a transcript set). At this stage cross-validation is used to estimate the errors 
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and generalizability of the classifier. There are several statistical procedures which can be used for cross 
validation: leave one out, hold-out, bootstrapping and k-fold cross validation (Jagga & Gupta, 2015) 
applied in this study. Bootstrap validation is based on subsampling performed with equal replacement 
from training dataset. In k-fold cross validation the dataset is split in k-mutually exclusive subsets, 
subsequently the classifier is trained on k-1 subsets and tested on the remaining one. The procedure is 
repeated k times and the average accuracy of k-folds is the estimated accuracy of the classifier. The 
classifier is then tested using the remaining, untouched data subset - testing dataset - thanks to which 
the performance and error of the classifier can be estimated. The validation dataset is derived from 
another corresponding study and it indicates if the model can be widely implemented. Therefore, 
additional features of a good ML model are cross comparability and wide implementation. The model 
should ultimately become publicly accessible for further testing, improvements and wider translation 
(Jagga & Gupta, 2015).  
Building a classifier can be preceded by feature selection – a technique used to reduce the 
dimensionality of the model, improve its performance, avoid overfitting, increase cost-effectiveness 
and ultimately also to gain insightful clues about the processes described by the data, e.g. disease 
pathogenesis and progression (Saeys, Inza, & Larranaga, 2007). Feature selection means determining 
the important features (in the case of this study: biomarkers) which the model should consist of, since 
the multidimensional “-omics” data is characterized by so called ‘curse of dimensionality’, which means 
that almost in every such study there are far more measured features than collected samples (Jagga & 
Gupta, 2015). For example, microarrays can measure around 40,000 genes while the microarray cohorts 
normally consist of between 10 and 1000 donors, and far fewer when we investigate an infectious 
disease like TB. This can lead to overfitting, which means that the classification model contains so many 
irrelevant features that it becomes over sensitive to the investigated training set. Feature selection solves 
this problem by identifying the meaningful, sensitive and specific disease markers. 
Feature selection algorithms can be independent of the classification algorithm, based on the 
data properties (filter methods), based on the evaluation of the learning models with selected feature 
subspace (wrapper methods) or estimate the optimal feature subset by grading feature importance within 
the classification algorithm (embedded methods). The last one has been applied in this thesis and they 
are less prone to overfitting and less computationally heavy than the wrapper methods while at the same 
time selected in cooperation with the learning algorithm in contrary to filter methods (Saeys et al., 
2007). 
A simplified workflow of supervised ML is presented in the Figure 3. 
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Figure 3 Example of workflow of supervised ML  
A dataset with class labels is divided into training and test set. The algorithm learns to classify the samples and uses the 
embedded feature selection method. The created model is first cross-validated using k-fold cross validation to estimate the 
errors. Then, the classifier is applied to identify classes in the test and independent validation dataset. 
1.2.5. Unsupervised Machine Learning – Principal Component Analysis  
Principal component analysis (PCA) is an unsupervised ML method reducing the 
dimensionality of multi-dimensional data (Shlens, 2014). Reducing the dimensionality simplifies the 
data and helps to understand it; it can explain where the variance in the data comes from, facilitate data 
visualization and description.  
PCA finds principle components of the dataset, which means the variables, which explain the 
largest portion of variance in the data. In the case of microarray analysis, it can be used to assess the 
influence of technical parameters of the experiment on its outcome as well as to find which of the sample 
characteristics are responsible for variability between patients (e.g. TB status, HIV coinfection or 
ethnicity as I will present in the Chapter 3). PCA transforms the data into a new coordinate system 
where the first axis corresponds to the first Principal Component (PC) along which the data presents 
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greatest variance (Shlens, 2014). Mathematically, the PCs are the eigenvectors of the covariance matrix 
of the original dataset. Since the covariance matrix is symmetrical, the eigenvectors must be orthogonal 
to each other. Every eigenvector possesses a corresponding eigenvalue, which is a number indicating 
how much variance there is in the data along its eigenvector (Shlens, 2014).  
Since PCA finds principal components with the greatest variance, data normalization helps to 
avoid a situation in which the first PC is dominated by variables with large values and large absolute 
variances and not by the attributes showing major biological differences. Data normalization keeps the 
variables on similar scale which gives every variable a chance to form part of the PCs (Hamilton, 2014). 
1.2.6. Supervised Machine Learning – Random Forest  
Random forest (RF) models can be used when the aim of the research is to classify samples 
into categories (called classes) of interest based on multiple measured or described variables which in 
biology can include any functional categories like disease status, gender or species. RF can also serve 
to regress features against quantitative data. They are based on decision trees, which can be used for 
classification of discrete variables or regression of a continuous variable, therefore being classified as 
Classification and Regression Trees (CART). 
RFs are based on generating many classifiers and aggregating their results (Liaw & Wiener, 
2002). Two well-known methods of classification are (i) boosting, where successive trees give extra 
weight to points incorrectly predicted by earlier predictors (Schapire, Freund, Bartlett, & Lee, 1998)), 
and (ii) bagging, where each successive tree is created independently of the previous trees using 
bootstrap of a dataset (Breiman, 1996). In this study I am using a method proposed by Breiman in 2001, 
in which each tree is constructed using a different bootstrap sample of the data and each node is split 
using the best among the subset of predictors randomly chosen on that node (Breiman, 2001). This 
method was shown to perform very well in comparison to many other classifiers and is robust against 
overfitting. Additionally, it demands only two parameters: the number of variables in the random subset 
and the number of trees in the forest.  
RF algorithm involves randomly subsetting samples from a dataset and building a decision 
tree based on those samples. At each node in the tree a number of features are selected and the feature 
providing best split given any preceding nodes is selected. The same principle is applied to multiple 
trees based on different sample subsets which prevents overfitting. In this study, each tree’s 
performance has been tested on the left-out samples using k-fold cross-validation. Later, the model 
derived from RF built on the training set with selected features sorted by variable importance was tested 
on the test set to evaluate the performance of the model and on an independent dataset to assure 
biological relevance.  
24 
 
RF modeling allows calculating the variable importance of all the features in the model, which 
creates grounds for biosignature detection. It is performed by re-running the RF algorithm on the same 
dataset but with one feature value scrambled across all samples and calculating the difference in 
accuracy between the two models. 
A scheme of RF decision making is presented in the Figure 4. 
 
Figure 4 Simplified scheme of the classification RF algorithm  
Single decision trees on each node make a decision leading to primary sample classification. Summary votes of the decision 
trees decide about the final sample classification. 
1.2.7. Approaches to identify diagnostic TB biomarkers in published studies 
Biomarkers discriminating between TB patients and healthy donors or OD patients have been 
identified by a number of studies.  
As early as 2007, Mistry et al. identified a set of 9 gene transcripts in blood which 
discriminated between the subjects cured from TB after conventional chemotherapy and the patients 
susceptible to recurrent disease (Mistry et al., 2007). The signature was based on the WB samples from 
10 individuals in each clinical group, all recruited in South Africa (SA). At the same time, Jacobsen et 
al. compared gene expression profiles of PBMCs from 9 TB patients and 9 LTBI donors recruited in 
Germany and proposed three other genes: lactoferrin, CD64 and the Ras-associated GTPase 33A for 
classification of TB patients (Jacobsen et al., 2007). Those first studies on limited numbers of 
participants were followed by several others involving increasing numbers of patients and different 
ethnic groups.  
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In 2010 Berry et al. identified a 393-transcript signature for active TB on patients from the 
United Kingdom (UK) and SA (altogether 54 TB patients, 105 healthy donors including LTBI) and a 
specific 86-transcript signature that discriminated between active TB and OD (altogether 193 patients 
with other pulmonary diseases). The signatures were dominated by IFN inducible genes consisting of 
both IFN type I and IFN type II signaling (Berry et al., 2010). Using flow cytometry, the study 
demonstrated that this profile was driven by neutrophils and that at the same time the relative content 
of B cells and CD4+ and CD8+ T cells was diminished in the TB patients compared to healthy. This 
change of balance could also influence the blood transcriptional profile differences between the patients 
and the healthy donors.   
In 2011 Maertzdorf et al. recruited 33 TB patients and 34 LTBI donors in SA as well as 9 
healthy donors in Germany to define biomarkers predictive of susceptibility and resistance to TB 
(Maertzdorf, Repsilber, et al., 2011). They identified Fc gamma receptor (FcGR) 1B gene as the most 
differentially regulated in TB vs LTBI and proposed that together with 4 other genes it forms a signature 
discriminating the individuals with Mtb infection from the patients with TB disease with high degree 
accuracy (sensitivity of 94% and specificity of 97%). Among the genes significantly regulated between 
TB and LTBI determined in the study there was a profound upregulation of Toll-like receptor-associated 
genes and IFN inducible genes.  
In the same year Lesho et al. published a study in which they recruited patients from USA and 
Brazil who were BCG-vaccinated, latently infected, suffering from TB or healthy and proposed 127 
genes capable of accurately classifying samples into the respective four groups (Lesho et al., 2011). 
They found 13 insulin-sensitive genes to be differentially regulated in all three Mycobacteria stimulated 
groups which suggested an important role of insulin signaling pathway in TB. Another study by 
Maertzdorf et al. validated the previously defined signatures on a cohort 46 TB patients, 25 LTBI donors 
and 37 healthy individuals from the Gambia (Maertzdorf, Ota, et al., 2011). It confirmed the 
involvement of FcGR 1 signaling in active TB but also pointed out similarities in gene expression 
profiles of TB and Systemic Lupus Erythematosus patients. Apart from looking at TB biosignature the 
study approached identification of functional gene clusters playing a role in TB, which resulted in novel 
insights into the immunoregulatory interactions in TB including the JAK-STAT pathway, microbial 
sensing by Toll-like receptors and IFN signaling.  
In line with these results, in 2012 the whole-genome PBMC expression profiling study by 
Ottenhoff et al. on 23 TB patients during disease, treatment and after recovery and 23 healthy household 
contacts from Indonesia emphasized the role of the detected signature of type I IFN signaling in active 
TB. The authors of the study suggested that the IFN type 1 signaling cascade could be used as a 
quantitative tool for monitoring active TB. They also showed that the observations acquired from 
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PBMC profiling were reflected by pulmonary and macrophage response to Mtb infection (Ottenhoff et 
al., 2012).  
A comparison of expression profiles of 8 TB patients, 18 LTBI and 18 sarcoidosis donors in 
2012 revealed that the two diseases manifesting in pulmonary pathology with similar histological and 
clinical symptoms but of different origins share a highly similar gene expression profile (Maertzdorf et 
al., 2012). Similar to previous studies it included a dominant IFN-inducible gene expression profile. 
The study pointed out the commonalities and unique signatures in WB gene expression profiles of the 
two diseases. These observations were confirmed in a study from 2013 (Bloom et al., 2013) which 
showed that there is a significant difference in the degree of transcriptional activity in TB and 
sarcoidosis and compared gene expression in those diseases to the transcriptional profiles of pneumonia 
and lung cancer. This study, conducted on 35 TB, 16 lung cancer, 14 pneumonia and 61 sarcoidosis 
patients and 113 healthy volunteers identified a set of 114 blood transcripts able to distinguish TB from 
the three other pulmonary diseases and described the transcriptional response to anti-TB treatment. 
They as well identified IFN-inducible blood transcriptional signature present in the pulmonary 
granulomatous diseases, TB and sarcoidosis, as distinct from other lung diseases representing acute and 
chronic conditions, pneumonia and lung cancer, in which the inflammatory signature was dominant.  
Another study dedicated specifically to gene expression changes during anti-TB treatment, 
was conducted on the WB from 29 treated TB patients and 38 LTBI individuals from SA and 8 treated 
TB patients from the UK (Bloom et al., 2012). It identified a treatment specific 320-transcript signature 
which significantly diminished during the first two weeks of treatment and continued to cease until the 
completion of the 6 months treatment regimen (Bloom et al., 2012). Those finding suggested that blood 
transcriptional signatures could be used as surrogate biomarkers of successful treatment response. 
Another study in this direction by Cliff et al. (2013) focused on the networks of genes regulated with 
time of TB treatment. It underlined relevance of the initial regulation of complement components C1q 
and C2 followed by slower changes in expression of B-cell markers, transcription factors and signaling 
molecules. These results were further confirmed by the study of Cai et al. in 2014, where complement 
gene expression in PBMCs of 9 TB patients, 6 LTBI and 6 healthy controls (HCs) from China was 
determined using whole genome transcriptional microarrays and presented significant increase in C1q 
expression in TB patients, which correlated with sputum smear positivity and was reduced after anti-
TB treatment (Cai et al., 2014).  
In a study from 2013, Kaforou et al. investigated blood transcriptional profiles of 311 South 
African and 273 Malawian adults including 194 TB cases with and without HIV coinfections, patients 
with other diseases and HCs (Kaforou et al., 2013). In this study, a 27-transcript signature was proposed 
to distinguish TB from LTBI and a 44-transcript signature to distinguish TB from OD. Additionally, 
the authors developed a method for translation of multiple transcript RNA signatures into a Disease 
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Risk Score (DRS) which can be applied to each patient to evaluate the signatures and developed as a 
test for TB.  
Since TB continues to cause a high toll of disease and death among children worldwide, two 
transcriptome studies have been dedicated to childhood TB. In the first of them, WB samples were 
analyzed to identify a minimal set of 9 genes predictive for TB vs LTBI in a group of 9 patients, 
(Verhagen et al., 2013). Validation of the biosignature on the previously published datasets showed that 
the biosignature was highly discriminative also for other ethnicities. Functional annotation of the genes 
suggested a role of calcium signaling and calcium metabolism in active TB. The other childhood TB 
transcriptomic study was published two years later and involved 114 TB patients, 57 LTBI and 175 OD 
donors from Kenya and Malawi (Anderson et al., 2014). Once again, the study identified a biosignature 
of active TB vs OD, which consisted of 51 transcripts; however the authors did not suggest any 
functional interpretation of this gene set.  
Similarly, in 2014 Dawany et al. analyzed global gene expression data from PBMC samples 
of 43 TB patients from SA with or without HIV coinfection and identified a 251 gene signature that 
accurately distinguishes HIV/TB coinfected patients from non-TB, HIV-infected patients. The signature 
diminished as a correlate of the length of anti-TB treatment (Dawany et al., 2014). In 2016 Walter et al. 
identified a WB TB biosignature among 35 American TB patients in comparison to 35 LTBI and 39 
pneumonia donors. However, the accuracy of the classifiers from this study decreased when tested in 
other populations, which suggested that further investigation is needed to provide generalizability of 
the signature (Walter et al., 2016). In the same year, Blankley et al. focused his research of finding 
biosignatures distinguishing TB patients from HCs and from sarcoidosis but with distinction of 
pulmonary and extra-pulmonary TB (Blankley, Graham, Turner, et al., 2016). They showed that the 
blood transcriptional responses in pulmonary and extra-pulmonary TB are distinct and reflect the extent 
of disease symptoms. In yet another approach to find correlate biomarkers of active TB a group from 
Taiwan investigated microRNA profiles of PBMCs of 7 TB, 7 LTB and 7 healthy donors (Wu et al., 
2014) resulting in identification of several microRNA-gene interactions that may serve as potential 
biomarkers of TB and LTBI.  
Biomarkers proved successful not only in identifying TB patients in a population but also in 
differentiating between infections caused by different Mycobacteria. In a study from 2015 
transcriptomic and metabolic profiles of Mtb and Mycobacterium africanum (Maf) infected patients 
were compared to identify host biomarkers associated with lineage-specific pathogenesis and response 
to anti-TB treatment (Tientcheu et al., 2015). Interestingly, transcriptomic profiles of the 12 Gambian 
TB patients infected with Mtb and the 14 infected with Maf were similar before treatment – however 
after treatment over 1600 genes related to immune responses and metabolic diseases were differentially 
expressed between the two groups. The differences in both PBMC and serum metabolic profiles 
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between the two clinical groups might be indicative of different treatment efficacy or to individual 
variability between hosts related to TB susceptibility. 
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Table 2. List of the TB studies described in the Chapter 1.2.7 
The table characterizes the studies with the original publication reference, GEO accession number if available, cohort origin, 
sample type and the number of donors included in each study (HC – healthy control donors including non-infected, HIV 
infected and LTBI; Maf – Mycobacterium africanum infected donors). 
Author GEO Cohort Sample Cases 
(Anderson et al., 2014) GSE39941 Malawi, Kenya, SA WB 114 TB,  
57 HC,  
175 OD 
(Berry et al., 2010) GSE19491 UK, SA WB 54 TB,  
105 HC,  
193 OD 
(Blankley, Graham, Turner, 
et al., 2016) 
GSE83456 UK WB 45 TB,  
61 HC,  
49 OD 
(Bloom et al., 2012) GSE40553 SA, UK WB 37 treated TB,  
38 HC 
(Bloom et al., 2013) GSE42834 UK, France WB 16 TB,  
113 HC,  
91 OD 
(Cai et al., 2014) GSE54992 China PBMC 9TB,  
12 HC 
(Cliff et al., 2013) GSE31348 SA WB 27 TB pre- and post-
treatment 
(Dawany et al., 2014) GSE50834 SA PBMC 21HIV/TB,  
22HIV 
(Jacobsen et al., 2007) GSE6112 Germany PBMC 23 TB,  
2 recovered TB,  
27 HC 
(Kaforou et al., 2013) GSE37250 SA, Malawi WB 194 TB,  
259 HC,  
83 OD 
(Lesho et al., 2011) NA USA, Brazil WB 5 TB,  
5 BCG,  
13 HC 
(Maertzdorf, Ota, et al., 
2011) 
GSE28623 The Gambia WB 46 TB,  
62 HC 
(Maertzdorf, Repsilber, et 
al., 2011) 
GSE25534 SA WB 33 TB,  
43 HC 
(Maertzdorf et al., 2012) GSE34608 Germany WB 8TB,  
18 HC,  
18 SARC 
(Mistry et al., 2007) NA SA 
 
10 TB,  
10 LTBI,  
10 cured,  
10 recurrent 
(Verhagen et al., 2013) GSE41055 Venezuela WB 9 TB, 
18 HC 
(Ottenhoff et al., 2012) GSE56153 Indonesia PBMC 23 TB ,  
23 HC 
(Tientcheu et al., 2015) GSE62147 The Gambia WB 12Mtb, 
14 Maf pre- and post-
treatment 
(Walter et al., 2016) GSE73408 USA WB 35 TB,  
35 HC,  
39 OD 
(Wu et al., 2014) GSE62525 Taiwan PBMC 7 TB,  
7HC 
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1.2.8. Approaches to identify prognostic TB biomarkers in cohorts 
Factors associated with the increased risk of progression to active TB include: HIV infection, 
age, weak immune system, sex, and above all recent contact with a patient with active pulmonary TB. 
Nevertheless, no diagnostic test to date can indicate if an Mtb-infected person will progress to the 
disease. Naturally, household, work and medical personnel contacts of a TB patient form a high-risk 
group and therefore finding a prognostic biomarker of TB to screen those groups will significantly 
improve the perspectives of decreasing TB burden.  
So far, two prognostic biosignatures of TB have been proposed. The first one resulted from 
following over 6000 adolescents infected with Mtb for two years (Zak et al., 2016). Among the infected, 
46 people developed active TB. The suggested biosignature was developed based on those 46 TB 
patients and 107 matched controls using k-top-scoring pairs ML method and consisted of 16 genes 
which predicted TB progression with a sensitivity of 66.1% (95% CI = 63.2% – 68.9%) and specificity 
of 80.6 % (95% CI = 79.2% - 82%) 12 months before diagnosis. The risk signature was tested on the 
test set and validated on an independent dataset from cohorts from SA and the Gambia from the Grand 
Challenges 6-74 study including household contacts of adults with sputum-smear positive TB. The 
study has also shown that it is possible to predict conversion from LTBI to TB up to 18 months before 
the disease manifestation. Another encouraging conclusion from the study is that the prognostic 
signature was universal for the investigated patients – since the training and validation cohorts varied 
in the age and origin of participants.  
Another study based on similar assumptions of following healthy household contacts of TB 
patients identified a four-transcript Pan-African prognostic biosignature of TB (Suliman et al., 2018). 
Between 3 and 24 months after exposure 79 people progressed to develop active TB in a cohort of 
almost 5000 HCs. The derived signature predicted progression to active TB up to two years before the 
diagnosis in the test set consisting of South African, Gambian and Ethiopian study participants. On top 
of that, the study identified several gene pairs that predict TB progression in various locations in Africa. 
Out of these C1QC and TRAV27 gene pair consistently predicted TB in adult HCs from multiple sites 
in Africa (Suliman et al., 2018). 
Successful applications of prognostic TB biosignatures could result in targeted treatment to 
prevent TB. Since around 30% of the population of the world is infected with TB it is not feasible to 
treat all infected individuals even with the assumption of developing a treatment with minor side effects. 
Currently used treatments pose risk of serious side effects and are definitely too expensive to be supplied 
for every infected person as preventive measure.   
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1.2.9. Approaches to identify universal TB biomarkers in multi-cohort studies 
Three studies published in 2016 and 2017 intended to integrate the listed transcriptomic 
studies. The first study focused on deriving a diagnostic gene set from TB patients which meets the 
requirements of WHO, including: (i) being derived from non-sputum samples, (ii) maintaining 
sensitivity of over 80% in patients co-infected with HIV, (iii) maintaining sensitivity of over 66% in 
children who are TB culture positive, (iv) being simple to conduct (WHO, 2014). The study included 
altogether 14 WB datasets containing samples from patients from 10 countries, both children and adults. 
It identified a three-gene set which differentiates between active TB and healthy, LTBI or OD with high 
sensitivity and specificity (Sweeney, Braviak, Tato, & Khatri, 2016), successfully generalizing the 
information derived from separate cohort studies. The authors used two meta-analysis methods to 
perform the study: combining gene expression effect size using DerSimonian-Laird method and 
combining p-values with Fisher’s sum of logs method. They thoroughly investigated the parameters 
characterizing performance of the three identified genes: KLF2, DUSP3 and GBP5 in diagnosing TB. 
This study focused on the technical performance of the meta-signature but did not approach 
interpretation of its biological meaning.  
Only four months later another multi-cohort study of TB patients revealed a 380-gene meta-
signature of TB vs healthy (Blankley, Graham, Turner, et al., 2016). There, meta-profiling of 
significantly regulated gene lists was applied to identify the number of overlaps between datasets 
required for inclusion in the meta-signature. Contrary to the previous study, here modular analysis 
framework (Chaussabel et al., 2008) was used to identify the common transcriptional responses of 
patients with TB as biologically meaningful gene modules. This study revealed similarities among all 
cohorts related to strong upregulation of genes involved in IFN signaling, inflammation, dendritic cells 
(DCs), apoptosis, cytotoxicity, and under-expression of genes related to B-cells, T-cells, lymphocyte 
activation and mitochondrial stress (Blankley, Graham, Turner, et al., 2016).  
The results were confirmed by a later study in which on the basis of meta-analysis a network 
of responses to active TB was generated and monitored during treatment (Sambarey et al., 2017). The 
core of this network consisted of 380 genes among which STAT1, PLSCR1, C1QB, OAS1, GBP2 and 
PSMB9 were pivotal hubs. Among those hubs, STAT1, PLSCR1, OAS1 and GBP2 are directly 
involved in IFN signaling pathways. The created network captured biological processes involved in 
response to TB, including pro-inflammatory responses, apoptosis, complement activation, cytoskeletal 
rearrangements, cytokine and chemokine signaling.  
Insights missing in the multi-cohort studies 
In each study, the analysis focused on the trends presented by the TB patients among all the 
cohorts. It accounted for the variation between different experimental settings and technical differences 
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providing platform-independent results. However, none of the mentioned meta-studies investigates 
individual variability of patients belonging to various cohorts. The assumption that the general trends 
are universally present in the TB patients poses a risk of ignoring alternative events occurring during 
the immune response to TB in subgroups of patients, for example those with coinfections, weaker 
immune systems or other unidentified factors. Therefore, in this thesis I investigated the individual 
variability in responses to TB presented by single individuals trying to answer the question of what 
types and elements of immune response to TB drive the observed trends.  
1.3. VARIOUS FACTORS INFLUENCE MTB INFECTION 
PROGRESS  
1.3.1. Variability in the Mtb infection outcomes 
Part of the challenge of combating TB is related to the fact that there are drastic differences 
between its active and latent form and even further – between the manifestations of active TB in 
different hosts. TB can be harmful even when characterized by low bacteria number and can be 
contained even by individuals infected with high bacterial loads.  
Even though we know some risk factors of active TB, we do not understand what leads to its 
development or containment among infected healthy adults. The prognostic biomarkers help to identify 
the individuals with highest risk of progression (Sweeney et al., 2016) but so far the mechanisms 
underlying them are obscure. Apart from a binary “TB/LTBI” classification the close look at TB 
patients reveals huge differences in disease scale, severity and manifestation among patients. As 
mentioned earlier the most common disease form is pulmonary TB but the bacteria can also invade 
other organs. There are patients who quickly react to anti-TB treatment and patients prone to relapse. 
Comparing the disease in humans is of course challenging not only due to the individual variability but 
also because of hard to control environment and daily routine of the patients. However, even the studies 
involving macaques living in controlled conditions and infected with equal Mtb doses result in varying 
disease outcomes (Gideon, Skinner, Baldwin, Flynn, & Lin, 2016). Not only do some of the animals 
remain latently infected and some progress to active disease, but they also develop disease with varying 
severity and lung pathology. Other animal models like mice can be divided into strains with low and 
high susceptibility to TB and in many cases, we do not know what their susceptibility depends on, which 
will be further discussed in the Chapter 1.4.1. 
The patients diagnosed with TB present a spectrum of pathology, ranging from influenza-like 
symptoms to fully symptomatic disease with blood-stained sputum, weight loss and detectable changes 
in the lungs. Further investment in analysis of transcriptomic biomarkers for TB early diagnostics is 
expected to enhance our understanding of susceptibility and resistance to TB (Maertzdorf et al., 2014). 
For those reasons, host gene expression changes during TB are extensively studied. Discovering the 
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role and correlates of individual variability in host response to TB is part of the motivation of this thesis 
and pursued by close investigation of variability of host immune responses among TB patients. 
1.3.2. Complexity of the immune response to TB 
As soon as an infectious droplet containing sufficient dose of Mtb is inhaled into the airways 
and alveoli of a susceptible person, the development of Mtb infection begins. The early series of events 
includes recruitment of phagocytic cells to the site of infection (Schlesinger, 1996). Macrophages and 
neutrophils contribute to the first-line of defense against TB, but their role in protection is complex and 
depends on the context of their activation. It has been shown that they can drive both containment as 
well as progression of the disease thus leading to variable outcomes in the hosts (Lowe et al., 2012; 
Schlesinger, 1996). Macrophages can contain mycobacterial spread through apoptosis or, opposite, 
contribute to its dissemination via necrosis followed by infection of the neighboring cells (O’Garra et 
al., 2013). Neutrophils play a detrimental role participating in granuloma formation and their levels 
have been shown to be elevated in TB susceptible murine models while their elimination led to 
increased protection in those animals (Eruslanov et al., 2005; Keller et al., 2006). At the same time, 
neutrophils promote the development of adaptive immunity against TB by delivering the bacteria to 
DCs which enhance the initiation of naive CD4+ T cells activation (Blomgran & Ernst, 2011). When 
the antigen presentation occurs, antigen-specific CD4+ T cell responses are initiated in local lymph-
draining lymph nodes, where the T-cell numbers rise and wherefrom the trafficking into the lung begins 
(Reiley et al., 2008).  
The immune response in TB is complex and despite all scientific efforts, so far remains only 
partially understood which is among others owed to drastically different infection and disease fate 
depending on the host. Major Histocompatibility Complex class II (MHC II) deficient mice present 
increased susceptibility to TB which suggests that the CD4+ T-cell mediated immunity is central to TB 
protection (Caruso et al., 1999). Likewise, patients with HIV infection, characterized by low levels of 
CD4+ T cells in blood are highly susceptible to TB (Cooper, 2009). CD8+ T cells have been shown to 
provide protective immunity against TB by production of IFN-γ and enhancing lysis of infected 
macrophages (Flynn & Chan, 2001). Other T cell subsets, like γδ T cells, CD1-restricted T cells, NK T 
cells, CD25+ 4+ T cells and Th17 cells play important regulatory roles in the response against TB 
(Behar & Boom, 2017).  
The knowledge about the roles of B-cells in TB containment is also very limited. Since Mtb 
is an intracellular pathogen, it is expected that the protection is mostly mediated by mechanisms 
activated in the macrophages by cytokine signaling. Nevertheless, aggregates of B-cell follicles have 
been observed in the lungs of TB mouse models (Chackerian, Alt, Perera, & Behar, 2002; Maglione & 
Chan, 2009; Maglione, Xu, & Chan, 2007) and of patients (Ulrichs et al., 2004). Activated B-cells are 
present in the granulomas of Mtb-infected macaques (Lin, & Flynn, 2012). 
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Due to the described variability of the roles of particular immune cell types visible already 
during primary events after Mtb infection I decided to focus my study on deciphering patterns of 
immune response activation presented by individual patients and by various mouse strains. As the focus 
and starting point of the analysis of differences presented on transcriptomic level by individual TB 
patients I chose a signaling pathway considered to play a crucial role in the development and 
containment of TB: the IFN signaling pathway. 
1.3.3. Interferon signaling pathways in TB 
IFN-γ and interleukin-12 (IL-12) signaling molecules have been established as central in 
providing protective T-cell mediated immunity to TB in both human and murine studies (O’Garra et 
al., 2013), however certain further discussed observations cast doubt on their role. Tumor necrosis factor 
α (TNFα) and interleukin-1 (IL-1) contribute to the protective immunity against TB and a number of 
other molecules, identified among others in the transcriptomic biosignatures of TB are being extensively 
studied (Donovan, Schultz, Duke, & Blumenthal, 2017; O’Garra et al., 2013).  
Interferons are proteins released by host cells in response to pathogens or tumors. They are 
classified into three types based on their cognate receptors: type I IFNs signal through IFN α/β receptor 
(IFNAR), type II IFN through IFN-γ receptor (IFNGR) and type III IFN through a receptor complex 
consisting of interleukin-10 receptor beta (IL10R2) and interleukin-28 receptor subunit a (IL28RA) 
(Platanias, 2005). The three different types of IFN response contribute to TB. The attribution of central 
role in TB pathogenesis and protection to IFN response has been in recent years supported by the 
abundant presence of genes involved in IFN signaling in the TB biosignatures identified by the 
previously listed transcriptomic studies (Berry et al., 2010; Kaforou et al., 2013; Maertzdorf, Ota, et al., 
2011).  
The type I IFN response has been shown to contribute to either protective or detrimental effects 
on bacterial infections depending on infectious agent, model system used and acute or chronic state of 
the infection (Boxx & Cheng, 2016). We do not fully understand the consequences of IFN I signaling 
in the context of Mtb infection. Data published in several studies suggest that the host resistance and 
disease severity are influenced by IFN I signaling depending primarily on the host immune competence 
and possibly - on the pathogen type (Donovan et al., 2017). The TB-susceptible and highly susceptible 
mice (A129 or 129S2 strains, Il1r-/- mice) survive the infection longer with IFNAR1-deficiency (Dorhoi 
et al., 2014), which suggests that type I IFN signaling in susceptible hosts infected with Mtb is 
detrimental. It has been confirmed by other types of studies (Manca et al., 2005; Mayer-Barber et al., 
2014; Ordway et al., 2007). In the slowly progressive mouse model for TB, B6D2/F1, administration 
of IFN α/β antibodies before Mtb infection decreased levels of type I IFNs, increased levels of IL-12 
mRNA and decreased STAT1 signaling in the lungs which correlated with longer survival (Manca et 
al., 2005). This suggests that the reduced levels of type I IFNs lead to upregulation of host Th1 
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immunity, causing decreased pathogenesis (Manca et al., 2005), which in turn could mean that the IFN 
response present in the host before Mtb infection influences the infection outcome. In summary, there 
is a collection of evidence that IFN type I signaling has a detrimental effect on the disease outcome in 
mice. At the same time, it has been also shown that the IFN-α (subtype of IFN type I) has a protective 
effect in the absence of IFN-γ signaling (Desvignes, Wolf, & Ernst, 2012; Moreira-Teixeira et al., 2016). 
To make it even more complex, there are several clinical reports where administration of 
antimycobacterial antibiotics together with inhalation or subcutaneous administration of IFN-α 
improved clinical outcomes of the patients (Bax et al., 2013; Giosue et al., 1998; Mansoori, Tavana, 
Mirsaeidi, Yazdanpanah, & Sohrabpour, 2002; Palmero et al., 1999; Ward et al., 2007; Zarogoulidis et 
al., 2012). In the patients with genetic lack of IFN-γ signaling, administration of IFN-α improved also 
the clinical outcome of the patients with mycobacterial non-tuberculous infections (Bax et al., 2013; 
Moreira-Teixeira et al., 2016; Ward et al., 2007).  
IFN type II response pathway involves IFN-γ. This molecule stimulates adaptive immune 
responses critical for the defense against intracellular pathogens such as Mtb (Bach, Aguet, & Schreiber, 
1997). The primary source of IFN-γ are CD4+ and CD8+ cells and recently it has been shown that the 
innate lymphoid cells, γδ T cells, NK T cells and NK cells can also produce IFN-γ in response to Mtb 
infection (Bach et al., 1997; Elemam, Hannawi, & Maghazachi, 2017). The secondary producers of 
IFN-γ play an important protective role in humans (Skeen & Ziegler, 2018). 
IFN-γ promotes cellular proliferation, cell adhesion and apoptosis, activates the NK cells, 
increases antigen presentation and lysosomal activity of macrophages and activates nitric oxide 
synthase (iNOS) (Zuñiga et al., 2012). At the same time, it can also transfer anti-inflammatory signals 
to limit inflammation in neutrophils in the chronic infection phase by inhibiting IL-17 production 
(Zuñiga et al., 2012).  
An important contribution of IFN-γ in TB is related to its activity as a mediator of macrophage 
activation. The dogma of its central role in protection against TB is based on the studies where mice 
with IFN-γ gene targeted disruption developed granulomas, but failed to produce reactive nitrogen 
intermediates and restrict bacterial growth (Cooper et al., 1993; Flynn et al., 1993). The mice with IFN-
γ knock-out presented heightened tissue necrosis and rapidly succumbed to TB. Administration of 
recombinant IFN-γ delayed but did not reverse this process (Flynn et al., 1993). Later it had been shown, 
that in the infected macrophages, IFN-γ induces g-reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) formation, thus enhancing containment of bacterial proliferation and regulation of 
intracellular signaling (Cooper, Adams, Dalton, Appelberg, & Ehlers, 2002; Nathan & Shiloh, 2000).  
It is still unclear if the role of innate lymphoid cells, γδ T cells, NK T cells and NK cells 
contribute to the control of Mtb infection through IFN-γ production when adaptive immune response 
already occurred. In 2006 it was demonstrated that Mtb stimulates NK cell-dependent IFN-γ production 
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in naive splenic cultures and in lungs of infected mice (Feng et al., 2006). In T cell deficient Rag-/- mice 
NK cells producing IFN-γ were responsible for the partial resistance of the animals to Mtb infection; 
however, depletion of NK cells in T-cell sufficient wild-type mice did not influence the infection 
development. 
A number of transcriptomic studies emphasize the regulation of IFN related genes as hallmark 
of TB. In the study by Berry et al. (Berry et al., 2010) a neutrophil-driven IFN-inducible genetic profile 
was used to distinguish between TB patients and other patients as well as healthy individuals. In this 
case both IFN type I and IFN type II inducible genes were included in the biosignature. In 2011, a study 
on PBMCs investigating differential expression of genes between TB and LTBI showed IFN-γ signaling 
pathways as significantly differentially regulated (Lu et al., 2011). A study by Harari et al. (2011) 
investigated the profile of cytokines: IFN-γ, TNF-α and IL-2 in Mtb specific CD4+ T cells in patients 
with TB and LTBI concluding that the proportion of single-positive TNF-α specific CD4+ T cells was 
increased among active TB patients, making this parameter the strongest predictor of diagnosis of active 
vs latent TB (Harari et al., 2011). Interestingly, in the recent study it has been shown that the growth 
arrest of Mtb can be achieved by T cells without IFN-γ production. During the first 21 days after aerosol 
infection, the growth arrest of Mtb occurred even in the animals unable to secrete IFN-γ (Gallegos et 
al., 2011). There is evidence that in vitro generated memory CD4+ cells can produce innate cytokines 
and chemokines providing protection after exposure to an antigen, independent of IFN-γ and TNF-α 
stimulation (Strutt et al., 2010), however we do not know if this mechanism plays a role in response to 
TB.  
One of the hypotheses explaining the inability of a host to eliminate Mtb is suboptimal 
production of IFN-γ in the lungs of infected animals. Bold et al. and Winslow et al. (Bold, Banaei, Wolf, 
& Ernst, 2011; Winslow, Roberts, Blackman, & Woodland, 2003) postulated, that even at the peak of 
immune response the frequency of activated CD4+ cells secreting IFN-γ is low and decreases during 
the chronic phase of the infection which favors Mtb persistence. Frequency of IFN-γ producing cells 
correlates with the availability of the antigen (Bold et al., 2011). In granuloma, the cells undergoing 
migration arrest can produce cytokines to closely adjacent infected cells, which suggests also a role for 
T cell derived IFN-γ in activation of infected phagocytes (Bold et al., 2011). 
IFN type I and IFN type II pathways often cooperate to efficiently activate innate and adaptive 
mechanisms leading to immune response (Pestka, Krause, & Walter, 2004). Observations made in IFN-
γ signaling deficient patients and IFNGR-/-/IFNAR-/- mice encourage further investigation of the 
mechanisms of this interaction in the context of TB (Desvignes et al., 2012; Moreira-Teixeira et al., 
2016). For these reasons, I decided to give attention to those two signaling pathways when investigating 
individual variability among TB patients. 
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1.4. THE ROLE OF MOUSE MODEL IN UNDERSTANDING 
HUMAN IMMUNE RESPONSE IN TB 
This part of the introduction has been adapted from my publication published in September 2017 in 
the Scientific Reports (Domaszewska et al., 2017).  
The understanding of pathophysiology of the infectious diseases has been largely broadened 
thanks to the use of animal models. Soon after the discovery of Mtb as infectious agent causing TB in 
the 19th century Robert Koch conducted first animal experiments to investigate TB transmission by 
injecting cultures of Mtb into mice (Gupta & Katoch, 2005). In the following years rabbits, guinea pigs 
and rats were shown to be susceptible to TB and soon it became apparent, that the reaction to Mtb 
infection is species-specific. Today, the most frequently used animal models of TB include mouse, 
zebrafish, guinea pig, rabbit, and non-human primates. 
1.4.1. Mouse models of TB 
Mouse, the animal of choice for immunological studies for the last century, has markedly 
broadened our knowledge of the structure and function of the mammalian immune system and 
understanding of disease mechanisms. Mice share mammalian organ systems present in man, their 
genome is well described, they breed relatively fast without excessive maintenance costs. Even though 
mouse and man are divided by 65 million years of evolutionary distance and the evolutionary pressure 
on immune system is high (Cagliani & Sironi, 2013), it is remarkable how the principles of the immune 
systems of these two species remain similar (Mestas & Hughes, 2004).  
The main discrepancies between murine and human immune systems include the different 
composition of blood, which is a carrier of immune system molecules. While human blood is rich in 
neutrophils, which consist 50-70% of all blood cells, mouse blood presents a predominance of 
lymphocytes, which content reaches up to 90% of total blood cells (Mestas & Hughes, 2004). Another 
important difference is the repertoire of immune signaling molecules and receptors in the two organisms 
and broader repertoire of T and B cells in man. For example, the antimicrobial peptides called defensins 
in humans are produced mainly by neutrophils, while murine neutrophils do not express defensins 
(Risso, 2000). In contrary, while murine Paneth cells of small intestine express over 20 different 
defensins, human guts can only produce two types of them. Another example is the molecule CD89, 
which is an important IgA receptor expressed by human neutrophils, eosinophils, macrophages, DCs 
and Kupffer cells but absent in mice, which likely use another receptors to bind IgA (Monteiro & van 
de Winkel, 2003).  
The key players in both innate and acquired immune response to TB are mononuclear 
phagocytes (Dorhoi & Kaufmann, 2015). In a healthy person, the number of macrophage precursors in 
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blood equals on average 200,000/ml of blood, i.e. 5–6% of the total white cell count (Krikorian, 
Marshall, Simmons, & Stratton, 1975), whereas in mice around 60,000/ml of blood, constituting around 
6% of circulating leukocytes (Krikorian et al., 1975; Sunderkotter et al., 2004). When the bacteria 
invade the lungs, tissue resident macrophages engulf and constrain them while in parallel recruiting the 
circulating monocytes and other leukocytes to the site of infection. This contributes to an influx of 
immune system cells to the lung and ultimately leads to the formation of granulomas in humans and 
granuloma-like lesions in mice. Therefore, mononuclear phagocytes are one of the most important cell 
types involved in TB pathogenesis and protection.  
Thanks to the mentioned similarities and despite all listed differences, the mouse provides a 
valuable model to study the response of mammalian immune system to Mtb infection. Owing to the 
good annotation of the mouse genome, both forward and reverse genetic approaches can be used to 
define the role of particular genes in the development of TB (Cooper, 2014). In the forward genetic 
screening approach, random mutations are generated in mice and their influence on TB is investigated. 
A broad repertoire of mouse strains used to mimic human TB and presenting varying susceptibility can 
also serve to compare roles of genetic traits in the susceptibility and disease development. Currently, 
the most widely used mouse strains susceptible to TB include the CBA, C3HeB/FeJ, also called 
Kramnik’s mice (Kramnik, Demant, & Bloom, 1998; Kramnik, Dietrich, Demant, & Bloom, 2000), 
DBA/2, I/St and 129SvJ, whereas the strains like C57BL/6, A/Sn and BALB/c are resistant (Driver et 
al., 2012; Medina & North, 2001). Crossing the strains resulted in the identification of several loci 
responsible for susceptibility, e.g. sst1 containing Ipr1 gene and loci Trl1-4 (Pan et al., 2005; Sánchez 
et al., 2003); however, as mentioned earlier, the mechanisms of susceptibility are not fully understood 
yet. I describe the susceptible 129S2 and the resistant C57BL/6 mouse strains in more detail further in 
this chapter. 
1.4.2. Mouse models have advanced the understanding of human TB 
Since it is possible to infect mice by aerosol which mimics human infection, we can study the 
early events after Mtb infection. In mice, the role of particular cell subsets in those early time points are 
studied by targeted depletion of cells (Kühn & Torres, 2002; Saito et al., 2001).  
Understanding the mechanisms of recognition of Mtb antigens and antigen-specific T-cells 
expansion is furthermore crucial for vaccine design, and here also the mouse model plays a pivotal role 
(Cooper, 2014). Since the early events following the aerosol infection are not well described, presence 
of the antigen can only be measured indirectly (Cooper, 2014). This is another area of research where 
the mouse model broadens our understanding of TB by enabling investigation of the T cell function in 
the site of infection. For example, use of mouse model confirmed the pivotal role of TNF-α-derived 
signals in T-cell recruitment and granuloma structure maintenance through its effects on uninfected 
macrophages (Egen et al., 2008). In another mouse model study it became clear that only small fraction 
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of Mtb-specific T-cells undergo migration arrest in granulomas, which results in a limited production 
of the immune signaling molecules (Egen et al., 2011). A study by Bold et al. correlated low level of 
antigens in granuloma with decreased cytokine production (Bold et al., 2011; Egen et al., 2011). 
Altogether, these observations led to the conclusion that T-cell location in relation to Mtb-infected 
macrophages is important for cytokine-mediated infection control.  
Another advantage of the mouse as an animal model for TB are established bone marrow 
chimera models in which bone marrow from the hosts differing in ability to express particular molecules 
is transferred to an irradiated host and repopulates the hematopoietic system (Cooper, 2014). Such a 
model has been used to show that within the same host, only the Mtb infected macrophages expressing 
MHC class II molecules managed to decrease the bacterial burden in a T-cell-dependent manner 
(Srivastava & Ernst, 2013).  
Even though different mouse models are characterized by different lung pathology upon Mtb 
infection, the human-like mouse granulomas also helped to understand the human pathology. For 
example, an observation of B-cell follicles associated with inflammation caused by Mtb infection in 
mice helped to broaden the knowledge of B-cell role in Mtb infection, which includes IL-17 regulation-
based reduction in neutrophil influx to the infected lung (Kondratieva et al., 2010; Kozakiewicz et al., 
2013; Srivastava & Ernst, 2013). Studying the role of T-cells in granuloma development in the mouse 
models showed, that despite T-cells low ability to undergo migration arrest, those cells can increase the 
inflammation in the infection site through macrophage activation. The early observations suggested that 
the molecules responsible for Mtb control are IFN-γ and IL-12p40 (Cooper et al., 1993; Cooper, 
Magram, Ferrante, & Orme, 1997), however those observations have been later questioned since in 
humans the increase in the IFN-γ producing T-cells did not correlate with improved infection outcome. 
Using gene-deleted and bone marrow chimera mice later on proved that T-cell produced IFN-γ prevents 
the accumulation of neutrophils and regulates IL-17 activity in the inflamed site, as well as it prevents 
the accumulation of activated T-cells in the lesions (Desvignes & Ernst, 2009; Nandi & Behar, 2011; 
Pearl, Saunders, Ehlers, Orme, & Cooper, 2001).  
Apart from all of the advantages of the mouse as a small and sustainable in-vivo model of TB, 
an additional opportunity is its use to test drug and vaccine efficacy and action (Cooper, 2014). In this 
case, due to the broad repertoire of available strains and mutants, it is up to the investigator to choose 
the most suitable model. The challenge of the study design lies in the choice of mouse in which crucial 
features influenced by the tested drug or vaccine precisely reproduce the human system. 
1.4.3. Murine models of TB: 129S2 and C57BL/6 
Murine models of TB include a broadly used low susceptible C57BL/6 strain and the highly 
susceptible 129S2 strain (Medina & North, 2001) on which I focus in this thesis. Even though the 
precise mechanisms responsible for the varying phenotype of those two mouse strains after infection 
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with intracellular pathogens have not been elucidated yet, it is speculated that the occurrence and the 
scale of IFN triggered inflammation as well as several identified genetic differences are among the 
contributors (Davidson et al., 2014; Dorhoi et al., 2014; Govoni et al., 1996; Howes et al., 2016; 
Kayagaki et al., 2011). The susceptible 129S2 mice succumb to TB within 40 days post infection (p.i.) 
which is related to excessive IFN type I signaling (Dorhoi et al., 2014), whereas the C57BL/6 mice 
remain healthy and control the infection up to 300 days (Dorhoi et al., 2014; Medina & North, 2001; 
Turner et al., 2001). While the lesions formed by the C57BL/6 strain are small and organized, with 
necrosis observed only at the very advanced infection stage, the 129S2 strain develops necrotic, human 
granuloma resembling structures (Beamer & Turner, 2005). One of the aims of this thesis is to assess, 
which of the human immune responses to TB are mimicked by the described mouse strains and what 
are the reasons underlying their different susceptibility to TB. 
1.4.4. Challenges related to the use of animal models 
With the rise of high throughput genetic technologies the accuracy of mouse model has been 
massively questioned (Lin et al., 2014; Mestas & Hughes, 2004; Seok et al., 2013; Shay et al., 2013; 
Takao & Miyakawa, 2014). On the transcriptomic level the two organisms reveal differences in some 
of the immune response elements, e.g. cytokine level or NK-cell signaling which, however, is difficult 
to directly associate with a phenotype. The comparison between heterologous data derived from 
species-specific experimental settings and different technology platforms, as is the case for human and 
murine studies, remains a challenge because the data cannot be aggregated and evaluated within a 
simple statistical framework. This can lead to controversial findings, as described in the following. 
In 2013 a comparison of transcriptional profiles of seven non-stimulated murine and human 
cell lineages collected during immune system development showed similar global expression profiles 
of corresponding cell types in mouse and man (Shay et al., 2013). A year later another study presented 
differences in the transcriptional landscapes of the two organisms by describing groups of genes which 
were tissue-specific or ubiquitous, and identifying a subset of the latter driving the species-specific 
expression (Lin et al., 2014; Shay et al., 2013).  
In 2013 and 2014, the first studies comparing murine and human response to immune system 
stimulation on the transcriptional level resulted in contradictory verdicts about similarity of gene 
expression regulation in the two species (Seok et al., 2013; Takao & Miyakawa, 2014). Both studies 
were conducted using the same datasets from total blood leukocytes from patients and corresponding 
murine models and applied a correlation approach to identify the similarities. However, not only the 
biological but also statistical assumptions of the two groups were incompatible, leading to markedly 
different findings. The first group assumed that the comparison of murine and human gene expression 
should be performed using all mice and measured features, while the second group hypothesized that 
due to evolutionary differences murine models should mimic human disease only partially and therefore 
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chose the most appropriate mouse model and selected only the genes, which were differentially 
expressed in both species. Seok et al. (2013) implemented Pearson’s correlation coefficient in the 
comparison, while the comparison by Takao et al. (2014) was based on the Spearman’s correlation. 
Recently, another study approached the identification of corresponding immune responses in mouse 
and man by collecting over 5,000 immune system-specific co-regulated gene sets based on publicly 
available datasets from mice and men (Godec et al., 2016). This collection defines gene modules 
regulated concordantly in immunologically relevant comparisons of various cell-state perturbations and 
diseases from either human or murine studies and suggests how to identify the genes which drive 
phenotypic differences in both species. 
So far, a universal method to compare transcriptome profiles from heterogeneous datasets has 
been missing. The existing approaches interpret lack of evidence for similarity as evidence of lack 
thereof and aim at detecting concordances disregarding possibly existing discordantly regulated 
elements of the immune response of two organisms. The vast collection of co-regulated genes applies 
exclusively to human and murine studies (Godec et al., 2016). The correlation coefficients-based 
methods create a risk of identifying a group of discordantly regulated genes as similar if they show a 
positive correlation coefficient. In analogy, relying on direction of regulation (up- or down-regulated) 
alone to define similarity of gene expression disregards the precision of the estimated changes in gene 
expression, including confidence intervals, p-value and effect size which are the indicators of biological 
importance of the genes regulated in a particular disease.  
In this thesis, I introduce a method which allows identifying highly concordantly as well as 
highly discordantly regulated gene sets between two organisms. The method is based on measuring 
concordance using directionality of change weighted by the magnitude of gene expression change in 
two heterologous datasets (for example, human and murine) and associated precision of its estimate. To 
this end, the approach combines a novel measure of similarity with GSEA and is validated by a 
simulation study as well as by identification of known similarities between datasets.  
1.5. GENE SET ENRICHMENT ANALYSIS REVEALS THE 
BIOLOGY BEHIND TRANSCRIPTOMIC PROFILES 
This part of the introduction has been adapted from the publication co-authored by me, 
published in September 2016 in the PeerJ Preprints (Weiner & Domaszewska, 2016).  
Functionally related, co-regulated or interacting genes are collected and annotated by 
biologists in clusters called gene sets. Gene sets derived from already described studies, related to 
known biological effects enable prediction of programs activated by an organism in novel datasets. In 
the context of gene expression studies in infectious diseases, transcriptomic profiles discriminating 
between infected and healthy individuals can help to monitor disease progression and reveal or compare 
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immune responses against pathogens. For this reason, I applied GSEA broadly in my research, to 
understand the biological background of the structure of the analyzed datasets as well as the analysis 
outcomes.   
Several studies attempted to determine meaningful relationships between genes based on their 
co-expression under various environmental conditions (Bar-Joseph et al., 2003; Liu, Jessen, 
Sivaganesan, Aronow, & Medvedovic, 2007). An important strategy for blood microarray data analysis 
by identifying genes co-expressed across multiple disease conditions and classifying them into 28 blood 
transcriptional modules was developed in 2008 (Chaussabel et al., 2008). Later, 334 BTMs were 
annotated according to biological function or tissue-specific expression (Li et al., 2014). Those two sets 
of BTMs have proved to successfully identify immune responses e.g. for autoimmune diseases or to 
pyogenic bacteria in patients carrying mutations in pathways responsible for pathogen sensing (Alsina 
et al., 2014; Pascual, Chaussabel, & Banchereau, 2010). Other widely used gene collections used in 
transcriptomic studies are gene ontology (GO) sets (Ashburner et al., 2000; 
The Gene Ontology Consortium, 2017), signaling pathway related sets such as KEGG pathways 
(Minoru Kanehisa, Furumichi, Tanabe, Sato, & Morishima, 2017) and the collections available in the 
Molecular Signatures Database (MSigDB; Subramanian et al., 2005). Given a wide scope of biological 
annotation and manual curation, the custom-created gene sets can serve to functionally annotate 
observed changes in gene regulation, pre-select transcripts crucial for a disease development and 
immune response and they can be used as a diagnostic tool for detection of disease (Berry et al., 2010), 
its progression, possible treatment outcomes or best vaccination type. 
A typical preliminary output of transcriptomic dataset analysis in a list of genes with their 
associated fold-changes and p-values in comparison between two conditions (e.g. disease and healthy). 
This list can serve as an input to GSEA which can be performed using the above-mentioned gene sets 
(in case of this thesis - mostly BTMs, if not described otherwise). In a first commonly used approach, 
the list of genes is divided into two groups: “foreground” with genes differentially regulated between 
the investigated conditions and “background” containing the remaining genes. Then a hypergeometric 
test is used to test for enrichment with the null hypothesis that there are no more genes belonging to a 
given module among the foreground than among the background genes. The drawback of this approach 
is a necessity of setting an arbitrary p-value or fold change threshold to define the foreground and the 
background, which influences the GSEA results and which results in incomparable results between 
studies with different sample sizes.  
A similar problem occurs if the GSEA is calculated based on statistics from differential 
analysis, for example by combining the p-values obtained for genes using Fisher’s method. In another 
approach the initial list of genes is ranked and ordered by the changes between experimental conditions 
and enrichment occurring towards the top of the list is detected, like in the widely-used GSEA analysis 
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of MSigDB collections using randomization tests (Subramanian et al., 2005). Here, sufficiently large 
sample size and high memory and CPU are required for efficient module detection due to use of 
randomization. GSEA is also not easily compatible with differential expression analysis, for example 
from the R package limma (Ritchie et al., 2015).  
Due to pitfalls of the above mentioned methods in this thesis, I implemented GSEA approach 
integrated in a novel R-package tmod (Weiner & Domaszewska, 2016) which endorses statistical test 
for enrichment on the ordered lists of genes and is based on an analytical solution rather than 
permutation or randomization. Tmod testing is suitable for integration with multivariate approaches and 
it supports use of the BTMs as well as any other custom-created gene sets. Importantly for the presented 
meta-analytical study as the one presented in my thesis tmod contains visualization strategies allowing 
comparisons of GSEA results among different time points and conditions. The package provides a 
choice of statistical methods to assign the significance of enrichment analysis including the 
hypergeometric test, Mann-Whitney “U” test and CERNO test (Yamaguchi et al., 2008). Both U test 
and CERNO test are performed on the ranked gene lists. The null hypothesis of the U test is that the 
genes belonging to different gene sets are distributed equally along the gene list and therefore that the 
mean ranks of the genes from every module are comparable. tmodCERNOtest originates from Fisher's 
combined probability test. It gives higher importance to lower ranking genes which results in p-values 
better corresponding to the observed effect size. In effect, modules with small effect but containing 
more genes get higher p-values than in case of the U-test. To overcome the biases of the hypergeometric 
test, in my analyses I used the highly sensitive CERNO test. 
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1.6. MOTIVATION 
This thesis consists of two parts, both of which are related to analysis of host transcriptomic 
data in TB and are influenced by the variety of symptoms and outcomes caused in hosts by Mtb 
infection.  
In the first part, I collected publicly available datasets of TB patients and analyzed them 
together in a single meta-analysis framework designed to identify individual variability in the response 
to TB presented by TB patients with use of GSEA, PCA, correlation networks and RF ML approaches. 
The aim was to investigate whether (i) the common trends described in the single transcriptomic studies 
of TB patient cohorts as well as in the meta-analyses capture variants of transcriptomic programs 
activated upon encounter with Mtb by individuals or whether (ii) they are representative only for the 
elements of immune response regulated in the highest order of magnitude, ignoring the immune 
response elements which are modified more subtly but at the same time influence the disease outcome. 
The answer to this question can change our current understanding of TB since presence of different 
types of immune response to Mtb infection in different hosts would mean that not only the scale of 
pathology can differ in individuals, but also the disease landscape, categorizing it as either inflammatory 
disease, immunodeficient or rather autoimmune reaction depending on the interaction with the 
individual host. 
 In the second part of this thesis, I collected human and murine datasets from TB patients and 
healthy donors acquired from publicly accessible sources and experimentally by my colleagues from 
the MPIIB, Department of Immunology. The murine datasets were derived from two different 
frequently used mouse models of TB presenting drastically different outcome of Mtb infection- one 
being susceptible and the other one resistant to TB. I used the acquired datasets to answer the question 
whether the used mouse strains are appropriate models of human TB. I assigned orthologous gene pairs 
between human and murine datasets and tested the previously described correlation methods to 
delineate similarity in gene expression between man and mouse but did not obtain any significant 
results. Therefore, I aimed to establish a method of comparison of human and murine datasets in order 
to answer the question as to which of the used murine models of TB closely mimics the active disease 
in man on transcriptomic level. In particular, I wanted to investigate if the similarity between human 
disease and its animal models can be assessed in a binary way- “similar” or “dissimilar” or if the 
evolution-based difference between the organisms implies that there are elements of immune response 
which are regulated in similar way and others which present independent or even discordant regulation. 
With a robust statistical method this question could be addressed in the context of the investigated 
mouse strains and human data as well as applied to other dataset comparisons.   
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2. CHAPTER 2: METHODOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The challenge in the analysis of datasets derived from various cohorts or different organisms, 
investigated with diverse study designs, and using distinct technologies lies in the data integration. It 
should allow the analysis of different datasets in a coherent, single pipeline and at the same time 
preserve the meaningful information contained in every separate study. Selection of datasets included 
in meta-analysis must assure data compatibility. It causes difficulties if the expression measurements 
have been conducted on different microarray platforms, for example when the arrays measured the 
expression of non-overlapping genes. Comparison of the gene expression data from different species 
adds another level of complexity imposed by genome evolution involving gene deletion and duplication 
events. This results in a challenging task of mapping the genes which cannot be straightforward mapped 
one-to-one. The aim of this section is to introduce and document the methods which I used to integrate 
the human datasets derived from different studies and to introduce the disco.score – a method created 
to compare gene expression data from different species. I list and briefly characterize the acquired 
datasets and explain the implemented normalization procedures. Next, I describe exploratory data 
analysis which was performed to understand the influence of population-related and technical factors 
on the differences seen between immune responses of TB patients. I explain the used unsupervised and 
supervised ML techniques to further explore the biological consequences of the observed variability 
among the TB patients. Last, I introduce and describe the validation of the disco.score. 
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2.1. OVERVIEW 
In this chapter I describe the implemented data analysis approaches which led to the 
identification of individual variability in immune response to TB among human patients and the 
methodology which allowed the identification of concordant and discordant elements of immune 
response to TB in mouse and man. 
All the subsequent data analysis steps have been performed in R programming language for 
statistical computing (R Core Team, 2018) and the code is available upon request. All the included 
datasets are publicly available on GEO database (Edgar, Domrachev, & Lash, 2002). The subchapters: 
2.2, 2.3 and 2.4 describe the data acquisition, preprocessing and normalization steps common for both 
projects. The subchapters 2.5 to 2.16 describe the analysis of individual variability among TB patients. 
The subchapters 2.17 to 2.20 describe the methods implemented in comparing murine with human 
transcriptomic datasets.  
Datasets collected within BioVacSafe project were kindly shared with me by Jeroen 
Maertzdorf and January Weiner.  
The experimental procedures described in the chapters 2.2.4, 2.2.5, 2.2.6, 2.2.7, and 2.2.8 have 
been performed by my colleagues Lisa Scheuermann, Anca Dorhoi, Karin Hahnke from MPIIB, 
Department of Immunology and Hans Mollenkopf from Microarray Core Facility of MPIIB, and 
described by Lisa Scheuermann and Anca Dorhoi. Those listed sub-chapters are identical as in the 
publication which we published in September 2017 in Scientific Reports (Domaszewska et al., 2017).  
The datasets generated during the current study are available in the GEO repository under 
accession ID GSE89392. The created R-package disco is available on CRAN, under the link: 
http://cran.r-project.org/web/packages/disco/. The created data collections and module sets can be 
accessed on the website: http://bioinfo.mpiib-berlin.mpg.de/TBprofiles/.  
2.2. DATA ACQUISITION 
All datasets used for multi-cohort analysis of human WB transcriptomic profiles of patients 
with TB are publicly available in GEO data repository (Edgar et al., 2002). The datasets have been 
acquired using the R-package GEOquery (Davis & Meltzer, 2007). Out of the datasets used for 
comparison of human and mouse transcriptomic responses to TB five were publicly available on GEO. 
One dataset was acquired experimentally and kindly shared with me by Anca Dorhoi from MPIIB, 
Department Immunology, and one dataset was acquired experimentally according to jointly planned 
experiment by my colleague Lisa Scheuermann from MPIIB, Department of Immunology. The 
microarray sample preparation was performed by Karin Hahnke from MPIIB, Department of 
Immunology and microarray experiments by Hans Mollenkopf in Microarray Core Facility of MPIIB 
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in Berlin. The datasets obtained in this study have been uploaded to GEO under accession ID 
GSE89392. 
2.2.1. Acquisition of publicly available datasets for TB multi-cohort analysis 
Out of multiple publicly available transcriptomic datasets from blood of TB patients I decided to 
include 7 studies to create a combined meta-dataset (MDS) and two validation datasets (Table 3). 
The presented datasets met the following criteria: 
 Contained at least data from untreated TB patients and HCs 
 Contained at least 8 samples in each of the groups: TB patients and HC (including 
LTBI) 
 Were performed using platforms which measured at least 18,000 common genes 
 Were performed using platforms with annotation available in BiomaRt R package 
(Durinck et al. 2005, 2009) 
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Table 3 List of publicly available studies acquired for TB multi-cohort analysis 
The accession number refers to the GEO dataset identifier. The study location refers to the cities or countries where the patients 
were recruited. Number of cases defines the number of TB patients, other disease (OD) patients and healthy (including latently 
infected) individuals (HC) included in each study. 
MDS 
Accession number Citation Study location Number of cases 
GSE19491 (Berry et al., 2010) London, SA 54 TB  
96 OD  
93 HC 
GSE47673 (Kaforou et al., 2013) Malawi, SA 215 TB  
194 OD  
175 HC 
GSE28623 (Maertzdorf, Ota, et al., 
2011) 
The Gambia 46 TB  
62 HC 
GSE34608 (Maertzdorf et al., 2012) Germany 8 TB 
18 sarcoidosis  
18 HC 
GSE42834 (Bloom et al., 2013) London 35 TB 
91 OD  
113 HC 
GSE39941 (Anderson et al., 2014) SA, Malawi, Kenya 114 TB  
175 OD  
57 HC 
GSE73408 (Walter et al., 2016) USA 35 TB  
39 pneumonia  
35 HC 
Validation datasets 
Accession number Citation Study location Number of cases 
GSE54992 (Cai et al., 2014) China 9 TB 
12 HC 
GSE83456 (Blankley, Graham, 
Turner, et al., 2016) 
 45 TB 
47 EPTB 
49 OD 
61 HC 
 
The dataset collection selected for the study can be accessed on the website: http://bioinfo.mpiib-
berlin.mpg.de/TBprofiles/  
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2.2.2. Acquisition of publicly available sepsis datasets for the validation of 
methods 
I acquired three publicly available sepsis datasets for the validation of methods used to analyze 
the TB datasets. 
Table 4 List of publicly available studies acquired for sepsis multi-cohort analysis 
The accession number refers to the GEO dataset identifier. The study location refers to the cities or countries where the patients 
were recruited. Number of cases defines the number of sepsis patients, other patients and healthy individuals (HC) included in 
each study. 
Accession 
number 
Citation Study location Number of cases 
GSE13904 (Wong et al., 2009) USA 32 sepsis 
67 septic Shock 
22 SIRS 
18HC 
GSE9960 (Tang, McLean, Dawes, Huang, & Lin, 2009) Australia 70 sepsis 
GSE28750 (Sutherland et al., 2011) Australia 27 sepsis 
30 post-surgical sepsis 
20 HC 
 
2.2.3. Acquisition of GEO datasets for the comparison of mouse and human 
This part of the Methods has been adapted from my publication published in September 2017 
in Scientific Reports (Domaszewska et al., 2017) and contains fragments related to the experimental 
procedures (2.2.4, 2.2.5, 2.2.6, 2.2.7,2.2.8) described by my colleagues Lisa Scheuermann and Anca 
Dorhoi from MPIIB, Department of Immunology, who conducted the experiments. Those listed sub-
chapters are identical as in the publication (Domaszewska et al., 2017). 
To compare transcriptomic responses against TB in man and mouse I investigated two types of cells: 
WB cells and macrophages. Blood is a carrier of immune system molecules in the organism and 
macrophages play a crucial role in the Mtb infection. Therefore, I acquired the following publicly 
available datasets to compare them with each other as well as with the datasets collected in MPIIB by 
Lisa Scheuermann and Anca Dorhoi (Department of Immunology) with the help of Karin Hahnke 
(Department of Immunology) and Hans Mollenkopf (Microarray Core Facility) (Table 5).  
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Table 5 List of publicly available studies acquired for comparison of human and murine immune response to TB  
The column “Dataset name” refers to the names further used in this chapter and in the Chapter 4. The cohort described by 
Kaforou et al. (2013) contains patients from two geographical locations: SA and Malawi, which have been analyzed separately. 
Accession 
number 
Citation  Organism Sample 
type 
Time points Number of 
cases 
Dataset 
name 
GSE37250 
  
(Kaforou et 
al., 2013) 
Homo sapiens blood N/A 215 TB  
194 OD  
175 healthy  
SA, Malawi 
GSE28623 (Maertzdorf, 
Ota, et al., 
2011) 
Homo sapiens blood 
  
N/A 46 TB  
62 healthy
  
The Gambia 
GSE11199 (Thuong et 
al., 2008) 
Homo sapiens MDM before infection, 
4h p.i. 
4 pulmonary TB  
4 TB meningitis  
4 healthy  
GSE11199 
GSE47673 (McNab et 
al., 2011) 
Mus musculus BMDM before infection, 
1h p.i., 6h p.i. 
4 M.tb. infected  
4 uninfected  
GSE47673 
GSE23508 (Carow et 
al., 2011) 
Mus musculus BMDM before infection, 
24h p.i. 
4 M.tb. infected  
3 uninfected  
GSE23508 
2.2.4. Mice and Mtb infection 
129S2 (129SvPas) mice were bred and kept under specific pathogen-free (SPF) conditions at 
the MPIIB in Berlin, Germany. C57BL/6 animals were purchased from Charles Rivers Laboratories. 
Mice were matched for age and sex and co-housed for at least two weeks under SPF conditions at the 
MPIIB in Berlin, Germany before start of the experiments. At the time of infection, all mice were 9–12 
weeks of age. Aerosol infection with Mtb strain H37Rv and enumeration of bacteria in lung tissue were 
performed as previously described (Dorhoi et al., 2013). All experiments were approved by the State 
Office for Health and Social Affairs (Landesamt fuer Gesundheit und Soziales) and conducted in 
accordance with German Animal Protection Law. 
2.2.5. Blood collection and RNA isolation 
At indicated time points mice were anesthetized by intraperitoneal injection of 16 mg/kg 
bodyweight Rompun and 120 mg/kg bodyweight Ketavet in PBS.  Blood was drawn from the inferior 
vena cava of all mice using a 26G needle. 200 μl of blood were directly transferred into 800 μl of 
TRIzol® (Invitrogen). Total RNA extraction of all blood samples was performed according to the 
manufacturer’s instructions. The RNA yield and A260/280 ratio were measured with a NanoDrop ND 
100 spectrometer (NanoDrop Technologies), and RNA integrity was verified using an 2100 Bioanalyzer 
(Agilent Technologies) with a RNA integrity number (RIN) higher than 7. 
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2.2.6. Blood microarrays 
Total RNA of blood samples was labeled with the Low Input Quick Amp Labeling (Agilent 
Technologies) according to manufacturer’s instructions. Quantity and labeling efficiency were verified 
before hybridization of the samples to SurePrint G3 Mouse GE 8x60K Microarray (Agilent 
Technologies, Product Number G4852A, Design ID 028005). Scanning of microarrays was performed 
with 3 μm resolution using a high-resolution laser microarray scanner (Agilent Technologies 
G2565CA). Quality, reproducibility, and reliability of single microarray data was accessed by the 1-
color gene expression QC report from Agilent Technologies. 
2.2.7. Acquisition of THP1 data  
The human monocytic cell line THP-1 (ATCC TIB-202) was maintained in RPMI 1640 
(Gibco), supplemented with 10% (v/v) heat-inactivated fetal calf serum (Gibco), 1% (v/v) penicillin–
streptomycin (Gibco), 1% (v/v) L-glutamine (Gibco), 1% (v/v) HEPES buffer (Gibco) and 0.05 M 2-
mercaptoethanol (Gibco). Cells were differentiated into macrophages by treatment with 50 ng/ml of 
phorbol 12-myristate 13-acetate (PMA, Calbiochem). Subsequently they were rested for 48 hours and 
afterwards infected with single-bacterial suspensions of the virulent strain H37Rv, at a multiplicity of 
infection of 5. At 1, 6 and 24 h following infection, macrophages were lysed with 4M guanidine 
isothiocyanate solution (Invitrogen), eukaryotic RNA was stabilized in Trizol LS (Invitrogen) and 
extracted according to vendor’s instructions. The RNA yield was detected with a NanoDrop ND 100 
spectrometer (NanoDrop Technologies), and RNA integrity was estimated using the 2100 Bioanalyzer 
(Agilent Technologies). 
2.2.8. Macrophage RNA microarrays 
Total RNA of infected and uninfected THP-1 control cells was labeled with the Quick Amp 
Labeling (Agilent Technologies) according to manufacturer’s instructions. After quality and labeling 
efficiency control samples were hybridized to 4x44K Whole Human Genome Microarray kits (Agilent 
Technologies, Product Number G4112F, Design ID 014850). Scanning of microarrays was performed 
with 5μm resolution using a G2565CA high-resolution laser microarray scanner (Agilent Technologies) 
using extended dynamic range (XDR). Raw microarray data were extracted with the Agilent FE 
software V10.5.1.1. and GE1_105_Dec08 protocol using default settings. 
2.3. DATA NORMALIZATION 
2.3.1. Data preprocessing 
Data analysis was performed in R version 3.4.3 (2017-11-30), and a script including all 
analytical steps is available upon request. The datasets have been analyzed with R package limma for 
differential expression analysis (Ritchie et al., 2015). In the studies where raw-datasets were available, 
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the background signal intensities have been corrected using normexp method with offset. The arrays 
have been quantile normalized. In the mouse-human study, the repeating probes were averaged in the 
last step of preprocessing which means that the intensities of the probes corresponding to the same gene 
have been combined. This step has not been made in the multicohort analysis, since the study involved 
biosignature identification on transcript level with the intention not to miss the transcripts which 
represent a biological difference, for example in case of alternative splicing. The different approaches 
result from the assumptions of the two projects: while in the inter-species comparison the conservative 
approach is preferred due to variability between host genomes, in the multi-cohort analysis I am 
intending to retain possibly high resolution.  
HGNC and ENSEMBL identifiers have been mapped to microarray probe names using 
biomaRt mapIds function (version 2.24.1; Durinck et al., 2005; Durinck, Spellman, Birney, & Huber, 
2009). 
2.3.2. Data normalization for multi-cohort analysis 
In the multi-cohort analysis, author-normalization of single studies was used. Each dataset was 
then divided into training set, containing randomly assigned 80% of the HC (including LTBI), 80% of 
other disease (OD) and 80% of the TB patients samples (or, in case of the sepsis validation dataset, 80% 
of the sepsis patient samples), and test set containing the remaining 20% of the samples. MDS was 
created out of the training sets from each study using only the common genes. Two types of 
normalization were tested to create the MDS: ComBat normalization from Bioconductor sva package 
and standardization based on median and interquartile range (IQR) values, calculated as follows: 
𝑒′𝑖,𝑗 =
𝑒𝑖,𝑗  − 𝑚𝑒𝑑𝑖𝑎𝑛 (𝑒∙,𝑗)
𝐼𝑄𝑅∙,𝑗
 
Equation 1 
Where: 
𝑒′𝑖,𝑗  – normalized expression value for gene i, 
𝑒𝑖,𝑗  – expression measurement of gene i, 
𝐼𝑄𝑅∙,𝑗  – interquartile range for expression measurement of gene i 
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2.4. DIFFERENTIAL EXPRESSION CALCULATION 
Differentially expressed genes between healthy individuals (or uninfected macrophages) and 
individuals suffering from TB (or Mtb infected macrophages) were identified by creating linear model 
which included the factors: stimulus type (“TB” and “healthy” or “Mtb infected” and “uninfected”) and 
time point using lmFit function from the R package limma (Ritchie et al., 2015). The p-values were 
calculated based on the moderated t-statistic.  
In multicohort analysis the differential regulation of genes was calculated after the 
preprocessing as well as after the normalization described in the chapter 2.3.2. To investigate the 
influence of normalization on the order of differentially regulated genes GSEA was performed for every 
dataset before and after the normalization using R package tmod (Weiner & Domaszewska, 2016). 
2.5. GSEA FOR INDIVIDUAL PATIENTS 
To perform GSEA for individual patients, gene expression was expressed as z-score. For every 
gene, mean expression and standard deviation of gene expression were calculated for healthy 
individuals from a given cohort. Then, the mean gene expression based on healthy individuals was 
subtracted from the expression measurement of every individual present in the MDS and the result was 
divided by standard deviation of gene expression for the healthy patients. The z-score was calculated 
based on two-sided t-test for the resulting values. 
𝑒′𝑖,𝑗 =
𝑒𝑖,𝑗  − 𝑚𝑒𝑎𝑛 (𝑒∙,𝑗)
𝑠𝑑∙,𝑗
 
Equation 2 
𝑧 − 𝑠𝑐𝑜𝑟𝑒 = 𝑝𝑛𝑜𝑟𝑚(𝑒′) 
Equation 3 
Where: 
i, j - sample, gene 
𝑒′𝑖,𝑗  – normalized expression value for gene ‘i’, 
𝑒𝑖,𝑗  – measured expression value of gene ‘i’, 
𝑚𝑒𝑎𝑛 (𝑒∙,𝑗)– mean measured expression of gene ‘i’ across all samples, 
𝑠𝑑∙,𝑗  – standard deviation of expression measured for gene ‘i’ across all samples   
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GSEA was performed for every individual on the list of genes sorted by increasing z-score 
using tmodCERNOtest function from the R-package tmod (Weiner & Domaszewska, 2016) and two 
sets of gene modules (Chaussabel et al., 2008; Li et al., 2014). 
2.6. DEFINITION OF IFN TYPE I AND IFN TYPE II MODULES 
The module sets defined by Li et al. (2014) and Chaussabel et al. (2008) are based on the 
analysis of gene co-expression, in contrast to other frequently used knowledge-based module sets (like 
GO sets or WikiPathways). It implies that the genes present in the same module might not share the 
same function or belong to the same signaling pathway. Moreover, a module can consist of a collection 
of genes the functions of which are only partly known or even completely undefined. For this reason, I 
decided to implement the knowledge-based distinction into IFN type I and IFN type II induced genes 
into the modules created by Li et al. and Chaussabel et al. and in each module identified the genes 
regulated by type I IFN, type II IFN and type I and II IFN signaling pathways together. I referred to 
Interferome v2.0 database (Rusinova et al., 2012) to specify which of the genes included in the 
immunological modules are classified as specifically type I IFN response genes, type II IFN response 
genes or both. The modules DC.M5.12, LI.M158.0 and LI.M158.1 contained mostly genes activated 
exclusively by type I IFN signaling, and the modules LI.M127, LI.M75, DC.M1.2, DC.M3.4 contained 
mostly genes activated by both type I and type II IFN signaling pathways. I created three module sets 
based on the published gene modules created by Li et al. and Chaussabel et al. (Chaussabel et al., 2008; 
Li et al., 2014) and the classification of genes into IFN type I activated genes, type II IFN activated 
genes and the genes activated by both type I and type II IFN signaling pathways according to 
Interferome v2.0 database (Rusinova et al., 2012) (Supplementary Tables 1-4). The created sets 
consisted of genes which overlapped between originally defined modules and the genes from the MDS 
classified by Interferome database either as IFN type I inducible genes, IFN type II inducible genes or 
IFN type I and type II inducible genes. Additional two modules contained (i) all genes classified as IFN 
type I genes and (ii) all genes classified as IFN type II genes, independent of their original module 
identity understood as presence in a particular Li et al (2014) or Chaussabel et al. (2008) module set. 
  
55 
 
2.7. IDENTIFICATION OF IFN+ AND IFN- PATIENTS 
GSEA was performed on the list of genes from every individual present in MDS sorted by 
increasing z-score using the three created module sets. The individuals presenting no significant 
enrichment in any of the IFN type I modules were classified as “IFN I-”. The individuals presenting 
enrichment in at least one IFN type I module were classified as “IFN I+”. Similarly, the “IFN II-” and 
“IFN I and II-” individuals presented no enrichment in the IFN type II or IFN type I and II module set 
respectively, and those presenting enrichment were classified as “IFN II+” or “IFN I and II+”. 
Ultimately, the overlap between “IFN I+”, “IFN II+” and “IFN I and II+” patients was analyzed and 
compared to classification to “IFN+” and “IFN-” patients based on the original sets of modules 
published by Li et al. (2014) and Chaussabel et al. (2008). 
2.8. LOGISTIC REGRESSION 
Each sample in MDS was characterized with the following criteria: study, ethnicity, residence, 
nationality, TB status, HIV status, other detected diseases and IFN status. Two logistic regression 
models were fit using glm function from R package stats (R Core Team, 2018), with IFN status as 
dependent variable and TB status, study, ethnicity, residence, HIV and OD as predictor variables using 
whole MDS (i), and study, ethnicity, residence, HIV and OD as predictor variables using only the subset 
of data characterized by active TB (ii). 
2.9. IDENTIFICATION OF CONCORDANT AND DISCORDANT 
GENES BETWEEN IFN+ AND IFN- TB PATIENTS 
I calculated differential expression of genes between TB IFN+ patients and healthy and TB 
IFN- patients and healthy. Subsequently, I used R package disco to calculate disco.score expressing the 
concordance and discordance of gene regulation to identify the concordantly and discordantly regulated 
genes between IFN+ and IFN- patients.  
2.10. CYTOKINE CONCENTRATIONS IN BLOOD OF IFN I+ 
AND IFN I- INDIVIDUALS 
Mtb infection is one of the many known stimulations of IFN response. To validate the 
approach of dividing people into IFN- and IFN+ individuals I searched for other stimuli inducing IFN 
response and datasets containing both transcriptomic studies of the WB of the patients with such 
stimulations as well as measurements of the actual levels of the IFN-inducible cytokines in blood of 
those patients. Other factors inducing IFN response include for example influenza virus infection. The 
vaccines against influenza cause strong IFN response in humans (Athale et al., 2017; Banzhoff et al., 
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2008). Datasets collected within BioVacSafe project kindly shared with me by Jeroen Maertzdorf and 
January Weiner were derived from blood of 114 healthy volunteers who underwent FLUADTM 
vaccination. I used the datasets to compare GSEA-based IFN I-status definition with the blood absolute 
concentrations of cytokines CXCL10 and CCL2, which are inducible by IFN type I signaling. Blood 
samples were collected before the vaccination on the vaccination day and at day 1 after the vaccination. 
The samples were used to perform microarrays and cytokine measurements. The dataset is available 
upon request.  
GSEA was calculated using the IFN type I module set and each sample was assigned IFN I+ 
or IFN I- status as described before. The fold change between absolute blood concentrations of 
cytokines CXCL10 and CCL2 in day 1 post vaccination and before the vaccination were calculated for 
the IFN I+ and IFN I- samples. 
2.11. CORRELATION BETWEEN IFN STATUS AND DISEASE 
SEVERITY 
The dataset GSE19491 (Berry et al., 2010) was used to compare the IFN status with the disease 
severity assessed on the basis of lung X-Ray studies of TB patients and HCs. The IFN type I status was 
assessed using microarray results and GSEA as described above for all the participants of the study (61 
TB patients, 105 HCs including 69 LTBI, and 274 OD patients). 72 individuals from the study cohort 
underwent the lung X-Ray investigation and were diagnosed as “healthy” (n = 34), “minimal disease” 
(n = 14), “moderate disease” (n = 13), or “advanced disease” (n = 11) by doctors blinded to the 
microarray results and the clinical diagnosis of the patients. The X-Ray based diagnosis was compared 
with the IFN I status calculated using GSEA. 
2.12. MACHINE LEARNING METHODS 
2.12.1. Unsupervised Machine Learning - PCA 
PCA was performed on the MDS as well as on the subset of MDS containing only samples 
from active TB patients using R-packages stats, pca3d and tmod (R Core Team, 2018; Weiner, 2017; 
Weiner & Domaszewska, 2016). The fraction of variance explained by each factorial predictor 
(including TB status, IFN status, study, ethnicity, residence, HIV, OD, microarray platform) was 
calculated for each principal component using prcomp function from the stats package which performs 
singular value decomposition of the centered and scaled data matrix (R Core Team, 2018). Among the 
first 11 PCs I searched for two PCs explaining the highest proportion of variance for each factor detected 
as significant by logistic regression (described in the chapter 2.8) using 100-fold randomization. The 
two PCs with the highest fit (r2 – coefficient of determination) were chosen. The randomization as well 
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as data distribution along the two chosen PCs was illustrated. GSEA for PCs was calculated on the 
genes ranked by their weights in a given PC and visualized using R-package tmod.  
2.12.2. Supervised Machine Learning - Random Forest models 
Random Forest models with 10-fold cross validation 
RF models were created to classify patients of TB with or without IFN response and (i) healthy, 
(ii) OD, (iii) non-TB (containing both healthy and OD) patients as shown in Table 8 in the Chapter 3. 
The appropriate subsets of the training MDS containing TB patients with or without IFN response and 
(i) HCs, (ii) OD patients, (iii) non-TB patients were selected and split into 10 folds. Class balancing 
was used to retain the proportion of one case to three control individuals. The RF models were 
repetitively trained on the data from 9 folds and tested on the remaining fold. Performance of the models 
was evaluated by creating receiver-operator characteristic (ROC) curves. 
Additional six RF models were created in analogical way with exclusion of genes involved in 
IFN I signaling to investigate their influence on the RF results (Table 8).  
The RF models were created using R package randomForest (Kuhn, 2008; Liaw & Wiener, 
2002) and cross-validation was performed using R package caret (Kuhn, 2008). The ROC plots were 
created using R package pROC (Robin et al., 2011). 
Determination of the signature size 
To determine the biosignatures of IFN- and IFN+ TB patients I used the models 5 and 6 
described in the Table 8 in the Chapter 3 since those models identified TB patients among all other 
patient groups – HC, LTBI and OD. To determine the minimal number of transcripts required to 
discriminate TB from other patient groups I sorted the transcripts in both models by decreasing variable 
importance. I defined the TB IFN+ and TB IFN- signatures consisting of top (i) 5, (ii) 7, (iii) 10, (iv) 
20, (v) 50 or (vi) 200 ranking transcripts, and created new models trained only with use of the selected 
transcripts. I then tested the new models using 10-fold cross validation within the training MDS and 
evaluated the performance of the models using ROC plot. The size of biosignature giving AUC higher 
than 0.8 with possible small number of included transcripts was chosen as the optimal biosignature size.  
Determination of the TB IFN+ and TB IFN- biosignatures 
For the detection of TB IFN+ and TB IFN- biosignatures two new RF models with class 
balancing retaining the proportion of one TB to three non-TB cases were trained using the subsets of 
the complete training MDS subsets containing (i) all TB IFN+ and non-TB (Biosignature Model 1), (ii) 
all TB IFN- and non-TB (Biosignature Model 2). A biosignature of 20 top ranking transcripts from the 
Biosignature Model 1 sorted by variable importance was defined as IFN+ biosignature. A biosignature 
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of 50 top ranking transcripts from the Biosignature Model 2 sorted by variable importance was defined 
as IFN- biosignature. 
Testing of the TB IFN+ and TB IFN- biosignatures 
The obtained TB IFN+ and TB IFN- biosignatures were tested on the test MDS and their 
performance has been evaluated using ROC. 
Validation of the TB IFN+ and TB IFN- biosignatures 
The obtained TB IFN+ and TB IFN- biosignatures were tested on the external dataset from 
Cai et al. and their performance has been evaluated using ROC. 
2.13. VALIDATION OF THE SIGNATURE FINDING PIPELINE 
ON SEPSIS META-DATASET 
Sepsis training and test MDS were created following the steps described in the chapters 2.2 
and 2.3. GSEA was calculated for individual patients in the sepsis training and test MDS and the IFN 
status was assigned to the individual donors as described in the chapters 2.5 and 2.7. For the detection 
of sepsis IFN+ and sepsis IFN- biosignatures two RF models with class balancing retaining the 
proportion of one sepsis to three HC cases were trained using the subsets of the complete training sepsis 
MDS containing (i) sepsis IFN+ and healthy (Sepsis Model 1), (ii) sepsis IFN- and healthy (Sepsis 
Model 2). Biosignatures of 10 top ranking transcripts from the Sepsis Model 1 and Sepsis Model 2 
sorted by variable importance were defined as IFN+ sepsis biosignature and IFN- sepsis biosignature, 
correspondingly. The obtained sepsis IFN+ and sepsis IFN- biosignatures were tested on the sepsis test 
MDS and their performance has been evaluated using ROC. The transcripts present in the biosignatures 
were compared with previously published sepsis biosignatures. 
2.14. CORRELATION MATRIX 
Gene sets like the above described BTMs capture the relationship between transcripts 
measured on the microarrays. When annotated, they suggest biological interpretation of activation 
programs launched by cells in response to stimulation. From the systemic point of view, the co-
expression modules are components of a meta-network which reveals a higher-level organization of the 
transcriptome (Langfelder & Horvath, 2008). In other words, understanding transcript-organization in 
modules is a preliminary step to understand the network of module interactions. Exploring this network 
can be executed thanks to finding module representatives. In case of modules containing groups of 
genes with correlated expression such a representative is the eigengene, which summarizes the module 
expression profile (Langfelder & Horvath, 2008). Such defined representatives or eigengenes of BTMs 
can be correlated creating a correlation matrix informative of relationships between the different 
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modules (Langfelder & Horvath, 2008). For example, as further presented in this thesis, we can learn 
that upregulation of gene expression in a particular module can be correlated with downregulation of 
the expression of genes present in another module.  
The framework of correlation network analysis applied in this study consists of the following 
steps: 
 Identification of the most significantly enriched gene modules among TB patients in 
comparison with healthy 
 Calculation of eigengene of each module 
 Calculation of correlation matrix between the eigengenes 
 Visualization of the correlation matrix using clustering according to the correlation 
level. 
The gene modules presenting enrichment in GSEA in (i) at least one TB patient with p-value 
lower than 10-11 and AUC of at least 0.85 (in case of the human MDS), or (ii) at least one Mtb infected 
macaque with p-value lower than 10-3 and AUC of at least 0.7 (in case of the macaque dataset) were 
selected for the correlation calculation. The eigengenes of every module as well as the Pearson 
correlation between the expressions of genes in every module were calculated using the function 
cormods from R package tmod (Weiner & Domaszewska, 2016) including only the genes which 
expression was measured across all samples. Hierarchical clustering was employed to cluster the 
enriched modules according to eigengene correlation using the functions dist and hclust from R package 
stats (R Core Team, 2018). The function dist calculates distances between vectors which are rows of 
expression matrix and the function hclust performs hierarchical clustering on the calculated distances 
by initially assigning objects to their own clusters and then iteratively joining the most similar clusters 
with Ward’s minimum variance method (Ward, 1963).  
The correlation of gene expression in the clustered modules was visualized using ggplot2 R package 
(Wickham, 2009).  
2.15. DISEASE RISK SCORE APPLICATION 
I used the method described by Kaforou et al. (2013) for converting complex multiple 
transcript RNA signatures to obtain disease risk score (DRS) which is a single value score for every 
individual. I calculated the DRS on the basis of TB signatures (Kaforou et al., 2013) for three setups: 
(i) TB patients and healthy, on the basis of 27-gene TB vs healthy signature, (ii) TB patients and OD 
patients, on the basis of 44- gene TB vs OD signature, and (iii) TB patients vs non-TB, on the basis of 
53-gene TB vs non-TB signature. Depending on the setup, the classification of TB/healthy/OD/non-TB 
status on the basis of DRS calculation was assigned to every individual and compared with the IFN 
status. 
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2.16. INFLUENCE OF TIME POST INFECTION ON 
INTERFERON STATUS 
To investigate if the IFN status in individuals with active TB is the result of time p.i., a 
longitudinal dataset generated to assess changes in WB gene expression after Mtb infection in 
Cynomolgus macaques was acquired from GEO database (GSE84152; Gideon et al., 2016). The dataset 
contained microarray results collected from 38 macaques at two time points before Mtb infection and 
at days 3, 7, 10, 20, 30, 42, 56, 90, 120, 150, 180 p.i.. The samples were normalized and z-score was 
calculated using the aforementioned method (chapter 2.3, 2.5). GSEA was performed on samples from 
individual macaques. The samples were assigned IFN I+/IFN I- status which was compared with their 
binary clinical diagnosis and lung inflammation. 
2.17. ORTHOLOGS ASSIGNMENT BETWEEN HUMAN AND 
MURINE DATASETS 
A table of expected comparisons between murine and human samples was created (Table 6). 
Orthologous genes were assigned to each other between corresponding human and mouse datasets used 
in each comparison. Probe names specific to the microarray used were assigned an ENSEMBL identifier 
with use of “mapIds” function from biomaRt package (version 2.24.1; Durinck et al., 2005, 2009). 
Then, orthologous human and mouse genes were identified with biomaRt getLDS function based on 
homology mapping between different species interlinked in Ensembl database (with attributes and 
filters defined as “ensembl_gene_id”). Only the putative orthologs with a 1:1 mapping (no potential in-
paralogs) were included in the further analysis. 
Table 6 List of the comparisons performed on the human and murine datasets  
“Comparison ID” is further used in the Chapter 4. “Human dataset” column refers to (i) the cohort origin as previously 
presented in the Table 5 (The Gambia, SA, Malawi) in case of publicly available human WB datasets, (ii) datasets from THP1 
cells acquired in the MPIIB (THP1) and (iii) datasets ID from GEO in case of the publicly available human macrophage 
datasets. The column “Murine dataset” refers to (i) datasets from murine WB acquired at MPIIB (“C57BL/6” and “129S2”), 
(ii) datasets ID from GEO in case of the publicly available murine macrophage datasets. N/A – not applicable. 
Comparison 
ID 
Human 
dataset name 
Human 
tissue 
Human time 
point 
Murine 
dataset name 
Murine 
tissue 
Murine time 
point 
1 The Gambia blood N/A C57BL/6 blood Day 1 
2 The Gambia blood N/A 129S2 blood Day 1 
3 Malawi blood N/A C57BL/6 blood Day 1 
4 Malawi blood N/A 129S2 blood Day 1 
5 SA blood N/A C57BL/6 blood Day 1 
6 SA blood N/A 129S2 blood Day 1 
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7 The Gambia blood N/A C57BL/6 blood Day 7 
8 The Gambia blood N/A 129S2 blood Day 7 
9 Malawi blood N/A C57BL/6 blood Day 7 
10 Malawi blood N/A 129S2 blood Day 7 
11 SA blood N/A C57BL/6 blood Day 7 
12 SA blood N/A 129S2 blood Day 7 
13 The Gambia blood N/A C57BL/6 blood Day 14 
14 The Gambia blood N/A 129S2 blood Day 14 
15 Malawi blood N/A C57BL/6 blood Day 14 
16 Malawi blood N/A 129S2 blood Day 14 
17 SA blood N/A C57BL/6 blood Day 14 
18 SA blood N/A 129S2 blood Day 14 
19 The Gambia blood N/A C57BL/6 blood Day 21 
20 The Gambia blood N/A 129S2 blood Day 21 
21 Malawi blood N/A C57BL/6 blood Day 21 
22 Malawi blood N/A 129S2 blood Day 21 
23 SA blood N/A C57BL/6 blood Day 21 
24 SA blood N/A 129S2 blood Day 21 
25 THP1 THP1 24h GSE23508 BMDM 24h 
26 THP1 THP1 6h GSE47673 BMDM 6h 
27 GSE11199 MDM 4h GSE23508 BMDM 24h 
28 GSE11199 MDM 4h GSE47673 BMDM 6h 
29 GSE11199 MDM 4h GSE23508 BMDM 24h 
30 GSE11199 MDM 4h GSE47673 BMDM 6h 
31 GSE11199 MDM 4h GSE23508 BMDM 24h 
32 GSE11199 MDM 4h GSE47673 BMDM 6h 
33 THP1 THP1 1h GSE47673 BMDM 1h 
34 GSE11199 MDM 4h GSE47673 BMDM 1h 
35 GSE11199 MDM 4h GSE47673 BMDM 1h 
36 GSE11199 MDM 4h GSE47673 BMDM 1h 
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2.18. DISCO.SCORE CALCULATION AND GENE SET 
ENRICHMENT ANALYSIS 
I have created an R-package disco for identification and visualization of concordant and 
discordant gene modules. The disco package is available on CRAN (http://cran.r-
project.org/web/packages/disco/). Disco score was calculated for each pair of orthologous genes using 
discoScore function. Concordantly and discordantly regulated gene sets were identified by performing 
GSEA with R-package tmod (version 0.27; Weiner & Domaszewska, 2016) using CERNO statistical 
test, which is a variant of Fisher’s method adapted to GSEA (Yamaguchi et al., 2008) on the list of 
genes sorted by the decreasing or increasing disco.score, respectively. Disco.score for particular genes 
has been visualized with the color gradient on the plots presenting log2 of fold change (log2FC) of gene 
expression in stimulated vs non-stimulated organisms. 
The general formula for disco score applicable to n datasets is defined by the equation 4: 
𝑑𝑖𝑠𝑐𝑜. 𝑠𝑐𝑜𝑟𝑒 = ∑ ∑ 𝑙𝑜𝑔2𝐹𝐶𝑖 ∙
𝑛
𝑗=𝑖+1
𝑛−1
𝑖=1
𝑙𝑜𝑔2𝐹𝐶j ∙ (𝑙𝑜𝑔10𝑃𝑖 + 𝑙𝑜𝑔10𝑃𝑗)  
Equation 4 
where: 
n – number of datasets analyzed 
𝐹𝐶𝑖 - fold change for gene in the dataset i, as calculated in differential expression analysis 
𝐹𝐶j - fold change for gene in the dataset j, as calculated in differential expression analysis 
𝑃𝑖 - p-value for human gene in the dataset i, as calculated in differential expression analysis 
𝑃𝑗 - p-value for murine gene in the dataset j, as calculated in differential expression analysis 
 
In this thesis I use the formula for disco score applicable to two heterologous datasets, e.g. one 
from human patients and one from mice, defined by the equation 5: 
𝑑𝑖𝑠𝑐𝑜. 𝑠𝑐𝑜𝑟𝑒 =  𝑙𝑜𝑔2𝐹𝐶𝐻𝑠 ∙ 𝑙𝑜𝑔2𝐹𝐶𝑀𝑚 ∙ |𝑙𝑜𝑔10𝑃𝐻𝑠 + 𝑙𝑜𝑔10𝑃𝑀𝑚| 
Equation 5 
where: 
𝐹𝐶𝐻𝑠 - fold change for gene in the human dataset, as calculated in differential expression analysis 
𝐹𝐶𝑀𝑚 - fold change for gene in the murine dataset, as calculated in differential expression analysis 
𝑃𝐻𝑠 - p-value for human gene in the human dataset, as calculated in differential expression analysis 
𝑃𝑀𝑚 - p-value for murine gene in the murine dataset, as calculated in differential expression analysis 
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2.19. VALIDATION OF DISCO.SCORE WITH SIMULATED 
MODULES 
I have used the human dataset from The Gambia and mouse dataset 21 days p.i. (129S2 mice) 
and a simulated set of modules to test the performance of disco.score algorithm in retrieving 
concordantly and discordantly regulated modules. I used the existing murine and human datasets, but I 
have simulated the assignment of genes to gene sets, thus defining a priori which gene sets contain 
concordant genes, which gene sets contain discordant genes, and which are negative controls. I then 
tested whether the disco.score algorithm is able to detect these a priori defined gene sets. 
I have simulated gene sets containing 10, 20, 30, 40 or 50 genes, out of which 10%, 20% or 
30% were either concordantly regulated or discordantly regulated. In addition, I have generated modules 
consisting of 10 to 50 genes, which contained equal number of either concordantly or discordantly 
regulated genes. Each parameter combination (number of genes, number of regulated genes, type of 
regulation: concordant, discordant or equal number) has been replicated 100 times; an equal number of 
100 replicates of a suitable negative control modules was then added to the superset. For concordant 
modules, the control modules contained only non-concordant genes (including discordant genes, non-
regulated genes or genes with significant differences only in one organism); for discordant, only non-
discordant genes; for equal number, only genes that were neither concordant nor discordant. 
Next, with each set of 200 modules (out of which 100 were concordant or discordant and 100 
were negative controls) I performed CERNO test on the list of genes sorted by disco.score and identified 
the concordant and discordant modules. Then, I sorted the detected modules according to the p-values 
for enrichment and calculated area under curve (AUC) that corresponds to how accurately the algorithm 
detected the concordant or discordant modules. 
2.20. POSITIVE CONTROLS 
I used the dataset from Maertzdorf et al., 2011 containing WB expression profiles from 
patients suffering from TB, from sarcoidosis and HCs as positive controls for disco.score. The two 
diseases give expression profiles indistinguishable from each other when compared to HCs. I calculated 
differential expression between the 18 sarcoidosis patients and 18 HCs and between the 8 TB patients 
and 18 HCs. I matched the genes between both groups and calculated disco.score for each pair of 
corresponding human genes. I then sorted the list of differentially expressed genes by decreasing 
disco.score and performed GSEA to distinguish concordant gene modules between the two groups. 
Then I sorted the gene list according to increasing value of the disco.score and performed GSEA to 
distinguish discordant gene modules.  
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3. CHAPTER 3: EXPLORATION OF INDIVIDUAL 
VARIABILITY IN HOST RESPONSE TO TUBERCULOSIS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this section I describe the outcome of the multi-cohort analysis of gene expression 
regulation in individual TB patients. I show how the conducted analysis brought the focus to individual 
variability in IFN response to TB among patients.  
The analysis of a large meta-dataset composed of 7 publicly available datasets is presented 
starting from a demonstration of how the choice of normalization method influences outcome of multi-
cohort study. Further, I guide the reader through a thorough analysis of the non-TB related factors 
which, if not accounted for, can affect the results of the analysis and occlude meaningful conclusions. 
Comparison of the TB patients and healthy individuals on the level of an individual indicates that there 
are patients who do not present typical for TB regulation in IFN signaling genes. I investigated how 
does the gene expression of those individuals correspond with the scale of the disease and prove the 
phenomenon of individual variability in the scale of presented IFN response using datasets where 
healthy individuals’ immune response was triggered by vaccination. The findings in human cohorts are 
compared to controlled animal TB studies. Finally, I present different biosignatures that characterize 
the subgroups of patients with strongly pronounced in contrast to insignificant IFN type I response and 
present the identified patterns of response to TB. 
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3.1. ABSTRACT 
In the last years significant progress has been made in the understanding of immunity against 
TB. To a large extent it is owed to the multiple published transcriptomic studies of TB patients across 
different geographical locations. Apart from the single-cohort studies, multi-cohort approaches 
integrated the publicly available datasets. Both the single and the multi-cohort analyses investigated the 
trends presented by gene expression regulation in TB patients vs non-TB and indicated gene signatures 
of TB. Various mechanisms dominating the immune response to TB including IFN and complement 
system signaling have previously been proposed.  
Here, I inspect the transcriptomic response to Mtb infection in individual TB patients WB 
samples collected from the published studies. To investigate individual variability I suggest a method 
of integration of the author-normalized data and transformation of the measured gene expression levels 
into z-score. I create a meta-dataset consisting of seven previously published transcriptomic studies 
from various geographical locations. This is followed by GSEA for individual patients by using two 
sets of previously published immunological gene modules and novel sets of modules related specifically 
to type I or type II IFN signaling. The obtained enrichment profiles revealed different patterns of 
immune response regulation in TB patients, in particular in the IFN responses of the individuals from 
every cohort. I further investigate the variability in the enrichment of IFN modules and assign the 
patients into one of the two groups: presenting or lacking the enrichment in IFN-related modules (IFN+ 
or IFN-).  
The variability between those two groups could not be fully explained by any of the factors 
characterizing the patients which I show using logistic regression models and unsupervised analysis. 
The division was reflected by higher levels of IFN-inducible cytokines in the WB of the IFN+ when 
compared to IFN- individuals and corresponded with the severity of the lung pathology of TB patients. 
ML models for classification of the TB patients among non-TB created based on IFN+ or IFN- TB 
patients profiles differed in size, composition and their performance in detecting TB patients in the test 
and validation sets. While the IFN+ TB biosignature presented very unstable behavior detecting TB 
IFN- individuals, the TB IFN- signature was characterized by stable performance and similar overall 
sensitivity and specificity of detecting TB IFN+ as well as TB IFN- among non-TB patients.  
I suggest that the response to TB is highly variable and dependent on the host and present six 
gene expression patterns characterizing different subgroups of the patients rather than, as suggested 
before, a universal transcriptomic response pattern and gene signature of all TB patients.  
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3.2. DATA ACQUISITION 
Seven datasets were analyzed in this study. To create a meta-dataset (MDS) representing 
possibly variable cohorts, studies conducted in 7 different geographical locations: UK, Germany, SA, 
The Gambia, Malawi, USA and Kenya were included. In the first step, participants undergoing 
longitudinal studies and participants which were undergoing anti-TB therapy were excluded since I did 
not intend to investigate treatment progress, which resulted in the total count of 1959 individuals 
included in the analysis, with 570 active TB patients, 827 OD patients and 562 healthy donors. 80% of 
the donors from each of the disease groups: TB, healthy (including uninfected as well as LTBI and 
HIV+ donors) and OD were randomly selected and collected as training MDS on which all the further 
analysis steps except for testing the RF models were performed. The other 20% of the donors were 
assigned to the test MDS. I created a table of metadata describing study participants, which included 
donor identifier as assigned on GEO, study affiliation, ethnicity, residence, TB status, HIV status and 
other known diseases according to the descriptions published on GEO database and in the corresponding 
publications to be able to include those factors in the further analysis (Table 7).  
Table 7 Example fragment of the created meta-data table 
The full meta-data table is available on the website: http://bioinfo.mpiib-berlin.mpg.de/TBprofiles/. The columns present the 
donor ID from the GEO database, reference to the original publication, ethnicity of the patients, country of residence, TB 
status, LTB infection, HIV infection and presence of other disease (OD). 
donor study ethnicity residence TB LTBI HIV OD 
GSM851868 (Maertzdorf et al., 
2012) 
European Germany yes no no no 
GSM709468 (Maertzdorf, Ota, et 
al., 2011) 
African The Gambia no yes no no 
GSM914451 (Kaforou et al., 2013) African Malawi yes no yes no 
GSM1050945 (Bloom et al., 2013) Asian Europe no no no pneumonia 
As a result, the training and test MDS were created which consisted of the samples from donors 
from 7 cohorts, including (i) 452 TB donors, 665 OD donors and 457 healthy donors in the training 
MDS and (ii) 110 TB donors, 162 OD donors and 113 healthy donors in the test MDS, which was at 
that moment left out of the analysis.  
3.3. DATA NORMALIZATION 
Data normalization has been performed separately for the training and test MDS. For each 
study in the MDS I calculated differential gene expression between TB patients and HCs. Since 
technical variation and batch effects play an important role in microarray-based transcriptome studies I 
tested two normalization procedures which should minimize their effects. The first, ComBat, is 
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implemented in the Bioconductor package sva and combines mean and variance adjustment for each 
batch and every gene separately with empirical Bayes normalization (Leek et al., 2018). In the second 
approach I made use of the fact that the median and interquartile range (IQR) of the expression of every 
gene are known and standardized their values between different studies according to Equation 1 in 
chapter 2.3.2.  
The data distribution after normalization with ComBat presented less variance than the data 
distribution after the median and IQR-based type of normalization (Figure 5). 
A B 
  
C  
 
 
Figure 5 Distribution of data in MDS before and after the tested normalizations 
(A) Datasets before normalization, (B) after ComBat normalization, (C) after normalization with median and IQR. The datasets 
are colored by study. The best normalization of data distribution is achieved with ComBat data normalization procedure.  
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Subsequently I applied GSEA to the lists of genes sorted by increasing p-values calculated for 
differential regulation in every study before normalization and after both normalization methods (Figure 
6). The resulting enrichments and density plots for all the datasets before and after normalization 
indicated that although the second method results in more variance in data distribution, it preserves the 
order of the genes when sorted by differential regulation, while the ComBat normalization significantly 
changed the gene order and reduced the enrichment. Therefore, this normalization reduced the relevant 
biological information contained in the separate studies compromising it for the sake of better variance 
reduction. 
 
Figure 6 GSEA performed on all the studies before and after the two tested normalization methods  
The columns are named after the study author. The column names of the columns presenting enrichment after the median and 
IQR normalization start with “norm_” and the column names of the columns presenting enrichment after Combat 
normaliyation start with “ComBat_”). The dots present enrichment in the modules described in the row names. The dot size is 
proportional to effect size and the intensity of the color is proportional to decrease in p-value of the enrichment. The red and 
blue colors are used only to facilitate distinguishing subsequent studies.  
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Since the median and IQR- based standardization procedure did not influence the gene order 
and at the same time standardized the data, I used these calculated standardized expression values in 
further analysis. For each standardized expression value I calculated the z-score according to Equation 
2 and Equation 3 (chapter 2.3.2). 
3.4. GENE SET ENRICHMENT ANALYSIS 
To identify mechanisms activated in TB patients in response to the disease I performed GSEA 
for individual patients on the lists of genes sorted by increasing z-score (Figure 7). 
 
Figure 7 GSEA results for individual patients with TB present in MDS  
The single patient profiles are represented in columns. The red dots present enrichment in the modules described in the row 
names. The dot size is proportional to effect size and the intensity of the color is proportional to decrease in p-value of the 
enrichment. 
GSEA for individual patients presented marked differences in immune responses between TB 
patients. Strikingly, IFN related modules as well as many other modules considered characteristic in 
TB patients were not uniformly enriched among the individuals (as shown in the sample of MDS 
presented in Figure 8). In every cohort, individuals without significant enrichment in IFN modules were 
present. There was a visible variability in immune responses to TB among individuals from the training 
MDS. I have shown that various patients present activation of different elements of immune system in 
response to TB on the gene expression level. 
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Figure 8 GSEA results for selected TB patients from every cohort 
Random groups of patients have been selected from every study cohort to show variability between patients within the cohorts. 
The single patient profiles are represented in columns. Column names correspond to the GEO ID of the study as described in 
the Table 3. The dots represent enrichment in the modules described in the row names. The dot size is proportional to effect 
size and the intensity of the color is proportional to decrease in p-value of the enrichment. 
3.5. DEFINITION OF TYPE I AND TYPE II INTERFERON 
MODULES 
For the primary enrichment testing I used the gene modules published by Li et al. (2014) and 
Chaussabel et al. (2008) among which altogether 7 modules were related to IFN signaling. However, a 
closer inspection of the genes in each of the 7 modules revealed that two of them contain mostly genes 
related to IFN-α signaling and are not enriched among TB patients, whereas all the remaining 5 modules 
presenting significant enrichment contain a mixture of IFN type I and type II signaling genes 
(Supplementary Table 1). As described in the introduction, chapter 1.3.3, the activation of type I and 
type II IFN signaling pathways results in dramatically different effects for TB patients, namely 
increased pathology in case of IFN type I signaling and control of infection in case of IFN type II 
signaling, therefore distinguishing these two types of response is crucial.  
To amend this I referred to the Interferome v2.0 database (Rusinova et al., 2012) which 
contains vast collection of manually curated publicly available microarray datasets examining IFN type 
I, II and III responses to various stimulations. I used the Interferome v2.0 database to select IFN-related 
genes from all the genes present in MDS and classified them as inducible by IFN type I exclusively, 
IFN type II exclusively or by both types of IFN. Hence, I created three novel sets of modules:  
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(i) related to IFN type I signaling, consisting of subsets of the original Li et al. (2014) 
and Chaussabel et al. (2008) modules which overlapped with the collection of IFN 
type I genes identified by Interferome v2.0 database and one module gathering all 
genes identified by the Interferome database as IFN I inducible (Supplementary 
Tables 1 and 2),  
(ii) related to IFN type II signaling, consisting of subsets of the original Li et al. (2014) 
and Chaussabel et al. (2008) modules which overlapped with the collection of IFN 
type II genes identified by Interferome v2.0 database and one module gathering 
all genes identified by the database as IFN II inducible (Supplementary Tables 1 
and 3),  
(iii) related to both type I and type II IFN signaling pathways, consisting of subsets of 
the original Li et al. (2014) and Chaussabel et al. (2008) modules which 
overlapped with the collection of IFN type I and II genes identified by Interferome 
v2.0 database and one module gathering all genes identified by the database as 
both IFN I and IFN II inducible (Supplementary Tables 1 and 4).  
3.6. IDENTIFICATION OF IFN+ AND IFN- PATIENTS 
To find individuals with strong IFN response to TB and examine, what types of IFN response 
are dominating in the patients, I subsequently performed enrichment testing using the three created 
module sets: IFN I module set, IFN II module set and IFN I and II module set. The donors presenting 
significant enrichment in the IFN I module set were classified as IFN I+, the donors presenting 
enrichment in the IFN II module set as IFN II+ and the donors presenting enrichment in the IFN type I 
and II module set as IFN I and II+. Out of 457 TB patients present in the MDS, 320 presented with 
enrichment in at least one of the modules from IFN type I module set, 293 in IFN type II and 314 in 
IFN type I and II module set. Altogether 234 TB patients presented enrichment in all three IFN module 
sets and 380 TB patients in any of them, indicating high degree of overlap between the patients which 
present with IFN type I and IFN type II responses (Figure 9). Therefore, I identified subgroups of TB 
patients which presented IFN response and showed that IFN type I and type II responses are coexisting 
in the majority of TB patients. 
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Figure 9 Individuals presenting enrichment in IFN I and IFN II modules  
(A) Numbers of patients presenting enrichment in general IFN modules defined by Li et al. (2014) and Chaussabel et al. (2008) 
(set “IFN”) and in IFN type I set (“IFN I”), IFN type II set (“IFN II”) and set with genes common for IFN type I and type II 
signaling (“IFN I and II”) defined in the section (3.5). (B) Numbers of individuals with IFN type II enrichment among 
individuals with and without IFN type I enrichment. (C) Numbers of TB patients with IFN type II enrichment among 
individuals with and without IFN type I enrichment. 
3.7. LOGISTIC REGRESSION AND PRINCIPAL COMPONENT 
ANALYSIS 
To examine the possibility, that IFN status can be influenced by one of the factors describing 
the included studies or characteristics of the patients I investigated the influence on the presence of IFN 
I response of the following factors: study, used microarray platform, ethnicity, residence, other diseases, 
HIV and TB status using ANOVA and logistic regression (GLM). Active TB, HIV and Streptococcus 
sp. and Staphylococcus sp. coinfection turned out to be significant predictors of IFN I+ status (Figure 
10). The IFN+ status of around 50% of patients without TB results from the fact that the “no TB” group 
also included patients with OD and HIV coinfection.  
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Figure 10 Percentage of IFN+ individuals in the MDS 
(A) with and without TB, (B) with and without Streptococcus sp. and Staphylococcus sp. coinfection, (C) with and without 
HIV infection. The error bars indicate 95% confidence intervals. The 95% CI for Streptococcus and Staphylococcus 
coinfection are wider, because among 1574 donors in the MDS only 21 were coinfected with those two pathogens. 
Clearly, active TB is the most significant predictor of the IFN+ status among the investigated 
factors, followed by HIV infection. The characteristics of the patients and different study details did not 
contribute significantly to the detection of IFN response. Nevertheless, there are TB patients who do 
not present IFN response. 
I subsequently used PCA to further investigate the factors correlated with IFN enrichment. 
Even though clearly separated clusters were not present in the data, the IFN I+ and IFN I- samples 
clustered together which was best illustrated by the PCs 1 and 2 (Figure 11 A).   
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Figure 11 PCs of the matrix of gene expression in the training MDS  
75% confidence interval ellipses for the groups are shown. (A) PC 1 and 2 colored by IFN status. (B) PC 1 and 8 colored by 
TB status. (C) Fraction of variance explained by IFN status as a predictor for each of the first 10 principal components of the 
gene expression matrix from MDS calculated using 100-times randomization. PC1 and PC2 explain the biggest fraction of the 
variance. (D) Fraction of variance explained by TB status as a predictor for each of the first 10 principal components of the 
gene expression matrix from MDS calculated using 100-times randomization. PC1 and PC8 explain the biggest fraction of the 
variance. 
GSEA performed on the list of genes sorted according to their decreasing weights in PCA 
resulted in the lists of enriched modules which was dominated by enrichment in T- and NK-cell related 
modules for PC1 and in elements of innate immunity (including IFN response) as well as cell cycle and 
transcription in case of PC2. The complete list of modules enriched in PC1 and PC2 can be found in the 
Supplementary Table 5 and the enrichment of the modules with the p-value lower than 10-7 is visualized 
in the Figure 12 A, B.  
The most significant variable according to the GLM influencing the IFN status - the presence 
of active TB was explained by the principal components (PCs) 1 and 8 (Figure 11). GSEA performed 
on the genes along those two PCs resulted in abundant list of the enriched modules typically found in 
TB patients (Supplementary Table 5, Figure 12 B, C), including IFN response, adaptive and innate 
immunity.  
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Figure 12 GSEA performed on the weighs of genes in PCs 
(A) PC1, (B) PC2, (C) PC8 of the gene expression matrix from training MDS. For visualization purposes, only the modules 
enriched with p-value <10-7 have been shown. The complete list of module enrichment can be found in the Supplementary 
Table 5. The score according to which the dots are colored is calculated by the tmod (Weiner & Domaszewska, 2016) package 
and is proportional to the rise in AUC and decrease of p-value of the module enrichment. 
This showed that also unsupervised analysis identifies clusters of IFN- and IFN+ donors. The 
GSEA on the genes sorted by the weights in PCA indicated that T cell response is a major contributor 
to the differences seen between the IFN- and IFN+ patient clusters. 
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To investigate the dependence of IFN response on the study, ethnicity, residence, other 
diseases and HIV status among TB patients only, I created another logistic regression model using only 
the subset of data characterized by active TB. HIV- status and use of Illumina HumanHT-12 V3.0 
platform were correlated with IFN+ status (Figure 13). 
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Figure 13 Percentage of IFN+ patients among TB patients from MDS 
(A) with and without HIV coinfection, (B) investigated with different microarray platforms. The error bars represent 95% 
confidence intervals. 
This means that even though normalization has been performed there are still platform-effects 
visible in the training MDS. 
Calculation of the fraction of variance explained different factors using 100-times 
randomization revealed that in the case of data collected among TB patients the PCs 7 and 10 best 
illustrated the variance in the data influenced by platforms, PCs 2 and 6 best illustrated the variance 
explained by IFN status while the PCs 6 and 8 best illustrated the variance caused by HIV status (Figure 
14). 
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Figure 14 PCs of the matrix of gene expression of TB patients from the training MDS  
75% confidence interval ellipses for the groups are shown. (A) PC 6 and 8 colored by HIV status. (B) PC 2 and 6 colored by 
IFN status. (C) Fraction of variance explained by HIV status as a predictor for each of the first 11 principal components of the 
gene expression matrix from TB patients from the training MDS calculated using 100-times randomization. PC6 and PC8 
explain the biggest fraction of the variance. (D) Fraction of variance explained by IFN status as a predictor for each of the first 
10 principal components of the gene expression matrix from TB patients from the training MDS calculated using 100-times 
randomization. PC2 and PC6 explain the biggest fraction of the variance. (E) PC 7 and 10 colored by used microarray platform. 
(F) Fraction of variance explained by the used microarray platform as a predictor for each of the first 11 principal components 
of the gene expression matrix from TB patients from the training MDS calculated using 100-times randomization. PC7 and 
PC10 explain the biggest fraction of the variance. 
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Again, a strong enrichment along the components 2 and 6 was detected, which differentiated 
between the IFN I+ and IFN I- patients (Figure 15 and Supplementary Table 6), with a dominating 
signature of T cells. Enrichment along the PC 8 explain together with PC 6 the biggest fraction of 
variance related to HIV status was related to cell cycle and IFN signaling. Enrichment in PC 7 presented 
only 5 significantly enriched modules while enrichment in PC 10 was non-significant, indicating that 
the platform effects did not convolute the biological effects. 
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Figure 15 GSEA performed on the weighs of genes in PCs 2, 6, 7 and 8 
(A) PC2, (B) PC6, (C) PC7, (D) PC8 of the gene expression matrix of TB patients from the training MDS. For visualization 
purposes, only the modules enriched with (A) p-value < 5∙10-4, (B) p-value <0.05, (C and D) p-value <10-3 have been shown. 
The complete list of module enrichment can be found in the Supplementary Table 6. The score according to which the dots 
are colored is calculated by the tmod (Weiner & Domaszewska, 2016) package and is proportional to the rise in AUC and 
decrease of p-value of the module enrichment. 
Among TB patients the T cell and NK cell responses dominated the differences observed 
between IFN+ and IFN- patients. Furthermore, HIV infection was related to enrichment in IFN related 
modules. Analysis of the overall patient cohort as well as of TB patients indicated, that the IFN+ and 
IFN- status is strongly related to the presence of active TB but cannot be fully explained by any of the 
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other investigated factors. Therefore, I continued to investigate the variability among TB patients that 
included the IFN status. 
3.8. EXPRESSION OF INTERFERON-STIMULATED GENES IN 
THE BLOOD OF IFN+ AND IFN- PATIENTS 
If the enrichment of IFN modules was a straightforward result of increased IFN-α, -β or -γ 
gene expression it would be possible to easily identify the correlation between the IFN status and the 
level of expression of the mentioned genes. Similarly, there could be such dependence of IFN receptor 
(IFNR) genes and the IFN status. Alternatively, if IFN and IFNR genes are not differentially expressed 
between the IFN+ and IFN- individuals it indicates, that the differences between IFN+ and IFN- patients 
should be related to the expression levels of the genes induced by IFNs. I investigated the expression 
of one IFN type I α, one IFN type I β and one IFN type II gene: IFNA2, IFNB1, IFNG, as well as their 
receptor genes: IFNAR2 and IFNGR2. I also compared the expression of three selected IFN-dependent 
genes: BATF2, CXCL10 and ANKRD22 in the IFN+ and IFN- groups of the six categories of donors: 
(i) TB positive, (ii) HIV positive, (iii) TB and HIV positive, (iv) OD, (v) LTB and (vi) healthy. The 
genes IFNGR2 and CXCL10 were present in the IFN gene modules used to identify IFN+ and IFN- 
patients, therefore the difference in the expression between IFN+ and IFN- patients was to be expected.  
There were no significant differences in the expression of IFNA2, IFNB1 or IFNG genes between IFN+ 
and IFN- subgroups of any of the six categories of patients. Nevertheless, there were differences 
between the expression of IFNAR2 receptor genes between IFN+ and IFN- TB and OD patients (Figure 
16). The expression of IFNGR2 gene was significantly different between IFN+ and IFN- subgroups in 
every category of donors except for LTBI. The expression of IFN-inducible genes BATF2, ANKRD22 
and CXCL2 was significantly different between IFN+ and IFN- subgroups of every category of patients 
with exception of LTBI and HC for BATF2 and LTB for ANKRD22. The observed results suggest that 
the difference in the IFN+ and IFN- status of TB patients is not a result of increased expression of 
IFNA2, IFNB1 or IFNG genes. However, it can be related to the increased expression of IFN type I and 
type II receptor genes and it is depicted by increased levels of the transcripts of IFN inducible genes in 
the IFN+ individuals. It is remarkable that the initially used enrichment analysis indicated pathways 
which present significant differences between the IFN+ and IFN- patients which are now validated by 
comparing the expression of genes related to those pathways but were not included in the transcriptional 
modules. The significant differences in the expression of IFN-inducible genes between IFN+ and IFN- 
TB patients confirms that there are differences in the extent of transcriptional activation of IFN signaling 
pathways between the identified patient groups.  
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Figure 16 Expression of IFN type I and type II related genes in the IFN+ and IFN- subgroups of TB positive, HIV 
positive, HIV and TB positive, OD patients, LTB and HCs 
The differences in the gene expression level of those genes is most significant between IFN+ and IFN- TB and OD patients. 
(A) IFNAR2, (B) IFNGR2, (C) CXCL10, (D) BATF2, (E) ANKRD22 gene expression is shown.  
3.9. THE EXPRESSION OF SEVERAL IMPORTANT GENES 
FOR TB IS MARKEDLY DIFFERENT BETWEEN IFN+ AND 
IFN- PATIENTS 
The division into IFN+ and IFN- TB patients could reveal other non-IFN related genes or gene 
modules that exist within these groups. To investigate if there are significant discordant genes between 
IFN- and IFN+ TB patients apart from the IFN-inducible genes, IFN genes and IFNR genes I calculated 
differential expression between IFN+ TB patients and healthy and IFN- TB patients and healthy. The 
lists of differentially expressed genes are available on the website: http://bioinfo.mpiib-
berlin.mpg.de/TBprofiles/. I calculated disco.score for the pairs of corresponding genes which is 
presented in the Figure 17. Disco.score analysis presents a different approach to comparing gene 
expression than the differential expression analysis. It results in an ordered list of genes sorted by 
similarity of their expression regulation in two groups. Therefore, it can indicate genes or gene modules 
which are characterized by opposite expression regulation (i.e. overexpression vs underexpression) as 
well as the genes with marked differences in the expression between two groups even though the 
expression is concordant (i.e. underexpression in both groups or overexpression in both groups). 
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There were no significantly discordant genes between the IFN+ and IFN- TB patients. 
However, the scale of gene regulation was markedly different in the two patient groups and several 
genes, including CD273, CD274, C1QC, PAR2, which were upregulated in both groups were 
characterized by around twice as high log2FC in IFN + as in IFN- patients. All of those genes have been 
previously reported to play a role in TB which I further discuss in the Chapter 5. 
 
Figure 17 Concordant and discordant genes between the IFN+ and IFN- TB patients  
Increasing intensity of the red color indicates increase in disco.score and illustrates higher degree of similarity between gene 
expression in the two patient cohorts. Increasing intensity of the blue color which is not observed in this figure would indicates 
decrease in negative disco.score and a higher degree of dissimilarity in gene expression between two patient cohorts. 
3.10. CYTOKINE LEVELS IN BLOOD CORRESPOND TO THE 
IFN I+/IFN I- STATUS 
I have shown that the GSEA-based division into IFN+ and IFN- patients corresponds with the 
levels of transcripts of IFN-inducible genes in blood of the IFN+ and IFN- TB patients. However, to 
show that this division reflects what is actually happening in blood on the level of IFN-inducible 
cytokines I needed to use a dataset where transcriptomic data would be accompanied by the 
measurements of cytokines in blood. Correlation of the IFN+ status with the increased level of IFN 
inducible cytokines in blood would be a direct proof of the functional consequence of the suggested 
GSEA-based division into IFN+ and IFN- patients. 
The expression of CXCL2 and CCL2 chemokines is triggered by IFN signaling. To compare 
the levels of those cytokines in WB with the IFN+/IFN- status of the patients, I used data from a study 
cohort where healthy volunteers were vaccinated with IFN response inducing influenza vaccination – 
FLUADTM. The datasets contained (i) gene expression measured by microarrays and (ii) cytokine 
absolute concentrations in WB from 114 volunteers, measured before the FLUADTM influenza 
vaccination and 1 day after the vaccination. To identify the IFN+ and IFN- individuals I used z-scores 
84 
 
calculated based on normalized gene expression values as described before, using average 
concentrations of the respective cytokines in the samples before vaccination as reference values.  
Based on the GSEA using IFN modules the samples collected before the vaccination were 
classified as IFN I-, whereas majority of the samples collected the day after the vaccination as IFN I+ 
(Figure 18). Four out of six placebo control samples were classified as IFN I-. The mean values of both 
CXCL10 and CCL2 concentration for study participants identified as IFN I+ were higher than the values 
for IFN- participants. Moreover, ROC curve for the IFN status based on the cytokine level as binary 
predictor showed that the concentration of CXCL10 in blood is a specific and sensitive classifier for 
IFN I+ status and CCL2 presents rather low sensitivity and specificity as a classifier for the IFN I+ 
status (Figure 19). 
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Figure 18 Fold changes of WB cytokine levels of volunteers vaccinated with FLUAD vaccine in day 1 after 
vaccination compared to the vaccination day  
Presented are levels of IFN inducible cytokines: CXCL10 (A) and CCL2 (B). The data points marked red are derived from 
Placebo-injected individuals.  
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Figure 19 ROC curves characterizing the sensitivity and specificity of CXCL10 and CCL2 as binary predictors of 
IFN status 
The level of IFN inducible cytokines CXCL2 (A) and CCL2 (B) can be used as binary predictors of IFN status.  
Therefore, I showed that the division into IFN+ and IFN- individuals based on the gene 
expression profiles is reflected by the levels of IFN inducible CXCL10 and CCL2 cytokines in blood. 
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3.11. CORRELATION BETWEEN INTERFERON STATUS AND 
THE DISEASE SEVERITY 
In the study by Berry et al. (2010) 80 randomly chosen study participants underwent lung X-
Ray investigation and the results of 72 of the lung images were classified by three independent 
physicians blinded to microarray data and clinical diagnosis to one of the four categories: (i) no disease, 
(ii) minimal disease, (iii) moderate disease, (iv) advanced disease. I defined IFN I+/IFN I- status for the 
participants of the study by Berry et al. and compared it with the X-Ray based disease classification. 
26% of the donors classified into “no disease” category presented IFN I+ status (Figure 20). Among the 
patients with “minimal disease” 57% were IFN I+, and in both categories “moderate” and “advanced” 
disease over 90% of the patients were IFN I+. 
 
Figure 20. IFN status of the patients with varying levels of pathology in lungs  
Almost all patients with moderate and advanced pathology present IFN+ status. The proportion of the IFN+ and IFN- patients 
was significantly different between the patients with no pathology compared to the patients with moderate (p = 1∙10-3 in 
pairwise comparisons using Fisher's exact test for count data with Bonferroni correction) and with advanced pathology (p = 
4∙10-4). 
This indicated that the activation of IFN signaling pathways on gene expression level 
corresponds with advanced pathology in the lungs of TB patients. 
  
**** 
*** 
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3.12. RANDOM FOREST CLASSIFICATION 
I used RF models to see how IFN status influences the ability of the models to classify TB 
patients. The preliminary RF models were trained using 10-fold cross-validation to distinguish between 
(i) IFN+ TB patients and healthy individuals, (ii) IFN- TB patients and healthy individuals, (iii) IFN+ 
TB patients and all non-TB individuals, (iv) IFN- TB patients and all non-TB individuals, (v) IFN+ 
patients and OD, and (vi) IFN- TB patients and OD (Table 8). Six models were created using the whole 
set of genes measured in the MDS and six models with exclusion of IFN I genes to investigate how the 
model’s performance changes when the IFN type I genes are excluded; specifically, whether the 
performance of the model based on the IFN+ individuals is more similar to the performance of the 
models based on IFN- individuals. The models were tested for their sensitivity and specificity in 
discriminating (i) TB patients from non-TB donors, (ii) IFN+ TB patients from healthy donors, (iii) 
IFN- TB patients from healthy donors, (iv) IFN+ TB patients from patients with OD, (v) IFN- TB 
patients from patients with OD.  
Table 8. Characteristics of the preliminary RF models  
Six RF models were built using all the genes in MDS (Models 1, 2, 5, 6, 9, 10) and 6 RF models were built with exclusion of 
the genes present in IFN type I module set (Supplementary Table 2). The models 1 - 4 were built using TB and healthy 
individuals, models 5 – 8 using TB and all non-TB individuals and models 9 – 12 using TB and OD patients. The models were 
built including either IFN+ (models 1, 3, 5, 7, 9, 11) or IFN- TB patients (models 2, 4, 6, 8, 10, 12). 
 All genes No IFN I genes 
TB IFN + TB IFN - TB IFN + TB IFN - 
healthy Model 1 Model 2 Model 3 Model 4 
non TB Model 5 Model 6 Model 7 Model 8 
OD Model 9 Model 10 Model 11 Model 12 
The models trained on the IFN+ TB patients showed high sensitivity and specificity in 
differentiating between IFN+ TB patients and healthy, AUC = 0.96 (95% CI = 0.95-0.97), but lower 
sensitivity and specificity in distinguishing IFN- patients from healthy donors, AUC = 0.81 (95% CI = 
0.77-0.86; Figure 21 A). Their ability to distinguish IFN- patients from OD patients was slightly better 
than random, AUC = 0.57 (95% CI = 0.52-0.62). Interestingly, the models trained on the IFN- patients 
and healthy individuals also showed highest sensitivity and specificity in distinguishing between IFN+ 
and healthy, AUC = 0.95 (95% CI = 0.94-0.97) and lower in distinguishing IFN- patients from healthy, 
AUC = 0.87 (95% CI = 0.83-0.91). They were not capable of distinguishing IFN- TB patients from 
patients with OD, AUC = 0.47 (95% CI = 0.41-0.52) and the overall sensitivity and specificity in 
distinguishing TB from non TB similar as in the case of the model based on the  IFN + patients, AUC 
= 0.77 (95% CI = 0.75-0.80; Figure 21 B). Both models showed significant differences when identifying 
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TB patients among different groups of patients (healthy, non-TB and OD). This can be understood as a 
flaw of the model, since an ideal model should identify any TB patients among healthy as well as OD 
patients. 
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Figure 21 Results of testing the RF models 1 and 2 using k-fold cross validation  
Model 1 (A) was trained to differentiate between IFN+ TB patients and healthy and tested for differentiating both subgroups 
of TB patients (TB IFN+, TB IFN-) from healthy (ROCs described as “vs healthy” in the figure legend) and from OD (ROCs 
described as “vs OD” in the figure legend) donors. Model 2 (B) was trained to differentiate between IFN- TB patients and 
healthy and tested for differentiating both subgroups of TB patients (TB IFN+, TB IFN-) from healthy and from OD donors. 
The overall performance of the models is presented by the ROCs described as “TB vs non-TB”. 
To investigate the influence of the presence of IFN I genes in the model I repeated the analysis 
excluding the genes present in IFN I module set from the MDS thus creating the models 3 and 4 (Table 
8). The resulting ROC curves were nearly identical to the ones in the Model 1 and Model 2, which 
indicated that the IFN genes did not significantly improve the diagnostic capability of the models 
(Figure 22). 
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Figure 22 Results of testing the models 3 and 4 using k-fold cross validation 
Models 3 (A) and 4 (B) were created with exclusion of genes present in IFN modules. Model 3 was trained to differentiate 
between IFN+ TB patients and healthy and tested for differentiating both subgroups of TB patients (TB IFN+, TB IFN-) from 
healthy (ROCs described as “vs healthy” in the figure legend) and from OD donors (ROCs described as “vs OD” in the figure 
legend). Model 4 was trained to differentiate between IFN- TB patients and healthy and tested for differentiating both 
subgroups of TB patients (TB IFN+, TB IFN-) from healthy and from all non-TB donors. The overall performance of the 
models is presented by the ROCs described as “TB vs non-TB”. 
Models 5, 6 7 and 8 were created analogously, but trained to distinguish between the IFN I+ 
or IFN I- TB patients and all non TB individuals present in the study, including LTBI, healthy and 
patients with other diseases. In this case the models trained on the IFN I- presented much more stable 
behavior (Figure 23). The sensitivity and specificity of distinguishing IFN- TB patients from the healthy 
donors or OD patients was increased in comparison to the models trained on IFN+ patients (AUC TB 
IFN- vs healthy = 0.81 (95% CI = 0.77-0.85), AUC TB IFN- vs OD = 0.80 (95% CI = 0.75 – 0.84); 
Figure 23 A, B), while the sensitivity and specificity of distinguishing IFN+ TB patients from the 
healthy donors or OD patients decreased in comparison to the model trained on IFN+ TB patients and 
non-TB donors (AUC TB IFN+ vs healthy = 0.78 (95% CI = 0.74-0.81), AUC TB IFN+ vs OD = 0.76 
(95% CI = 0.72 – 0.79)). Overall the model performance was better than of the comparable models 
trained against only healthy donors (AUC TB IFN+ vs non TB = 0.82 (95% CI = 0.80 – 0.85), AUC 
TB IFN- vs non TB = 0.77 (95% CI = 0.75 – 0.80)). The exclusion of IFN genes did not influence the 
model performance (Figure 23 C, D). 
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Figure 23. Results of testing the models 5, 6, 7 and 8 using k-fold cross validation 
Models 5 (A) and 6 (B) were created using all genes present in MDS while models 7 (C) and 8 (D) were created with exclusion 
of genes present in IFN modules. Models 5 and 7 were trained to differentiate between IFN+ TB patients and non-TB and 
tested for differentiating both subgroups of TB patients (TB IFN+, TB IFN-) from healthy (ROCs described as “vs healthy” in 
the figure legend) and from OD (ROCs described as “vs OD” in the figure legend) donors. Models 6 and 8 were trained to 
differentiate between IFN- TB patients and all non-TB and tested for differentiating both subgroups of TB patients (TB IFN+, 
TB IFN-) from healthy and from OD donors. The overall performance of the models is presented by the ROCs described as 
“TB vs non-TB”. 
The last four models were created analogically but trained to distinguish between IFN I+ or 
IFN I- TB patients from patients with OD. In this case, the performance of the model trained on the IFN 
I- TB patients was characterized by significantly lower overall sensitivity and specificity than the 
models trained on the IFN I+ TB patients (AUC TB vs non TB trained on IFN- TB and OD = 0.63 (95% 
CI = 0.60-0.66), AUC TB vs non TB trained on IFN+ TB and OD = 0.82 (95% CI = 0.80-0.85), Figure 
24 A, B); interestingly, those parameters were better in Model 9 than in the Model 10 for all patient 
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groups except for IFN I- TB patients. Again, exclusion of the IFN genes did not significantly influence 
the model performance (Figure 24 C, D). 
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Figure 24. Results of testing of the models 9, 10, 11 and 12 using k-fold cross validation 
Models 9 (A) and 10 (B) were created using all genes present in MDS while models 11 (C) and 12 (D) were created with 
exclusion of genes present in IFN modules. Models 9 and 11 were trained to differentiate between IFN+ TB patients and OD 
and tested for differentiating both subgroups of TB patients (TB IFN+, TB IFN-) from healthy (ROCs described as “vs healthy” 
in the figure legend) and from OD (ROCs described as “vs OD” in the figure legend) donors. Models 10 and 12 were trained 
to differentiate between IFN- TB patients and OD and tested for differentiating both subgroups of TB patients (TB IFN+, TB 
IFN-) from healthy and OD. The overall performance of the models is presented by the ROCs described as “TB vs non-TB”. 
In summary, the most stable were the models trained on IFN- TB patients and non-TB 
individuals (Model 6 and 8). They were characterized by the overall AUC of 0.77 and 0.78, 
correspondingly. I summarize the results of all created models in the Figure 25.  
92 
 
The modes 6 and 8 were not only most robust in a sense of being trained to identify TB patients 
among all non-TB individuals, but also characterized by the best cumulative AUC. The model trained 
on the IFN- and non-TB donors was characterized by the highest stability. 
 
Figure 25 Summary of the performance of the created RF models  
The preliminary RF models were trained using 10-fold cross-validation to distinguish between (i) IFN+ TB patients and healthy 
individuals (Panel 1 and 3), (ii) IFN- TB patients and healthy individuals (Panel 2 and 4), (iii) IFN+ TB patients and all non-
TB individuals (Panel 5 and 7), (iv) IFN- TB patients and all non-TB individuals (Panel 6 and 8), (v) IFN+ patients and OD 
(Panel 9 and 11), and (vi) IFN- TB patients and OD (Panel 10 and 12). Six models were created using the whole set of genes 
measured in the MDS (Panels 1, 2, 5, 6, 9, 10) and six models with exclusion of IFN I genes (Panels 3, 4, 7, 8, 11, 12). For 
each model the AUC with 95% confidence intervals is shown for identification of: TB patients among all non-TB patients in 
a given model (red); IFN- TB patients among healthy patients in a given model (olive green); IFN+ TB patients among healthy 
patients in a given model (green); IFN- TB patients among OD patients in a given model (blue) and IFN+ TB patients among 
OD patients in a given model (pink). The most stable results are given by the models 6 and 8. Models 3 and 4, 7 and 8, and 11 
and 12 are almost identical as models 1 and 2, 5 and 6 and 9 and 10, correspondingly. This means that the exclusion of genes 
present in IFN modules does not significantly influence the performance of the models.  
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3.13. BIOSIGNATURES OF THE IFN + AND IFN - TB 
PATIENTS 
The biosignature of TB patients should be sufficiently specific to distinguish them not only 
from healthy blood donors but also from patients with OD. At the same time, the models trained on the 
IFN- and IFN+ TB patients and non-TB individuals were characterized by the best cumulative AUC 
and IFN- and non-TB based model by the best stability. Therefore in order to identify biosignatures of 
IFN+ and IFN- TB patients I trained the RF models using  (i) IFN+ TB patients and non-TB individuals 
containing healthy, LTBI as well as OD patients and (ii) IFN- TB patients and non-TB individuals 
containing healthy, LTBI as well as OD patients, corresponding to the model 5 and model 6 (Table 8). 
The biosignature should ideally consist of a small number of genes which still retains high sensitivity 
and specificity. To choose the appropriate biosignature size I first investigated how the AUC of ROC 
curves presenting sensitivity and specificity of classification of the individuals as TB or non-TB 
individuals depend on the signature size. Therefore I divided the training set into 10 folds and using 9 
of them I created RF models for (i) IFN+ TB patients and non-TB and (ii) IFN- TB patients and non-
TB individuals and derived biosignatures of 6 different sizes: 5 genes, 7 genes, 10 genes, 20 genes, 50 
genes and 200 genes. In the next step, I used the remaining fold as a test set to estimate the performance 
of the derived biosignatures. The 20 gene biosignature showed optimal performance for classification 
of TB and non-TB individuals based on the model trained on IFN+ TB patients and non-TB individuals, 
achieving AUC of 0.83 in the test set. For the model built on IFN- TB patients and non-TB individuals 
the optimal signature size was 50 genes (Figure 26).  
 
Figure 26 Dependence of the AUC of TB patients classification on the number of genes in the biosignature 
The bars indicate 95% confidence intervals of calculated AUC. 
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I derived the IFN+ TB biosignature using the whole training MDS to build the RF model. 
Subsequently, 20 top genes sorted by variable importance were chosen and tested on the previously 
unused test MDS containing 20% of untouched samples from every study. Similarly, I derived the 50-
gene signature of TB IFN- patients. 
Table 9 Signature transcripts of IFN+ and IFN- TB patients  
The transcript ENSEMBL IDs and corresponding HGNC gene names are given. The third column indicates the transcripts 
overlapping in the IFN+ and IFN- biosignature. The column “Kaforou 53 Transcript Signature overlap indicates the transcripts 
previously indicated as biosignature of TB vs non-TB by Kaforou et al. (Kaforou et al., 2013). The last column indicates 
transcripts which were indicated as IFN type I inducible or inducible by both IFN type I and type II by Interferome v2.0 
database. 
ENSEMBL ID HGNC symbol 
IFN-/IFN+ TB 
Signature overlap 
Kaforou 53 
Transcript 
Signature overlap 
Present in IFN I or 
IFN I and II module 
IFN+ TB Biosignature 
ENSG00000002549 LAP3   + 
ENSG00000070501 POLB + + + 
ENSG00000100911 PSME2   + 
ENSG00000108387 SEPT4 + + + 
ENSG00000108861 DUSP3  +  
ENSG00000120217 CD274   + 
ENSG00000135148 TRAFD1   + 
ENSG00000150337 FCGR1A + + + 
ENSG00000152223 EPG5    
ENSG00000152766 ANKRD22 + + + 
ENSG00000154451 GBP5 + + + 
ENSG00000162645 GBP2   + 
ENSG00000163568 AIM2   + 
ENSG00000168062 BATF2 +  + 
ENSG00000168899 VAMP5 +  + 
ENSG00000173369 C1QB   + 
ENSG00000185338 SOCS1 +  + 
ENSG00000225492 GBP1P1   + 
ENSG00000225967 TAP2    
ENSG00000265531 FCGR1CP +   
IFN- Biosignature 
ENSG00000001084 GCLC    
ENSG00000003436 TFPI    
ENSG00000004939 SLC4A1    
ENSG00000070501 POLB + + + 
ENSG00000089057 SLC23A2    
ENSG00000090659 CD209    
ENSG00000100568 VTI1B    
ENSG00000108387 SEPT4 + + + 
ENSG00000112640 PPP2R5D    
ENSG00000119906 SLF2    
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ENSG00000126012 KDM5C    
ENSG00000128274 A4GALT    
ENSG00000129003 VPS13C    
ENSG00000137959 IFI44L   + 
ENSG00000140105 WARS   + 
ENSG00000140287 HDC    
ENSG00000145685 LHFPL2  +  
ENSG00000145936 KCNMB1   + 
ENSG00000149131 SERPING1   + 
ENSG00000150337 FCGR1A + + + 
ENSG00000152229 PSTPIP2    
ENSG00000152766 ANKRD22 + + + 
ENSG00000154451 GBP5 + + + 
ENSG00000159173 TNNI1    
ENSG00000161133 USP41   + 
ENSG00000164330 EBF1  +  
ENSG00000165416 SUGT1    
ENSG00000167995 BEST1    
ENSG00000168062 BATF2 +  + 
ENSG00000168899 VAMP5 +  + 
ENSG00000174944 P2RY14   + 
ENSG00000180185 FAHD1    
ENSG00000185338 SOCS1 +  + 
ENSG00000186625 KATNA1    
ENSG00000187608 ISG15   + 
ENSG00000188820 FAM26F  + + 
ENSG00000188938 FAM120AOS    
ENSG00000196141 SPATS2L   + 
ENSG00000196961 AP2A1    
ENSG00000198019 FCGR1B + + + 
ENSG00000204257 HLA-DMA    
ENSG00000205730 ITPRIPL2    
ENSG00000211978 IGHV5-78    
ENSG00000226264 HLA-DMB    
ENSG00000228163 HLA-DPA1    
ENSG00000234154 HLA-DMB    
ENSG00000239329 HLA-DMB    
ENSG00000241394 HLA-DMA    
ENSG00000242574 HLA-DMB    
ENSG00000265531 FCGR1CP    
 
The classification of the samples in the test set based on the IFN+ and IFN- TB biosignatures was 
characterized by better overall sensitivity and specificity than the classification using the 10-fold cross 
validation (Figure 27). The IFN+ TB biosignature presented the best performance on classifying the 
IFN+ TB patients (AUC = 0.93, 95% CI = 0.89 – 0.96), however the overall performance of the TB 
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IFN+ biosignature (AUC 0.78, 95% CI = 0.73 – 0.84) as well as the stability of the model were worse 
than the performance of the IFN- biosignature (AUC = 0.84, 95% CI = 0.79 – 0.89). In both IFN+ and 
IFN- TB biosignatures there were genes overlapping with the 53 transcript signature of TB vs non-TB 
identified by Kaforou et al. (Kaforou et al., 2013). Interestingly, 18 out of 50 genes present in IFN- TB 
biosignature were the genes inducible by type I IFN.  
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Figure 27 Performance of the TB biosignatures on the test MDS 
The overall performance of the TB IFN- biosignature (B) is more robust than of the IFN+ TB biosignature (A; AUC = 0.84 
for IFN- TB biosignature vs AUC = 0.78 for IFN+ TB biosignature). Additionally, the performance of the TB IFN- biosignature 
is more stable in identification of TB patients among various non-TB patient groups. 
Altogether, the optimal biosignature sizes for IFN- and IFN+ TB were 50- or 20- transcripts, 
respectively. The performance of the biosignatures in identifying TB patients was even better on the 
test than on the training MDS. The IFN- based models were significantly more stable than the IFN+ 
based models and were characterized by high sensitivity and specificity for detection of all subgroups 
of TB patients in contrast to the IFN+ models which did not sensitively or specifically detect IFN- TB 
patients among OD patients. 
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3.14. PERFORMANCE OF THE TB IFN- AND TB IFN+ 
BIOSIGNATURES ON AN EXTERNAL DATASET FROM CHINA 
To test the derived biosignatures I acquired an additional dataset from the WB of TB patients 
and HCs from China (Cai et al., 2014). After exclusion of the individuals who underwent anti-TB 
treatment the set contained 9 active TB cases, 6 LTBI and 6 uninfected control individuals. GSEA based 
identification of IFN+ and IFN- individuals showed that all the active TB cases from this dataset were 
IFN+. Nevertheless, I tested the performance of both the 20-transcript IFN+ TB biosignature and the 
50-transcript IFN- TB biosignature for the classification of the TB cases in this dataset and visualized 
it using ROC curves. Since not all the transcripts from IFN- TB biosignature were measured in the 
dataset, I reduced the signature to 48 genes present in the dataset. 
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Figure 28 Performance of the TB biosignatures on the validation dataset from China 
(A) 20-transcript IFN+ TB biosignature, and (B) 48-transcript IFN- TB biosignature were tested on the external validation 
dataset from China. 
The TB patients from the external test dataset from China were classified with AUC of 0.99 
(95% CI = 0.97 – 1.00) by the 20-transcript IFN+ TB biosignature and with AUC of 0.93 (95% CI = 
0.78 – 1.00) by the 48-transcript IFN- TB biosignature. The biosignatures obtained based on the MDS 
were therefore sensitive and specific to detect TB also in an independent dataset (Figure 28). 
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3.15. PERFORMANCE OF THE TB IFN- AND TB IFN+ 
BIOSIGNATURES IN DIFFERENTIATING BETWEEN TB AND 
SARCOIDOSIS PATIENTS  
In the previous tests and validation I have shown that the TB IFN+ and IFN- biosignatures 
identify TB patients among other patients and healthy subjects with high accuracy. Sarcoidosis is a 
disease that on the molecular level has been described to be hardly distinguishable from TB (Maertzdorf 
et al., 2012). I tested if the derived biosignatures are able to identify TB patients among patients 
suffering from sarcoidosis using dataset containing 45 TB and 49 sarcoidosis patients and 61 healthy 
individuals (Blankley, Graham, Turner, et al., 2016). GSEA based identification of IFN+ and IFN- 
individuals showed that all the active TB cases from this dataset were IFN+. Nevertheless, I tested the 
performance of both the 20-transcript IFN+ TB biosignature and the 50-transcript IFN- TB biosignature 
for the classification of the TB cases in this dataset and visualized it using ROC curves.  
The TB patients from the external test dataset from London were classified with AUC of 0.9 
(95% CI = 0.85 – 0.95) by the 20-transcript IFN+ TB biosignature and with AUC of 0.75 (95% CI = 
0.67 – 0.82) by the 50-transcript IFN- TB biosignature (Figure 29). There was a significant difference 
in the performance of the two signatures, which was the largest in the sensitivity and specificity of 
detection of the TB patients among the sarcoidosis patients. Strikingly, the IFN- signature was not able 
to identify the IFN+ TB patients among the sepsis patients. This suggests that in the regulation of IFN 
signaling pathways is crucial for differentiation between TB and sarcoidosis, two diseases inducing 
similar gene expression patterns. This could also indicate that on the gene expression level the 
sarcoidosis patients are more similar to IFN- TB patients than IFN+ TB patients. 
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Figure 29 Performance of the TB biosignatures on the validation dataset including sarcoidosis patients 
(A) 20-transcript IFN+ TB biosignature, and (B) 50-transcript IFN- TB biosignature were tested on the external validation 
dataset from London. The IFN- TB signature is not specific for detection of TB patients among the sarcoidosis patients.  
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3.16. VALIDATION OF THE METHODS ON SEPSIS DATASETS 
I have acquired three datasets from sepsis patients and HCs in order to test the method 
identification of IFN- and IFN+ individuals and to check what performance will characterize 
biosignatures of IFN- and IFN+ sepsis patients derived with the presented above methods. Data 
acquisition, normalization and GSEA were performed as described in the Methods section. Only 
transcripts measured in TB MDS were included in the sepsis MDS in order to derive a biosignature that 
could be later tested on the TB MDS. The sepsis MDS was split into the training and test dataset. In the 
training Sepsis MDS there were 32 IFN- Sepsis patients, 46 IFN+ Sepsis patients and 44 HC samples. 
RF models were trained using 10-fold cross validation, separately on sepsis IFN+ individuals and HCs, 
and on sepsis IFN- individuals and HCs. To acquire signatures of comparable size corresponding with 
TB IFN+ and TB IFN- signatures, 20-transcript sepsis IFN+ and 50-transcript sepsis IFN- signatures 
were derived from the RF models and applied to the test set. The sensitivity and specificity of sepsis 
patients classification was visualized using ROC curves (Figure 30).  
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Figure 30 Performance of the sepsis biosignatures on the sepsis test MDS 
(A) 20 transcript IFN+ sepsis biosignature and (B) 50 transcript IFN- sepsis biosignature were tested on the sepsis test set. 
The 20-transcript sepsis IFN+ signature based models classified the sepsis patients in the test 
set with overall AUC of 0.83 (95% CI = 0.67 – 0.99) while the 50-transcript sepsis IFN- biosignature 
classified patients in the test set with even higher AUC of 0.85 (95% CI = 0.68 – 1.00).The 95% CI 
were broad due to small number of samples in the sepsis test MDS. The classification of IFN – sepsis 
patients was less sensitive and specific independent of the model used. There was only one transcript 
overlapping between the IFN+ and IFN- sepsis signatures and one between the sepsis IFN+ and TB 
IFN+ biosignature (Table 10). 4 out of 20 genes present in IFN+ sepsis biosignature and 7 out of 50 
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genes present in IFN- sepsis biosignature were classified as IFN type I inducible by Interferome v2.0 
database. Some of the genes present in the sepsis IFN+ and sepsis IFN- biosignatures have been 
previously listed among significantly regulated genes in studies on sepsis or one of its causes - bacterial 
meningitis (Foell et al., 2013; Lill et al., 2013; Zhang et al., 2014). 
Table 10 Biosignatures of the IFN+ and IFN- sepsis  
ENSEMBL transcript identifiers and HGNC gene names are listed. There was no overlap between sepsis IFN+ and sepsis IFN- 
signature. Many of the genes present in IFN+ Sepsis signature have been previously reported in the studies on Sepsis or 
bacterial meningitis – examples of them are presented in the column “Previously listed” as the references to publications in 
which they have been listed. 6 out of 20 genes from IFN+ sepsis biosignature and 7 out of 50 genes from IFN- sepsis 
biosignature have been classified as IFN type I inducible by Interferome v2.0 database. 
ENSEMBL ID HGNC symbol 
sepsis 
Signatures 
overlap 
TB 
signatures 
overlap 
Previously listed 
Present in IFN I 
or IFN I and II 
module 
IFN+ sepsis BIOSIGNATURE 
ENSG00000090376 IRAK3 - - (Lill et al., 2013) + 
ENSG00000104814 MAP4K1 - - (Priya et al., 2017)  
ENSG00000129682 FGF13 - - (Basu et al., 2011)  
ENSG00000131378 RFTN1 - -   
ENSG00000135404 CD63 - - (Lill et al., 2013; Wan-
Chung Hu, 2013) 
 
ENSG00000137767 SQOR - -   
ENSG00000138772 ANXA3 - - (Fiusa et al., 2014)  
ENSG00000150045 KLRF1 + - (Wan-Chung Hu, 2013)  
ENSG00000152766 ANKRD22 - +  + 
ENSG00000156414 TDRD9 - - (Davenport et al., 2016)  
ENSG00000159339 PADI4 - - (Lill et al., 2013)  
ENSG00000163754 GYG1 - - (Lill et al., 2013)  
ENSG00000166507 NDST2 - - (Oshima, Haeger, 
Hippensteel, Herson, & 
Schmidt, 2018) 
 
ENSG00000166527 CLEC4D - -   
ENSG00000183019 MCEMP1 - -   
ENSG00000187554 TLR5 - - (Lill et al., 2013) + 
ENSG00000198814 GK - -  + 
ENSG00000206379 FLOT1 - - (Lill et al., 2013)  
ENSG00000230143 FLOT1 - - (Lill et al., 2013)  
ENSG00000236271 FLOT1 - - (Lill et al., 2013)  
IFN- sepsis BIOSIGNATURE 
ENSG00000008130 NADK - -  + 
ENSG00000010244 ZNF207 - -   
ENSG00000023516 AKAP11 - -   
ENSG00000065154 OAT - -  + 
ENSG00000085788 DDHD2 - -   
ENSG00000100207 TCF20 - -   
ENSG00000101000 PROCR - - (Schouten et al., 2014)  
ENSG00000101665 SMAD7 - -   
101 
 
ENSG00000103174 NAGPA - -   
ENSG00000105607 GCDH - -   
ENSG00000108106 UBE2S - -  + 
ENSG00000109063 MYH3 - -   
ENSG00000110108 TMEM109 - -   
ENSG00000110880 CORO1C - -   
ENSG00000111671 SPSB2 - -   
ENSG00000113368 LMNB1 - - (Zhang et al., 2014) + 
ENSG00000114251 WNT5A - -   
ENSG00000117133 RPF1 - -   
ENSG00000118418 HMGN3 - -  + 
ENSG00000123159 GIPC1 - -   
ENSG00000129187 DCTD - -   
ENSG00000129351 ILF3 - -   
ENSG00000135241 PNPLA8 - -   
ENSG00000143889 HNRNPLL - -   
ENSG00000150045 KLRF1 + - (Wan-Chung Hu, 2013)  
ENSG00000155256 ZFYVE27 - -   
ENSG00000161944 ASGR2 - -   
ENSG00000163251 FZD5 - -  + 
ENSG00000164047 CAMP - -   
ENSG00000173372 C1QA - - (Wan-Chung Hu, 2013) + 
ENSG00000174695 TMEM167A - -   
ENSG00000177479 ARIH2 - -   
ENSG00000184922 FMNL1 - -   
ENSG00000185905 C16orf54 - -   
ENSG00000187475 HIST1H1T - -   
ENSG00000187764 SEMA4D - -   
ENSG00000188636 RTL6 - -   
ENSG00000196653 ZNF502 - -   
ENSG00000198018 ENTPD7 - -   
ENSG00000198258 UBL5 - -   
ENSG00000198736 MSRB1 - -   
ENSG00000203666 EFCAB2 - -   
ENSG00000239961 LILRA4 - -   
ENSG00000241468 ATP5MF - -   
ENSG00000275596 KIR2DL5A - -   
ENSG00000276068 NAIP - -   
ENSG00000276461 TCF20 - -   
ENSG00000277667 TMC4 - -   
ENSG00000278481 KIR2DL5B - -   
ENSG00000281794 MUC20-OT1 - -   
In summary, the GSEA-based method of identification of IFN+ and IFN- subgroups of patients 
detected those two subgroups among sepsis patients. The derived sepsis biosignatures presented 
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variable performance: with high sensitivity and specificity of sepsis patient classification based on IFN+ 
patients and lower performance based on IFN- sepsis patients. 
3.17. TESTING TB BIOSIGNATURES ON SEPSIS PATIENTS 
Various infectious diseases share many common mechanisms of the response to the invading 
pathogen. For example, even though TB and sepsis involve different disease mechanisms, they both are 
characterized by strong inflammatory and IFN response. To investigate, how specific to TB are the 
obtained TB IFN- and TB IFN+ transcript signatures, I tested their performance on identification of the 
sepsis patients using sepsis test MDS. I used the TB IFN+ and TB IFN- RF models to predict which 
donors in sepsis test MDS are sick. 
The AUC of the classification of sepsis patients from healthy based on 20-transcript TB IFN+ 
signature equaled 0.62 (95% CI = 0.40-0.83) which was significantly less than in the case of the 20-
transcript sepsis IFN+ signature and not significantly better than random prediction (Figure 31). The 
AUC of the classification of sepsis patients from healthy based on 50-transcript TB IFN- signature was 
even worse and equaled 0.54 (95% CI = 0.31-0.76). In the case of both signatures the sensitivity and 
specificity of detecting IFN- sepsis patients was lower than that of detecting IFN + sepsis patients which 
suggests that the common IFN response in IFN+ TB and IFN+ sepsis patients share part of their gene 
regulation profile, which is not disease but IFN specific.  
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Figure 31 Performance of the TB biosignatures on the sepsis test MDS 
(A) 20 transcript IFN+ TB biosignature and (B) 50 transcript IFN- TB biosignature were tested on the sepsis test set. The TB 
IFN+ and IFN- signatures are not sensitive and specific towards detection of sepsis. 
I observed that the IFN- TB signature presents higher specificity for the detection of TB which 
is likely due to the fact that it is not convoluted with the IFN pathway activation occurring in many 
infectious diseases.  
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3.18. TESTING SEPSIS BIOSIGNATURES ON TB PATIENTS 
I subsequently tested the performance of the obtained sepsis biosignatures on the TB test MDS. 
The AUC of the classification of TB patients from non-TB based on the 20-transcript TB IFN+ signature 
equaled 0.69 (95% CI = 0.63-0.75) which was significantly less than in the case of the 20-transcript TB 
IFN+ signature (Figure 32). The AUC of the classification of TB patients from non-TB based on the 
50-transcript TB IFN- signature was similar and equaled 0.65 (95% CI = 0.59-0.71). In the case of both 
signatures the sensitivity and specificity of detecting IFN- TB patients from OD patients was not 
significantly different than 0.5. The sensitivity and specificity of detecting IFN+ TB patients was in 
both cases highest, which indicates that the IFN signaling convoluted the transcriptional differences 
between the two diseases.  
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Figure 32 Performance of the sepsis biosignatures on the TB test MDS 
(A) 20 transcript IFN+ sepsis biosignature and (B) 50 transcript IFN- sepsis biosignature were tested on the TB test set. The 
overall performance of the signatures is better than random.  
3.19. PROFILES OF IMMUNE RESPONSE IN TB PATIENTS 
Not only IFN response but also various other modules presented variable enrichment among 
TB patients compared to healthy. To investigate how the gene expression profiles in different modules 
differ between patients I performed correlation analysis of the gene expression in transcriptomic 
modules. Since every module consists of multiple genes, I calculated eigengenes representing the gene 
expression in modules and visualized the correlation between them on the heatmap (Figure 33).  
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Figure 33 Heatmap of correlations of gene expression in modules  
Every row and column represent the module which ID is described in the row name. The modules are clustered based on the 
correlation and groups of modules are annotated on the left according to the dominating term in the module cluster. The six 
described major clusters are marked on the right. 
The correlation matrix indicated 6 different patterns of gene expression regulation:  
(i) Strong up-regulation of genes related to cell cycle, T-cells, NK-cells and B-cells 
correlated with strong down-regulation of genes related to IFN type I and type II response and 
inflammatory processes, and mild down-regulation of genes related to erythrocytes, platelets, and 
neutrophils, as well as mild up-regulation of genes related to cell division processes in activated CD4+ 
T-cells;  
(ii) Strong up-regulation of genes related to cell division processes in activated CD4+ T 
cells correlated with mild down-regulation in the modules related to inflammatory processes and 
erythrocytes and mild up-regulation of genes related to NK-cells, T-cells, IFN type I and II response 
and cell cycle;  
(iii) Strong up-regulation of genes related to erythrocytes corresponded with mild up-
regulation of genes related to neutrophils and platelets, as well as mild down-regulation of genes related 
to cell division in activated CD4+ T cells, inflammation, cell cycle, T-cells, B-cells and NK-cells; 
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(iv) Strong up-regulation of genes related to neutrophils and platelets, up-regulation of 
genes related to type I and type II IFN signaling, inflammation, erythrocytes and down-regulation of 
genes related to cell division in activated CD4+ T-cells, protein synthesis, NK-cells, T-cells and cell 
cycle; 
(v) Strong up-regulation of IFN type I and type II IFN signaling genes correlated with up-
regulation of genes related to inflammatory processes, strong down-regulation of genes related to 
protein synthesis and T-cells and mild down-regulation of genes related to cell cycle and NK-cells;  
(vi) Strong up-regulation of genes related to inflammatory response correlated with up-
regulation of genes related to IFN type I and II signaling, neutrophils, platelets and down-regulation of 
genes related to NK cells, T-cells, B-cells, cell cycle and mild down-regulation of genes related to cell 
division processes in CD4+ T cells. 
In summary, I identified six different patterns of immune response against TB presented by 
the subsets of TB patients. 
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3.20. DISEASE RISK SCORE DOES NOT CORRESPOND TO 
INTERFERON STATUS 
To assess if the IFN positivity status correlates in TB patients with disease risk score (DRS) 
calculated as proposed by Kaforou et al. (2013), I classified each study participant as “DRS TB” or 
“DRS healthy” based on the calculated DRS score. The DRS assigned 84% of IFN- patients as “not 
TB” and 51% of IFN+ as “not TB”. The pairwise comparison of proportions using a Fisher's exact test 
with Bonferroni correction indicated significant difference between the proportions of patients 
classified as “TB” and “not TB” in the IFN+ and IFN- group (Figure 34).  
 
Figure 34 Proportions of the IFN+ and IFN- individuals from MDS assigned as “TB” and “not TB” by the DRS  
The TB patients are marked green. The non-TB individuals are marked red. The pairwise comparison of the proportions using 
the exact Fisher’s test with Bonferroni correction was significant. 
Closer inspection of the classification of the patients by DRS score indicated that depending 
on the real status of the individual (TB, OD or healthy), the DRS was characterized by varying 
performance in correctly classifying the patients as “TB” and “not TB”. In every group of individuals 
(TB, healthy, OD) samples classified as “not TB” as well as “TB” consisted of a mixed population of 
IFN- and IFN+ individuals. The DRS classified correctly 95% of healthy (including LTB) patients as 
“not TB”. Among the patients suffering from other pulmonary diseases it wrongly assigned 33% of 
them as “TB” and among the TB patients it assigned 27% as “not TB”. Half of the TB patients assigned 
as “not TB” were IFN-. Comparison of the classification as “not TB” or “TB” by the DRS was 
significantly related to the assignment of “IFN-” and “IFN+” status in all the groups. This suggests that 
the DRS is dependent on the strength of IFN response in the patients (Figure 35).  
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Figure 35 Fraction of IFN- and IFN+ samples among individuals classified as non-TB and TB by DRS in the three 
groups of donors: healthy, OD and TB 
The IFN- patients are marked green. The IFN+ individuals are marked red. The pairwise comparison of the proportions using 
the exact Fisher’s test with Bonferroni correction was significant 
10 out of 53 transcripts in the 53-gene “TB vs non TB” signature of Kaforou et al. (Kaforou 
et al., 2013) were assigned as IFN type I inducible by the Interferome v2.0 database. The bias towards 
assigning of the IFN+ patients as “TB” could be explained by two hypotheses: either the DRS is strongly 
influenced by the presence of the 10 IFN type I genes in the 53 transcript used to create the DRS, or the 
IFN- TB patients present too small extent of gene regulation upon TB to be correctly detected by the 
DRS. In both cases, considering the IFN status of the patients proves important for the diagnosis based 
on the DRS. 
3.21. INFLUENCE OF TIME POST INFECTION ON 
INTERFERON STATUS 
Generally, it is not known how much time has passed since the primary infection until the 
moment of diagnosis of TB in patients. Therefore, we cannot exclude that the differences seen in IFN 
status of TB patients are results of the different disease development stage with IFN responses becoming 
stronger with the ongoing infection. To investigate this hypothesis I acquired a dataset from blood of 
38 macaques (Macaca fascicularis, also referred to as cynomolgus macaques) infected with Mtb and 
followed in 11 serial time points for 6 months after the infection (Gideon et al., 2016). At each time 
point the blood transcriptome of the macaques was quantified with microarrays and the infection 
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outcome was defined using clinical definitions of active TB and LTBI, as well as on the basis of total 
lung inflammation measured as levels of [18F] fluorodeoxyglucose (FDG), a surrogate marker for 
disease severity in lungs, measured by positron emission tomography - computed tomography (PET-
CT). Out of the 38 animals, 16 developed active TB and 22 remained latently infected. I calculated z-
scores for the gene expression as described before and GSE with the type I IFN module set for individual 
macaques at every time point. I observed that the peak of type I IFN response fell between the 20th and 
42nd day after infection (Figure 36). Interestingly, there was no clear pattern in IFN type I module 
enrichment distinguishing the macaques which developed active TB from those remaining latently 
infected. There was a trend towards long lasting IFN type I response in the animals presenting active 
TB: 75% of them still presented with enrichment (p-value lower than 10-4.3) at day 56 p.i., whereas 
among the latently infected animals it was presented in only 27% of the animals. On the other hand, 
among the latently infected animals the enrichment in type I IFN response was observed earlier, e.g. at 
the day 3 p.i.. 
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Figure 36 Enrichment of the “IFN type I” module in the individual macaques over the time pre- and post infection  
The enrichment in these modules is significant in both LTB and TB macaques.  
In conclusion, the study with controlled time p.i. suggested that all Mtb infected animals 
develop IFN type I response but the strength and time of the response is heterogeneous between 
individuals. 
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4. CHAPTER 4: IDENTIFICATION OF CONCORDANT AND 
DISCORDANT IMMUNE RESPONSES TO TUBERCULOSIS 
IN MOUSE AND MAN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Here, I introduce a method which allows identifying highly concordantly as well as highly 
discordantly regulated gene sets between two organisms. The method is based on measuring 
concordance using directionality of change weighted by the magnitude of gene expression change in 
two heterologous datasets (for example, human and murine) and associated precision of its estimate. To 
this end, the approach combines a novel measure of similarity with GSEA. To validate this approach, I 
identified modules of genes concordantly and discordantly expressed in WB during TB in human 
populations from different regions and two different murine TB models. I then verified whether the 
differences found in WB are present also in human and murine macrophages. 
  
111 
 
4.1. ABSTRACT 
Understanding of human immune response to infection is in a large extent based on knowledge 
derived from the mouse model system. However, there are major differences between the disease 
outcome and symptoms in man and experimental mouse strains, conditioned by large evolutionary 
distance, individual variability which in mouse is influenced by inbreeding and the fact that mouse is 
not a natural host of many human pathogens. 
I propose a novel data integration approach which identifies concordant and discordant gene 
expression patterns of the immune responses in heterologous datasets: disco.score. The method 
accounts for the directionality and magnitude of the expression change of every gene in stimulated vs 
unstimulated groups of samples. The main assumption is that parts of the immune response remain 
conserved between species, while other aspects have diverged over time of evolution.  
Using the publicly available datasets as well as datasets collected by my colleagues form 
MPIIB Department of Immunology, Lisa Scheuermann and Anca Dorhoi, I compared human and 
murine transcriptional responses to Mtb infection in WB. In a complementary approach I also compared 
responses of macrophages from mouse and man to the Mtb. The results indicate profound differences 
between regulation of innate and adaptive immunity in man and mouse upon Mtb infection. I 
characterized differential regulation of T-cell related genes corresponding to the differences in 
phenotype between TB high and low susceptible mouse strains and identified the time point of 21 days 
p.i. of mice as best reflection of transcriptional responses in the studied human cohorts.  
The implemented approach facilitates the choice of an appropriate animal model for studies of 
the human immune response to a particular disease and provides the basis for better understanding of 
differences leading to success or failure in translation of laboratory findings to clinical trials. 
The study was published in September 2017 in Scientific Reports (Domaszewska et al., 2017). 
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4.2. COMPARABLE DATASET ACQUISITION 
I calculated differential gene expression between WB transcriptome profiles of (i) TB patients 
and HCs; (ii) Mtb infected and uninfected 129S2 and C57BL/6 mice as well as between transcriptional 
profiles of Mtb infected and uninfected human and murine macrophages.  
I created a list of possible comparisons between the human and mouse samples, separately for 
WB and macrophage samples, and identified orthologous gene pairs between human and murine genes 
for each such comparison (Table 11). Only the genes having 1:1 orthologs assigned by species 
interlinking in the Ensembl database, where homology predictions are generated by implementing 
maximum likelihood phylogenetic gene trees (Vilella et al., 2009) were included. Exclusion of potential 
in-paralogs and genes without mapped orthologs resulted in truncated list of genes remaining in every 
comparison.  
Table 11 Characteristics of the performed mouse-human comparisons 
The table contains IDs of the comparison as described in the Methods section (Table 6), number of genes represented on the 
human microarray from each comparison, number of genes represented on the murine microarray from each comparison and 
the identified 1:1 orthologous gene number. 
Comparison IDs # genes represented on 
human microarray platform 
#genes represented on 
murine microarray platform 
# 1:1 
orthologs 
1, 2, 7, 8, 13, 14, 19, 20 19743 21662 14712 
3- 6, 9- 12, 15- 18, 21- 24 21714 21662 15004 
25 19743 19946 14314 
26 19743 20665 13881 
27 20477 19946 11695 
28 20477 20665 11630 
29 20477 19946 11688 
30 20477 20665 11409 
31 20477 19946 11694 
32 20477 20665 11416 
33 19743 20665 13885 
34 20477 20665 11417 
35 20477 20665 11412 
36 20477 20665 11419 
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4.3. CORRELATION OF THE ACQUIRED DATASETS 
I tested the methods described in the studies of Seok et al. and Takao and Miyakawa (Seok et 
al., 2013; Takao & Miyakawa, 2014) to investigate how the human gene expression regulation upon 
TB is mimicked by murine gene expression regulation using the two presented correlation approaches. 
According to the method presented by Seok et al., I calculated the squared Pearson's correlation 
coefficients (r2) of the fold changes of all significantly differentially expressed gene pairs (p-value 
<0.05). No significant correlation in the gene expression of human and murine WB or macrophage 
transcriptomic profiles upon Mtb infection was detected as indicated by the obtained r² values which 
were lower than 0.1 (Table 12). The Spearman's rank correlation coefficients (r) calculated according 
to the method described by Takao and Miyakawa resulted in maximal value of 0.559 for the comparison 
#33; however, the criterion of including only the genes significantly regulated in both species resulted 
in a minute number of genes included in the comparison, i.e. 101 out of 13,885 orthologous gene pairs 
in this specific comparison. The previously described correlation-based approaches tested in performed 
comparisons did not answer the question of the level of similarity of gene expression regulation in the 
investigated mouse models and human TB. 
Table 12. Results of the correlation-based comparisons of the murine and human datasets  
The comparison ID, number of identified 1:1 orthologs between murine and human genes, calculated squared Pearson’s 
correlation coefficient (r2) and number of genes included in the calculation according to the criteria described by (Seok et al., 
2013), calculated Spearman’s correlation coefficient (r ) and number of genes included in the calculation according to the 
criteria described by (Takao & Miyakawa, 2014) are given. 
Comparison ID # 1:1 orthologs r2 included genes 
(Seok) 
r included genes 
(Takao) 
1 14712 0.001 5709 0.05 221 
2 14712 0.003 6368 0.163 699 
3 15004 0.003 4381 0.238 211 
4 15004 0.023 5212 0.343 704 
5 15004 0 5570 0.081 251 
6 15004 0.002 6332 0.067 813 
7 14712 0.024 5658 -0.215 275 
8 14712 0 5798 -0.064 289 
9 15004 0.003 4399 -0.042 228 
10 15004 0.004 4483 0.037 254 
11 15004 0.007 5542 -0.156 314 
12 15004 0 5650 -0.089 316 
114 
 
13 14712 0.001 6720 0.076 1065 
14 14712 0 7019 0.148 1248 
15 15004 0.002 5764 0.152 1008 
16 15004 0.012 5877 0.268 1066 
17 15004 0 6754 0.081 1247 
18 15004 0.006 6905 0.237 1267 
19 14712 0 10334 0.08 3772 
20 14712 0.009 10409 0.231 3519 
21 15004 0.009 1000 0.218 7979 
22 15004 0.033 9708 0.363 1698 
23 15004 0.004 10535 0.165 3753 
24 15004 0.025 10235 0.331 3400 
25 14314 0.031 10395 0.296 3821 
26 13881 0.042 5779 0.417 488 
27 11695 0.032 4945 0.314 159 
28 11630 0.068 4352 0.242 135 
29 11688 0.052 4972 0.369 214 
30 11409 0.052 4582 0.374 162 
31 11694 0.061 4949 0.468 158 
32 11416 0.081 4542 0.367 126 
33 13885 0 5739 0.559 101 
34 11417 0.002 375 0.119 24 
35 11412 0.012 451 0.319 21 
36 11419 0.021 373 0.177 22 
4.4. GENE SET ENRICHMENT ANALYSIS 
In the next step I calculated GSE based on gene modules from Molecular Signatures Database 
(MSigDB; Subramanian et al., 2005), gene modules created by Chaussabel et al., Godec et al. and Li et 
al. (Chaussabel et al., 2008; Godec et al., 2016; Li et al., 2014). The module sets from Li et al. (2014) 
and Chaussabel et al. (2008) were particularly informative because of their thorough biological 
annotation and focus on immune response elements. Therefore I used them in further described analysis 
referring to them as “immune modules”. GSE testing on the genes sorted by increasing p-value for 
differential regulation in each comparison resulted in lists of significantly enriched transcriptional 
115 
 
modules which varied in length, being most abundant for the human WB samples and mouse WB 
samples from the time points of 14 and 21 days p.i (Figure 37). The innate immunity modules typically 
enriched among TB patients (as shown in Chapter 3), like “antiviral IFN signature”, “enriched in 
neutrophils” or “enriched in monocytes”, were present among the significantly enriched modules in all 
the samples and multiple other modules enriched in both datasets were overlapping, indicating that there 
might be functionally related sets of genes regulated concordantly in spite of the lack of significant 
correlation between the datasets. 
 
Figure 37 Gene expression patterns in the investigated human cohorts and murine WB from the 129S2 and C57BL/6 
mice in days 1, 7, 14 and 21 p.i.  
P-value of module enrichment is illustrated by the intensity of the color and the effect size by the size of the dot. There were 
no overlapping concordant modules present in these comparisons. The modules are described by the titles followed by the 
original number of genes in module and ID. Module IDs correspond to modules IDs in R package tmod (Domaszewska et al., 
2017).  
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4.5. INTRODUCTION OF DISCO.SCORE 
Since data heterogeneity did not allow meaningful statistical analysis of this phenomenon with 
currently available methods, I developed a measure to assess the similarity of gene expression regulation 
for each orthologous gene pair in two datasets. The following criteria were used to quantify this effect: 
●  magnitude of gene expression change (effect size) 
● significance of gene expression change 
● direction of gene expression change  
I combined them into a single mathematical equation expressing a score of 
concordance/discordance in gene expression regulation between two datasets. The score, which I 
termed `disco.score` increases proportionally to both human and murine log2FC increase (or decreases 
analogously), increases with the decrease of summed p-values of genes in pair, and has negative sign if 
the expression change has opposite direction (Equation 5, page 62). 
The theoretical distribution of disco.score depending on log2FC values in both datasets is illustrated in 
the (Figure 38). 
 
Figure 38 Theoretical distribution of disco.score function depending on log2FC values of both species  
Increasing intensity of the red color indicates increase in disco.score and illustrates higher degree of similarity between human 
and murine gene expression. Increasing intensity of the blue color indicates decrease in negative disco.score and a higher 
degree of dissimilarity between human and murine gene expression.  
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Using such defined formula I calculated disco.score for each pair of orthologous genes in every 
comparison. Then, I performed GSE on the list of genes from the two datasets ranked by decreasing 
disco.score to identify similar elements of immune response in every dataset pair. Moreover, using the 
list of genes sorted by increasing disco.score I identified the most dissimilar elements of immune 
response between each dataset pair. I termed the modules enriched in the dataset sorted by decreasing 
disco.score `concordant` and those enriched in dataset sorted by increasing disco.score `discordant` 
(Figure 39). 
 
Figure 39 Algorithm used to identify concordant and discordant gene modules  
The log fold changes and p-values between groups were calculated with R-package limma. The orthologous genes or genes 
corresponding to each other (if compared datasets derive from two groups of the same species) were mapped to each other. 
Then, disco.score was calculated for each pair of corresponding genes. GSE analysis was performed on the list of genes sorted 
by increasing disco.score to distinguish discordant gene modules and on the list of genes sorted by decreasing disco.score to 
distinguish concordant gene modules. 
At the same time, I tested the performance of disco.score with log2FC values substituted by t-
statistic for differential expression. In this case, the modified version of disco.score was illustrated by 
the formula: 
𝑑𝑖𝑠𝑐𝑜. 𝑠𝑐𝑜𝑟𝑒 =  𝑡. 𝑠𝑡𝑎𝑡𝐻𝑠 ∙ 𝑡. 𝑠𝑡𝑎𝑡𝑀𝑚 
Equation 6 
where: 
𝑡. 𝑠𝑡𝑎𝑡𝐻𝑠 - t-statistic for a gene in the human dataset, as calculated in differential expression analysis 
𝑡. 𝑠𝑡𝑎𝑡𝑀𝑚 - t-statistic for a gene in the murine dataset, as calculated in differential expression analysis  
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The results of both disco.score methods were similar (Figure 40). Still, its first version remains more 
universal since depending on the method used to calculate differential expression the t-statistic is not 
always available, opposite to the universally used measure of gene expression change: log2FC and p-
values. 
 
Figure 40 Sorting genes by disco.score results in more sensitive concordance and discordance detection compared 
with t-statistic  
Concordant (red) and discordant (blue) modules enriched in comparison of WB expression profiles of patients from Gambia 
and 129S2 mice at day 21 p.i. detected with disco.score and on the basis of t-statistic. Only three modules vary between the 
results obtained using the two methods. P-value is illustrated by the intensity of the color and the effect size by the size of the 
dot. Only the modules with p-value for the enrichment lower than 0.005 are shown. The modules are described by the titles 
followed by the original number of genes in module and ID.   
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Figure 41 Three modules varying in the results obtained by disco.score and t-statistic  
The classification of module LI.M4.2 as concordant as well as classification of modules LI.M222 and LI.M87 as discordant 
was detected by disco.score, but not by t-statistic gene sorting. 
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4.6. VALIDATION TESTS 
4.6.1. Validation with simulated modules 
Disco.score is a novel method to identify concordant and discordant elements of immune 
response in heterogeneous datasets, and, to my knowledge, the only such method dedicated not only to 
assess similarity between datasets but also to indicate their most dissimilar elements. Therefore 
evaluation of its performance is difficult due to lack of an objective measure of success. For this reason 
I validated the method in two contexts: first, to prove its technically correct performance, by simulating 
the concordant and discordant modules in two of the acquired datasets and detecting them with use of 
disco.score; and second, to verify the biological interpretability of the results, by identification of 
concordance and discordance in the datasets with known similarities.  
4.6.2. Validation using two diseases with very similar transcriptomic profile 
In the first step, I used the 129S2 mouse WB dataset and the human WB dataset from The 
Gambia (Maertzdorf, Ota, et al., 2011) to validate the ability of disco.score for detecting simulated 
concordant and discordant modules. I simulated a set of 100 concordant, 100 discordant and 100 random 
modules for every combination of two parameters: number of genes in a module (ranging from 10 to 
50) and percentage of significantly regulated genes in a module (ranging from 10 to 30%). Using such 
defined modules I tested the ability of disco.score to correctly identify the concordant and discordant 
ones. The disco.score algorithm was able to correctly detect and classify the discordant and concordant 
modules and the sensitivity of detection increased with the larger number of genes per module and with 
the higher percentage of regulated genes per module. Not only the modules containing the discordant 
or concordant genes, but also the modules containing a mixture of discordant and concordant genes 
were detected correctly.  
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Figure 42 Results of the simulation test 
Accuracy of the detection of (A) concordant modules, (B) discordant modules, and (C) modules concordant and discordant at 
the same, time illustrated by AUC corresponding to different numbers of genes in the modules and different percentage of 
regulated genes in the modules. 
4.6.3. Validation using two cohorts of patients suffering of TB 
In the next step, I tested whether the known biological similarities in two datasets are 
reproduced by disco.score. The transcriptomic regulation in patients suffering from TB and from 
sarcoidosis is highly similar compared to healthy individuals (Maertzdorf et al., 2012). In line with this 
observation,  analysis of genes in Kyoto Encyclopedia of Genes and Genomes pathways (KEGG; (M 
Kanehisa & Goto, 2000; Minoru Kanehisa et al., 2017; Minoru Kanehisa, Sato, Kawashima, Furumichi, 
& Tanabe, 2016) revealed similar differential expression patterns in TB and sarcoidosis, including genes 
involved in systemic lupus erythematosus, complement and coagulation cascades, toll-like receptor 
signaling, and FcGR–mediated phagocytosis (Maertzdorf et al., 2012). Having acquired the WB 
transcriptional datasets from patients of both diseases I used disco score and GSE to identify 
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concordance and discordance between gene expression regulation in the two diseases. 83% of genes 
had a positive disco.score and the identified concordant gene sets were virtually identical as the gene 
sets enriched in comparison of both TB as well as sarcoidosis patients to healthy patients (Figure 43). 
There were no discordant modules enriched in the comparison of TB to sarcoidosis patients, which is 
in accordance with the previously described observation of lack of significant transcriptional differences 
in the patients of both diseases. 
 
Figure 43 Disco.score-based concordance detection illustrates known biological background of disease similarity  
P-value is illustrated by the intensity of the color and the effect size by the size of the dot. Modules enriched in test datasets 
derived from GEO (Maertzdorf et al., 2012, GSE34608). The gene modules enriched in TB patients, sarcoidosis patients, 
concordant gene modules identified with disco.score among the two groups of patients and discordant gene modules identified 
with disco.score are presented in the picture. 
I performed another validation of disco.score by identifying similarities and differences in 
gene expression regulation among TB patients from Malawi and SA (Kaforou et al., 2013). Similarly 
as in case of TB and sarcoidosis patients, the differences between those two patient populations in 
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comparison to healthy were expected to be minor, and the similarities were expected to include the 
modules enriched in the two datasets in comparison to healthy. Visualization of the log2FC values of 
the Malawian and the South African cohort plotted against each other and coloured by disco.score 
showed that the majority of the genes were regulated concordantly and were characterized by a positive 
value of disco.score (Figure 44). 
 
Figure 44 Distribution of disco.score in the assessment of similarity of gene expression changes in TB in a cohort from 
Malawi and cohort from SA  
Increasing intensity of the red color indicates increase in disco.score and illustrates higher degree of similarity between gene 
expression in the two patient cohorts. Increasing intensity of the blue color indicates decrease in negative disco.score and a 
higher degree of dissimilarity in gene expression between two patient cohorts. 
The GSE performed on the list of genes sorted by decreasing disco.score resulted in the 
identification of 94 concordant modules which were also enriched in the two datasets separately (Figure 
45). The enriched modules contained elements characteristic for the TB response: T cell activation, DC 
signature, NK cell enrichment and IFN signaling. Sorting the genes according to increasing disco.score 
resulted in identification of only 4 discordant modules, related to transcription and to cell cycle. 
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Figure 45 Modules enriched in test datasets from Malawi and SA 
The gene modules enriched in TB patients from Malawi (TB/Malawi), TB patients from SA (TB/SA), concordant (red) and 
discordant (blue) gene modules identified with disco.score in the two groups of patients are presented in the picture. The 
modules are described by the titles followed by the original number of genes in module and ID. 
I investigated the expression regulation of genes in each concordant and discordant module. 
The regulation of genes in the detected discordant modules was minute. The module “LI.M144 Cell 
cycle, ATP binding” identified as discordant possessed both discordant and concordant genes (Figure 
46). In this case, the disco.score was sensitive to detect the discordant genes but failed to detect the 
concordant ones. 
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Figure 46 The modules assigned as discordant in the comparison of the South African and Malawian cohort  
In the modules LI.M213 and LI.M144 concordantly regulated genes are also present.  
The concordant modules consisted of genes regulated in the same directions and with similar 
magnitude (Figure 47). 
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Figure 47 Log2FC of gene expression of the cohort from SA plotted against log2FC of gene expression of the cohort 
from Malawi 
The plot presents the genes belonging to module “Immune activation - generic cluster”, which was identified as concordant. 
The intensity of the color represents disco.score. Bars represent 95% confidence intervals (CI) for the log fold change. 
4.6.4. Validation on human burn dataset and the corresponding mouse model 
In the previously described studies approaching comparison of murine and human 
transcriptome data with correlation (Seok et al., 2013; Takao & Miyakawa, 2014) one of the 
investigated reactions was a response to burn trauma in patients as well as in C57BL/6J mice. Seok et 
al. (2013) indicated squared correlation coefficients between the datasets equal to 0.08 and identified 
“FcGR-mediated Phagocytosis in Macrophage and Monocytes”, “IL-10 Signaling”, “Integrin 
Signaling”, “B cell receptor signaling” and “Toll-like receptor signaling” as the five most activated 
pathways in human burn. The r2 for the correlation of the five most regulated pathways between man 
and mouse was ranging from 0 to around 0.5. Takao & Miyakawa (Takao & Miyakawa, 2014) excluded 
all the genes with log2FC < 2 for man and log2FC < 1.2 for mouse which resulted in the correlation 
coefficient between the same datasets equal to 0.68. They identified signaling pathways in which human 
and murine genes were regulated in the same direction, which included “Innate immune response”, 
“Genes involved in Cytokine Signaling in Immune System” and “Lymphocyte Differentiation”. I 
compared these results with the results of the disco.score-based concordance detection. I assigned the 
orthologs between human and murine genes from both datasets used by Seok et al. (2013) and Takao et 
al. (2014), separately in early response (time points up to 24 h after the burn trauma) and late response 
(time points between 24 h and 168 h after the burn trauma), calculated the disco.score for the orthologs 
127 
 
and performed GSE on the lists of genes sorted by disco.score. I identified concordant and discordant 
elements of immune response between C57BL/6J mice and man in early and late time points following 
the burn trauma (Figure 48, for visualization purposes only 35 modules are shown). There were 68 
concordant modules between mouse and man in the first day after infection. They included several 
modules related to NK cells and to innate immunity, e.g. the module “immune activation – generic 
cluster” (LI.M37.0) which was most significantly enriched, modules related to adaptive immunity, like 
“T cell activation” or  the module “antigen presentation (lipids and proteins)” (LI.M28) which had the 
largest effect size (Figure 48). Additionally, there were two discordant modules: “NK cell surface 
signature” (LI.S1) and a non-annotated module (LI.M151, not shown), however the enrichment in the 
discordant modules was characterized by larger p-value and smaller effect size than in the concordant 
modules. One week after stimulation many of the adaptive immunity-related modules were still 
regulated in the human dataset, but not in the murine one. At that time point the concordances 
encompassed innate immunity and metabolism. The two discordant modules detected at this time point 
were “type I IFN response” (LI.M127) and “NK cell surface signature” (LI.S1). 
  
Figure 48 Concordant and discordant modules enriched in burn datasets  
The datasets were derived from GEO (Calvano et al., 2005; GSE3284). The gene modules enriched in patients after burn and 
mouse model of burn in time points of 1 day and 1 week are presented in the picture. P-value in illustrated by the intensity of 
the color and the effect size by the size of the dot. Only the modules with p-value for the enrichment smaller than 10-7 are 
shown. The modules are described by the titles followed by the original number of genes in module and ID.  
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The previous studies (Seok et al., 2013; Takao & Miyakawa, 2014) identified the innate 
immunity-related modules as similar in the human and murine response to burn, which is compatible 
with the results obtained using the disco.score even though the calculated correlation coefficients 
between murine and human expression values are low. In contrast to the preceding studies, which 
focused entirely on the detection of similarities, the application of disco.score enabled as well 
identification of the opposite gene expression change in NK cells or IFN modules (Figure 49). Briefly, 
disco.score algorithm-based analysis not only identified previously described similarities between 
human and murine burn datasets, but also indicated gene modules regulated in opposite manner between 
the two species. 
  
Figure 49 The module “Type I IFN response” is discordant one week after the burn 
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4.7. DISCO.SCORE IDENTIFIES CONCORDANCE AND 
DISCORDANCE OF RELATED HUMAN AND MURINE 
DATASETS IN TB 
I acquired publicly available datasets from TB patients and murine TB. My colleagues from 
MPIIB Department of Immunology, Lisa Scheuermann and Anca Dorhoi, conducted the experiments 
to acquire blood from two infected and uninfected mouse models of TB, the low susceptible C57BL/6 
mouse strain and the highly susceptible 129S2 mouse strain as well as from Mtb stimulated and 
unstimulated human macrophage-like THP1 cells. Karin Hahnke from MPIIB, Department of 
Immunology and Hans J. Mollenkopf from Microarray Core Facility, MPIIB prepared the samples and 
conducted microarray experiments on the acquired tissues. For each acquired dataset I calculated 
differential expression of genes between infected and uninfected groups. Next, I calculated the 
disco.score for each pair of orthologous genes and identified concordant and discordant immune 
modules and MSigDB Hallmark Gene Sets (Figure 50) and verified concordance of gene expression 
change by visualizing the gene expression in the identified concordant and discordant modules. The 
genes belonging to concordant modules were regulated in the same direction and the majority of them 
(for example 56% in comparison 2) had non-negative weighted correlation coefficients. In contrast to 
the assignment of genes which were significantly regulated in the same direction in both mouse and 
man but at the same time characterized by negative correlation or correlation coefficient close to 0 as 
‘not similar’ by the correlation approach, such modules were identified as concordant by the disco.score 
approach. Similarly, modules containing genes regulated in opposite direction were identified as 
discordant even if they presented positive correlation coefficient. If not indicated otherwise, the results 
presented in the following text are based on transcriptomic modules created by Li et al. (2014). 
130 
 
 
Figure 50 Results of disco.score based module detection with use of MSigDB modules in comparison of human and 
murine datasets  
Concordant (red) and discordant (blue) MSigDB Hallmark Gene Sets enriched in human WB dataset from SA and WB datasets 
from C57BL/6 and 129S2 mice at day 21 p.i. The modules “Hallmark IL2 STAT5 signaling” and “Hallmark IL6 STAT3 
signaling” are concordant in comparison of South African cohort to both 129S2 and C57BL/6 strains. The modules are 
described by the titles followed by the original number of genes in module and ID. 
Concordant modules were present between both mouse strains and man at every time point 
p.i. of mice and their number increased towards day 21 p.i. of mice (Figure 51 and Figure 52). The 
number of discordant modules, however, was highly dependent on the compared mouse strain: it 
decreased with time p.i. in the comparison of man and 129S2 mice, but remained at high level 
independent of the time point in the comparison of man and C57BL/6 mice (Figure 53 and Figure 54). 
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Figure 51 Concordant modules in comparisons of 129S2 WB with human datasets 
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Figure 52 Concordant modules in comparisons of C57BL/6 WB with human datasets 
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Figure 53 Discordant modules in comparisons of 129S2 WB from different time points with human datasets 
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Figure 54 Discordant modules in comparisons of C57BL/6 WB from different time points with human datasets  
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4.8. SIMILARITY OF MURINE AND HUMAN RESPONSES TO 
INFECTION CHANGES OVER TIME 
The blood samples analyzed by microarrays from 129S2 and C57BL/6 mouse strains were 
collected before infection (day 0) as well as at the following time points: day 1, 7, 14 and 21 p.i.. I 
calculated differential gene expression comparing each time point p.i. with the day 0 as control healthy 
sample. Next, I compared the time series data from both mouse strains with publicly available datasets 
from human cohorts from The Gambia (Maertzdorf, Ota, et al., 2011), SA and Malawi (Kaforou et al., 
2013), which included HIV negative (HIV-) TB patients, and HIV- and HIV+ individuals with latent 
TB infection (LTBI) from the same locations as controls. In every comparison of each human dataset 
with each time point p.i. in both mouse strains I detected concordant and discordant gene modules. 
Similarly, I compared the corresponding time points p.i. between the two mouse strains to test whether 
the phenotype differences in their reaction to Mtb infection are illustrated by concordant and discordant 
gene expression. For both highly susceptible 129S2 and low susceptible C57BL/6 mouse strain the 
amount of significantly differentially regulated genes as well as the degree of concordance with any of 
the human datasets increased towards day 21 p.i (Figure 55), reaching above 100 concordant modules 
for the 129S2 and above 70 for the C57BL/6 mouse. The highest number of 29 discordant modules 
between the human and murine data appeared on day 1 p.i. of mice. In such an early time point, the 
immune response to TB is not fully established yet and is referred to as early response. Notably, there 
was a different trend in the amount of the identified discordances between the two mouse strains and 
man: while their number decreased towards day 21 p.i. in the comparison of human data with 129S2 
mouse data, it remained at a high level of around 40 modules in the comparison of human vs C57BL/6 
strain. In comparison of the two mouse strains the number of concordant modules doubled between day 
1 and day 14, but only sparingly increased between days 14 and 21 p.i.. There were no discordant gene 
modules in comparison of the two mouse strains up to day 14 p.i., which changed in the day 21 p.i. 
when 24 modules containing genes regulated in opposite directions were observed. 
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Figure 55 Module counts in comparisons of different human and mouse datasets 
Red color refers to concordant and blue to discordant modules. Upper panel: Comparisons of 129S2 mouse strain data with 
human datasets from cohorts from The Gambia, SA, Malawi and with C57BL/6 mouse strain. Lower panel: Comparisons of 
C57BL/6 mouse strain data with human datasets from cohorts from Gambia, SA, Malawi and with 129S2 mouse strain. 
 
4.9. DISCORDANCE IN 129S2 AND C57BL/6 GENE 
EXPRESSION CHANGES CORRESPONDS WITH THE HIGHLY 
SUSCEPTIBLE PHENOTYPE 
Different susceptibility to low dose aerosol Mtb infection characterizes the 129S2 and 
C57BL/6 mouse strains. The highly susceptible 129S2 mice suffer from progressive TB and succumb 
to disease within 40 days p.i., while low susceptible C57BL/6 mice develop chronic TB and survive for 
more than 100 days p.i.. At very early time points p.i. there are no visible phenotypic differences in the 
disease development between C57BL/6 and 129S2 mouse strains. In the days 7-10 p.i. inflammatory 
cells such as neutrophils begin to infiltrate the site of infection in 129S2 mice, which is not observed in 
the C57BL/6 mice until approximately day 14 p.i. By 21 day p.i. the 129S2 strain develops severe lung 
pathology characterized by large, necrotic lesions, whereas in the C57BL/6 strain smaller non-necrotic 
lesions with less inflammation are formed.  
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I expected those differences to be illustrated on the transcriptional level. To test this 
hypothesis, at each investigated time point p.i. I compared the gene expression in the two mouse strains. 
There were no discordances present on the day 1 p.i. and the concordant modules encompassed 
“Complement and other receptors in DCs” (LI.M40), “complement activation” (LI.M112.0), “enriched 
in monocytes” (LI.M11.0), “immune activation- generic cluster” (LI.M37.0). All the enriched 
concordant modules were related to innate immunity, immune signaling and platelets. The same 
similarities remained present on day 7 p.i., when also spliceosome and proteasome related genes became 
co-regulated. On day 14, the amount of concordantly regulated modules further increased with the TB 
characteristic modules - “type I IFN response” and “antiviral IFN signaling” added to the ones present 
in earlier time points. The same set of modules additionally complemented by cell cycle related genes 
remained concordant on the day 21 p.i..  
At this last investigated time point some sudden differences appeared between the two mouse 
strains. A set of 13 T-cell related modules was identified as discordant, including “T cell activation and 
signaling” (LI.M5.1), “enriched in T cells” (LI.M7.0) and “enriched in NK cells” (LI.M7.2). Those 
modules were also identified as discordant between C57BL/6 mice and men. For the first time, the 
number of concordant modules for the two mouse strains was lower than the number of concordant 
modules between the 129S2 mice and man. Among the concordant modules between the two mouse 
strains there were modules related to innate immunity detected also at the earlier time points p.i.. In 
summary, the T-cell response has been identified as the major difference between 129S2 and C57BL/6 
mice at day 21 p.i., when the disease progressed more profoundly in the highly susceptible compared 
to the low susceptible mouse strain.  
4.10. T CELL CO-RECEPTOR GENES DRIVE THE 
DISCORDANCE BETWEEN HIGHLY SUSCEPTIBLE AND LOW 
SUSCEPTIBLE MICE 
I further investigated the expression of genes in four of the modules identified as discordant 
between 129S2 and C57BL/6 mouse strains on day 21 p.i.: “enriched in T cells (I)” (LI.M7.0), “T cell 
activation and signaling” (LI.M5.1) and “T cell activation (I)” (LI.M7.1). Between day 14 and 21 p.i. 
those genes were regulated in opposite directions between the strains (Figure 56). The genes driving 
those differences included Cd28, Cd3d, Cd3e, Cd3g, Cd5, Cd7 and Cd96, which encode T-cell co-
receptors. They were up-regulated in the low susceptible strain C57BL/6 but down-regulated in the 
highly susceptible 129S2 strain. To investigate how those genes are regulated in human TB patients in 
comparison to the both mouse strains I analyzed their expression in The Gambian cohort. Interestingly, 
the genes were highly concordantly regulated between the 129S2 mice and humans, and highly 
discordantly regulated between C57BL/6 mice and humans (Figure 57). Therefore, I identified 16 genes 
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related to T cell co-stimulation with opposite expression changes in human and highly susceptible 
129S2 mice vs low susceptible C57BL/6 mice. 
 
Figure 56 Expression changes of selected genes belonging to the T-cell related modules  
The pictured genes belong to the modules: “enriched in T cells (I)”, “T cell activation and signaling” and “T cell activation 
(I)”. The illustrated time points are: day 1, day 7, day 14 and day 21 p.i.. The selected genes drive the differences in the patterns 
of T-cell expression changes in (A) 129S2 and (B) C57BL/6 mice. 
 
Figure 57 Log2FC of the set of 16 genes plotted for mouse data vs data from patient cohort from Gambia  
(A) 129S2 mouse strain data plotted vs human data; (B) C57BL/6 mouse strain data plotted vs human data. Bars represent 
95% confidence intervals for the log fold change.  
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4.11. GENE EXPRESSION IN RESPONSE TO MTB INFECTION 
IS CONCORDANT IN HUMAN AND MURINE MACROPHAGES 
The discrepancies between human and murine C57BL/6 response to TB were related entirely 
to the adaptive immunity. Since macrophages are a crucial subset of cells taking part in Mtb infection 
and at the same time are innate immune cells, I investigated whether the discordances found in blood 
are also present in gene expression profiles of macrophages. In the first step I calculated differential 
gene expression between human THP1 cells 6 h p.i. and uninfected cells in a dataset collected by my 
colleague from MPIIB, Department of Immunology, Anca Dorhoi as well as in a murine dataset derived 
from a study by McNab et al. (2013) (comparison 26). 34 concordant modules including “antiviral IFN 
signature” (LI.M75), “RIG-1 like receptor signaling” (LI.M68), “chemokine cluster (I)” (LI.M27.0) and 
no discordant modules were detected in this comparison. This observation was reproduced in the other 
datasets derived from macrophages (Carow et al., 2011; Kaforou et al., 2013; Thuong et al., 2008; 
comparisons 25, 27-32 and 34-36). Those datasets covered a broad range of TB cases and time points 
p.i.: for example, in the dataset collected by Thuong et al. (2008) the macrophages were derived from 
patients who had recovered from pulmonary TB (samples referred to as PTB), TB meningitis (samples 
referred to as TBM) and individuals with LTBI. The macrophages were derived from isolated PBMCs 
and infected with Mtb for 4 h. I compared the LTBI samples (comparison 27), PTB samples 
(comparison 29) and TBM samples (comparison 31) with mouse bone marrow derived macrophages 
(BMDMs; Carow et al., 2011) non-stimulated and infected for 24 h with Mtb.  
22 modules were universally identified as concordant in each performed macrophage 
comparison (comparisons 25-36, Figure 58). They included the TB-characteristic IFN response related 
genes: “antiviral IFN signature” (LI.M75), “type I IFN response” (LI.M127), “chemokine clusters” 
(LI.M27.0, LI.M27.1), and “innate activation by cytosolic DNA sensing” (LI.M13), “cell cycle and 
growth arrest” (LI.M31) and “enriched in activated dendritic cells/monocytes” (LI.M64). No 
overlapping discordant modules were detected in the comparisons of different human and murine 
macrophage datasets. The detected concordances in the early time points after infection were related to 
innate immunity (e.g. “innate activation by cytosolic DNA sensing” (LI.M13), “chemokine cluster” 
(LI.M27.0), “chemokines and receptors” (LI.M38). The time points of 24 h p.i. presented also 
concordant IFN response and DC activation. 
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Figure 58 Concordant modules in the comparisons of murine and human macrophages 
While the WB response to Mtb infection involved T- and B-cell signaling, in macrophages the 
enrichment was mostly clustered in cell cycle, metabolism and innate immunity. As stated before, 
macrophages are critical elements of the first line of defense against Mtb infection (Dorhoi & 
Kaufmann, 2015; Thuong et al., 2008). Absence of discordant modules indicates that the expression 
regulation of the macrophage response to Mtb is largely conserved in mouse and man. 
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5. CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the last chapter of my thesis I summarize the conducted analysis and comment the obtained 
results. Advantages and flaws of the presented methods and approaches are addressed. I compare the 
findings described in this thesis to the previously published statements. I describe the conclusions 
derived from analysis of individual variability among TB patients in the first part of the chapter and 
those derived from the comparison of transcriptomic responses to TB in man and mouse in the second 
part of the chapter, and describe how the developed methods and pipelines could be used for the analyses 
of different problems. 
No scientific work can be contained in one independent publication, because it is inspired by 
previously performed research or previously asked questions, and it should still inspire scientists to 
continue, validate or contradict it in the future. This thesis is deeply rooted in the questions arising 
around the problem of understanding TB as well as in everyday questions asked by the scientists in a 
TB laboratory, for example: which animal model to use to mimic certain aspect of TB? It also makes 
use of multiple previously published studies and data collections. In the discussion of my results I look 
at the results again from a wider perspective of the TB research field and suggest how will those results 
influence the current understanding of TB and how can future research benefit from the results presented 
in this thesis.  
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5.1. THE ACHIEVEMENTS OF THIS THESIS 
5.1.1. Analysis of individual variability among TB patients 
In the presented analysis of individual variability among TB patients I have shown that 
subgroups of them are characterized by various activation profiles of immune response. Specifically, I 
focused on the scale of IFN signaling in particular patients and have shown that there are TB patients 
who do not develop strong IFN responses when undergoing TB which is correlated with less severe 
disease.  
In order to show it, I collected publicly available data from seven TB patient cohorts into one 
meta-dataset and performed GSEA for each patient on the list of genes sorted by the z-score 
corresponding to the probability that the expression value of particular gene belongs to the distribution 
of the expression values of this gene in healthy individuals. The results clearly showed that even though 
enrichment of modules including T-cells, B-cells, innate immunity, IFN signaling, monocytes and many 
others typically enriched in TB patients is significant in majority of the TB patients, in each study cohort 
there are individuals who lack this characteristic enrichment. Moreover, there were visible patterns of 
gene expression among the TB patients which were independent of the study they originally participated 
in. This raised further questions I asked in this thesis: are there several coherent, identifiable genetic 
profiles that can be activated by different individuals in response to TB? What are the correlates of the 
differences in transcriptomic profiles of the TB patients? To answer these questions, I focused on one 
of the most striking differences among the studied patients: IFN response, which has been previously 
described as dominant response in TB on transcriptomic level.  
Division into IFN- and IFN+ patients 
Two types of IFN signaling which have been shown to be crucial for the outcome of TB are 
(i) the mostly detrimental type I IFN signaling pathway and (ii) the protection mediated by IFN type II 
signaling pathway. However, around 17% of the TB patients collected in the training MDS did not 
present enrichment in the modules related to IFN signaling. Out of the patients with enrichment in the 
IFN modules, 89% were enriched in both IFN type I and II IFN modules, 6% in IFN type I and 5 % 
with IFN type II modules only. To further investigate the patients presenting enrichment in IFN type I 
gene modules, I split the cohort of TB patients from the MDS into IFN I positive and IFN I negative 
donors based on the enrichment in IFN type I modules and further investigated the differences between 
them.  
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Investigation into the differences in the gene expression between the IFN- and IFN+ 
patients 
In the first step I used logistic regression models and unsupervised ML models to test whether 
the IFN status is related to any other known factors influencing the datasets: the HIV status of the 
patients, their ethnicity and residence, and the microarray platforms used to conduct experiments. TB 
was the most significant factor influencing the IFN+ status; on the other hand, coinfection with HIV 
and Streptococcus sp. and Staphylococcus sp.  was also significant. GSEA on the weights of genes 
calculated in PCA in the components differentiating between IFN+ and IFN- patients has shown that 
contribution of T cells and NK cells is dominant in this division. PCA of samples from TB patients 
revealed that even though the data has been normalized, the differences between datasets derived from 
different studies still stratify the data. However, it does not translate into significant biological 
differences: the enrichment in genes sorted by weights in the principal components differentiating 
between the studies resulted in only 4 significantly enriched modules.  
The differences in the enrichment of IFN related modules could be a consequence of varying 
levels of IFN-α, IFN-β or IFN-γ signaling molecules in the WB. However, the IFN+ and IFN- patients 
presented similar expression of IFNA2, IFNB1 and IFNG genes. Despite that, there were significant 
differences in the expression of IFN-α and IFN-γ receptor genes and IFN-inducible genes such as 
BATF2, CXCL10 and ANKRD22 between IFN+ and IFN- patients. This indicated that the regulation 
of the gene expression in IFN+ and IFN- TB patients does not happen through increased or decreased 
expression of IFN-α,-β or -γ signaling molecules.  
Investigation into the biological differences between the IFN+ and IFN- TB patients 
The GSEA-based stratification of the individuals into IFN- and IFN+ groups was shown to be 
biologically relevant using two independent datasets: one containing samples from individuals after and 
before influenza vaccination and one which contained individuals suffering from sepsis. In both studies 
I identified IFN+ and IFN- individuals. Moreover, I compared the IFN status of the IFN- and IFN+ 
volunteers after the FLUAD® vaccination with the measured total levels of IFN-inducible CCL2 and 
CXCL2 cytokines in their blood and showed that there is a significant difference in the levels of those 
cytokines between IFN+ and IFN- donors, which showed that the observations made on the 
transcriptomic level have their functional consequence in blood. 
Comparison of the biosignatures of the IFN- and IFN+ TB patients 
I identified the biosignatures of IFN+ and IFN- TB patients using ML methods. First, I created 
multiple RF models trained to detect the TB patients among healthy people, people with OD and all 
non-TB individuals. I derived various sizes of biosignatures of both IFN+ an IFN- TB patients and 
tested the performance of the biosignatures in identifying TB patients depending on their size (number 
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of included transcripts). The optimal size of IFN+ biosignature was 20 transcripts, while the optimal 
size of the IFN- biosignature was 50 transcripts. Next, using the training MDS I derived the gene 
signatures of IFN+ and IFN- TB patients. One of the features of an efficient biosignature of any disease 
is that it should detect all forms of this disease among healthy people as well as among people suffering 
of OD. The identified biosignatures of TB IFN+ and TB IFN- patients consisted of varying numbers of 
genes among which only one transcript was present in both biosignatures: ANKRD22. Among the 
transcripts present in the TB IFN+ signature 6 transcripts, and among the transcripts present in the TB 
IFN- signature 9 transcripts overlapped with the 53-transcript biosignature of TB identified by Kaforou 
et al. in 2013. 
The derived signatures have been tested on the test MDS as well as on two independent 
datasets, one including healthy and TB patients from China (Cai et al., 2014) and one including healthy, 
TB and sarcoidosis patients recruited in London (Blankley, Graham, Levin, et al., 2016). The signature 
derived from IFN+ TB patients was highly sensitive and specific towards IFN+ TB patients, however 
its performance was significantly worse in identification of IFN- TB patients among HCs and in 
particular among patients with OD. On the other hand, the IFN- TB biosignature presented slightly 
lower AUC values for identification of TB patients overall, but the classification based on it was 
characterized by similar sensitivity and specificity of detection of IFN- and IFN+ patients among HCs, 
OD or all non-TB individuals. The exception was the detection of TB patients among sarcoidosis 
patients, in whom only IFN+ TB biosignature detected the TB patients correctly. The obtained results 
showed that (i) the IFN+ and IFN- TB patients are characterized by different biosignatures, and (ii) that 
the IFN- TB biosignature can be used to detect IFN+ TB patients with better outcome than the other 
way round, (iii) that even though the TB IFN- signature is more universal, it fails to differentiate 
between IFN+ TB patients and sarcoidosis patients.  
As a control for the method of identification of IFN- and IFN+ patients as well as for the 
specificity of the derived biosignatures I identified a 20-transcript sepsis IFN+ signature and a 50-
transcript sepsis IFN- biosignature. Interestingly, the TB patients could also be identified on the basis 
of sepsis biosignatures with moderate accuracy. However, the TB biosignatures were highly specific 
and did not correctly classify the sepsis patients. This indicated that the sepsis IFN+ signature is in part 
TB-specific, but also partially IFN-response specific. This might cause false negative results when 
applied to patients without a strong IFN response.  
Analysis of the concordance of the gene expression between IFN+ and IFN- patients 
The expression of several genes, e.g. CD274 and CD273, was strikingly different between 
IFN+ and IFN- TB patients which I have shown using disco.score. The CD274 and CD273 genes encode 
programmed-death ligands 1 (PD-L1) and 2 (PD-L2). PD-L1 and PD-L2 are immunomodulatory 
molecules that act largely through interaction with PD-1 receptor. PD1 interacts with PD-L1 and PD-
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L2 delivering inhibitory signals to regulate T-cell and other responses (McNab et al., 2011). In TB it 
has been shown that antibodies blocking PD-L1, PD-L2 enhanced Mtb antigen-specific IFN-γ responses 
and CD8+ T cell cytotoxicity from peripheral blood and pleural fluid mononuclear cells (Hassan, 
Akram, King, Dockrell, & Cliff, 2015; McNab et al., 2011; Alvarez et al., 2010; Trinath et al., 2012). 
It has been previously observed that among TB patients who in general have increased levels of CD274 
there are individuals with surprisingly low levels of expression of this gene (McNab et al., 2011). 
However, those patients were considered exceptional. In this thesis I show, that this phenotype is present 
among majority of the published TB transcriptomic studies. Thus, rather than being outliers, these 
patients form a subgroup presenting a different activation profile in response to TB. In the study by 
McNab from 2011 it has been stated that those exceptionally low level of CD274 expression were 
identified in a patient who at the same time did not present pathology in lungs in spite of being diagnosed 
with TB. This corresponds well with the findings of the work presented here. Using datasets containing 
X-Ray studies of lungs of the TB patients whose blood has been profiled on microarrays I present that 
IFN+ status corresponds with high level of pathology in lungs. However, I do not approach the question 
of whether the high level of IFN signaling promotes disease burden increase or rather the higher level 
of pathology induces stronger IFN response. The answer to this question cannot be drawn from the data 
analyzed here.  
Other genes with significantly different but still concordant expression between IFN+ and 
IFN- patients include PAR2, C1QC, CARMIL2 and CAPN5. All of these genes have been previously 
reported to play an important role in TB or in immunity. The C1QC is a complement cascade gene and 
is present in some of the previously published TB biosignatures (Kaforou et al., 2013). PAR2 has been 
recently described as important for the inhibition of Mtb growth (Chávez-Galán, Ramon-Luing, 
Carranza, Garcia, & Sada-Ovalle, 2017). The differential expression of those genes between IFN+ and 
IFN- patients could therefore be involved in the observed relationship between the IFN levels and lung 
pathology in TB patients. 
Immune response profiles of the TB patients 
Focusing on the differences in the IFN response among TB patients is an approach to the main 
question of this thesis, which is whether different patterns of the immune response in TB exist. IFN 
response is only one of the elements of immune response against TB and is strongly related to T cells 
and NK cells which are responsible for IFN production. By creating the correlation matrix of the 
eigengenes of the modules enriched in TB patients I show that indeed also the other elements of immune 
responses differ between patient subgroups. The main division is related to innate and adaptive 
immunity – in most cases, increased transcript levels of the genes in the modules related to innate 
immunity correlated with decreased transcript levels of the genes in modules involved in adaptive 
immunity. In analogy, decreased transcript levels of the innate immunity genes were correlated with 
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increased transcript levels of the adaptive immunity genes. However, the patterns of immune response 
presented by groups of individuals were not as simple as that. The response of monocytes, platelets, 
modules related to erythropoesis and to activated CD4+ T cells also presented great variability and 
altogether the investigated modules formed six patterns of gene expression activation including 
activation and suppression of transcripts involved in particular modules. 
I tested if differences related to the adaptive and innate immunity activation are explained by 
the phase of the disease which an individual is undergoing and which corresponds to the time p.i.. Since 
such hypothesis cannot be tested on human data because the infection time is not known, I used dataset 
from a study conducted on macaques. Analysis of datasets collected from 38 Mtb infected macaques 
among which 16 developed active TB and 22 remained latently infected (Gideon et al., 2016) 
contradicts this possible explanation of the mentioned differences. The variability in IFN response is 
observed in those animals independent of their disease status and severity and has different strength 
independent of time p.i.. Even though the general trend of the development of IFN response between 
20 and 40 day p.i., which corresponds with the establishment of adaptive immunity, is visible, the fate 
of IFN response is variable in both active TB and LTBI macaques. Some of the LTBI animals retain 
strong IFN response also in the later days p.i. whereas some of the animals suffering of TB present very 
weak IFN response even throughout the time of peaking adaptive immunity phase. This suggests that 
strong IFN response does not depend on a particular stage of the disease development, but rather that 
its dynamics is highly host-related.  
Limitations of this study 
The presented study is an insight into individual variability among TB patients and it is 
characterized by many limitations among which some have been included already in its assumptions. 
First and foremost, human cohorts present a marked challenge to study because apart from genetic 
variability also the conditions of human life and circumstances of the infection and disease development 
are uncontrollable and untraceable. We do not know with what doses of Mtb the host got infected, 
neither in which moment of life or under what temporary state of host’s organism the infection 
happened. Even the time points of TB diagnosis strongly differ: while some patients could have been 
identified during systematic screening for TB, others only come to the clinics while already having 
developed severe pathology. Moreover, another portion of variability is related to experiment planning 
and conducting, technical variation and various samples processing methods used in different studies. 
For this reason, in the presented work I proposed multi-level validation of my results. Primarily, I used 
k-fold cross-validation on the training MDS containing 80% of the acquired samples. The remaining 
20% of the samples remained untouched and served for independent testing. Last, the obtained results 
were validated on two independent validation datasets and the whole pipeline on datasets from different 
diseases. I did also compare the transcriptomics-based results with the results of different types of 
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measurements: cytokine levels in blood and X-ray based detection of lung pathology. I compared my 
findings to previously noted observations in TB showing that in many of the published studies patients 
with weaker or unexpected gene expression profiles have been observed as well as that the expression 
of IFN-related genes was linked with the outcome of TB. 
Useful methods and data collections presented in this study 
I applied the proposed normalization and analysis methods in several external datasets not 
only from TB but also sepsis and influenza studies. The suggested analysis framework was robust and 
in the future can be used in other multi-cohort studies. A useful dataset collection has been selected out 
of the published TB datasets and can be accessed on the website: http://bioinfo.mpiib-
berlin.mpg.de/TBprofiles/. Additionally, a new set of IFN type I, IFN type II and IFN type I and II 
inducible genes have been created. 
Outlook  
An important message from this study, strengthened by the inclusion of multiple human cohort 
datasets, platforms and studies, is that the attempts to define TB signature may involve a significant 
bias if they do not account for individual variability between hosts. Variable outcomes, pathology and 
even drastically different consequences of Mtb infection imply that it is not enough to assign the patients 
with TB into one of the general classes: “sick” or “healthy”. The representations of this disease can on 
transcriptomic level be similar to inflammatory, immunosuppressive or chronic disease and I suggest 
that this should also be accounted for in TB diagnosis. 
5.1.2. Comparison of the response to TB among different mouse strains 
In this study, with the help of my colleagues from the Department of Immunology and 
Microarray Core Facility of MPIIB I identified elements of the immune response to TB which are 
conserved and which are divergent between man and two different mouse strains. Importantly, I 
demonstrated that a highly susceptible mouse strain 129S2 mimics human active TB more closely than 
the resistant C57BL/6 strain.  
The development of a novel comparison method for heterogeneous datasets 
The achievements of this project include development of a universal method for comparison 
of heterogeneous datasets - disco.score.  
Intending to compare transcriptomic datasets from different mouse models of TB with the 
patients’ data I tested the existing approaches of assessing similarities in gene expression in different 
species. Since none of the methods resulted in biologically meaningful conclusions I created an 
algorithm, disco.score, directed at identification of concordantly and discordantly regulated genes in a 
set of heterogeneous datasets. The motivation behind developing the disco.score was to create a 
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comparison algorithm which assumptions would encompass not only existence of similarities but also 
discordances in the responses to threat evolved by different organisms. Identification of these 
differences can be accompanied by the observation of the diverse phenotypes presented by the 
organisms from which the datasets were derived. This way, the identification of concordance and 
discordance is a source of information helping to explain the occurring different outcomes of particular 
disease. This information cannot be derived in a straightforward way from other common approaches 
like differential expression analysis which are not designed to be used directly with heterogeneous 
datasets, i.e. derived from different experiment types. Complemented by GSEA, the algorithm 
developed in this thesis indicates which elements of immune response are regulated in a similar or in 
opposite way between the compared datasets.  
The proposed method was validated on datasets comparing responses to the same immune 
system stimulations in mouse and man or in different human populations and to compare the human 
immune responses to TB and sarcoidosis, diseases with nearly identical gene expression profile. 
Ultimately, the method was applied to compare transcriptional responses to TB in human and murine 
WB and monocytes. I acquired publicly available datasets from human WB and macrophages and my 
colleagues Lisa Scheuermann, Anca Dorhoi, Karin Hahnke (MPIIB, Department of Immunology) and 
Hans Mollenkopf (MPIIB, Microarray Core Facility) performed experiments to generate comparable 
datasets from WB of two mouse strains differing in susceptibility and frequently used to model TB as 
well as from murine macrophages and human macrophage-like THP-1 cells.  
Characteristics of the disco.score 
Disco.score can be applied to any number of gene expression datasets with calculated p-values 
and log2FC values for differential gene expression, but at a time it compares two datasets only. Instead 
of evaluating the overall similarities between the datasets, it identifies the most concordant and 
discordant genes or gene modules, which is reasonable in the light of evolutionary principles which 
imply that parts of the original systems, for example of the immune system, remain conserved and parts 
diverge over time.  
Since disco.score can be calculated for every pair of heterologous genes present in the 
compared datasets it circumvents the bias of arbitrary gene choice. Lastly, the score is not restricted to 
be used in the comparison of immune system stimulation events, but it includes the possibility of using 
any gene sets of interest (e.g. GO terms or self-created gene modules). 
Even though disco.score has been designed for the purpose of identifying similar and different 
elements of immune response between mouse and man, it can also be used in different types of analysis. 
For example, in the studies focusing on a particular gene or gene set, disco.score can serve to compare 
the expression regulation of the genes of interest among different conditions. The score can be used to 
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create novel gene sets – e.g. top ranking genes in disco.score can be combined in a new module 
characterizing a particular disease model.  
Disco.score accuracy highly depends on the quality of the investigated data and availability of 
gene annotation. The algorithm does not allow correction for cell numbers which influence 
interpretation of the transcriptional studies and should be performed independently. Lack of an 
analytical distribution of disco.score means that no direct p-value can be derived for the score. 
Comparison of the human datasets with two mouse models of TB using disco.score 
Using disco.score I inspected the comparison of the gene expression patterns in two mouse 
strains, highly susceptible to TB 129S2 mouse and low susceptible C57BL/6 mouse upon the time 
course of infection. The number of concordances between them was increasing with time p.i. without 
any identified discordances. However, after the day 14 p.i. TB rapidly progressed in the susceptible 
mice. At the same time, discordant gene modules appeared between low susceptible vs highly 
susceptible mice and TB patients. 
The highest number of similarities between the transcriptional profiles of patient cohorts from 
different geographical locations in Africa and mice was detected at day 21 p.i. The similarities 
encompassed IFN response, innate immunity mechanisms and B-cell signaling. At day 21 p.i. very few 
gene modules were discordant between the highly susceptible 129S2 mouse strain and TB patients. In 
contrast, significant number of modules remained discordant between the low susceptible C57BL/6 
strain and TB patients. Those numbers reflected the fact, that TB patients as well as highly susceptible 
mice 21 days p.i. suffered from active TB, while the low susceptible C57BL/6 mice remained 
asymptomatic. This suggests that active TB is more accurately mimicked by the susceptible 129S2 
mouse.  
Investigation into the differences underlying the observed discordance in gene 
expression patterns of the C57BL/6 mouse strain and man 
The discordances present at the 21st day p.i. between the human cohorts or highly susceptible 
129S2 mice and low susceptible C57BL/6 mice were related to T cell functions. I inspected the 
regulation of the genes present in those modules in the course of infection and identified 16 of them as 
responsible for the discordance between 129S2 and human vs C57BL/6 gene expression. The 16 genes 
were regulated in opposite directions in the highly susceptible mouse vs low susceptible mouse and 
man at every time point p.i. T cell proliferation differences in lungs of susceptible mouse strain I/St and 
resistant mouse strain A/Sn have already been described, however without indicating genes responsible 
for this phenomenon (Eruslanov et al., 2004). Another study performed on susceptible and resistant 
macaque lineages also points out those differences (Javed et al., 2016). In the TB-susceptible macaques 
T-cell related genes were down-regulated at week 6 p.i. when animals had lost 10% body weight. The 
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genes CD28, CD3E and T-cell co-stimulatory molecules down-regulated in the macaques were at the 
same time identified as discordant by disco.score between susceptible and resistant mouse strains. It is 
therefore tempting to speculate that the 16 identified genes play a crucial role in acquired susceptibility 
and resistance in TB.  
Interpretation of the obtained comparison results 
The results of comparison of human and murine WB transcriptome need to be interpreted 
carefully, with attention paid to the fact that they might be influenced by the variation in the composition 
of human and murine blood. Apart from the differences in the healthy organisms, the cell counts change 
upon infection. For example, the CD4+ and CD8+ cell counts decrease in blood of TB patients 
compared to healthy individuals (Berry et al., 2010). 33 genes have been previously identified as 
disease-associated in a study on gene expression in sorted CD4+ and CD8+ T cell populations from TB 
patients, LTBI and controls (Jacobsen et al., 2011). This set of genes was enriched in JAK-STAT 
signaling pathway. I have found several of those genes present in the enriched module “Hallmark IL2 
STAT5 signaling” identified as concordant in comparisons of South African and murine WB data from 
C57BL/6 and 129S2 strains.  
Conclusion from comparing the high- and low susceptible mouse strains with human 
datasets 
The conclusion of analysis of the two murine models´ similarity to human TB is that out of 
the investigated time points, mice at the time point of 21 days p.i. most resemble TB patients. At this 
time point the highly susceptible 129S2, but not the low susceptible C57BL/6 mice closely mimic 
genetic response in WB of the patients. However, since I did not investigate late time points p.i. of 
C57BL/6 mice, I cannot exclude that the WB transcriptional profile of these mice becomes more similar 
to human TB WB profile with time.  
The obtained results demonstrate that depending on the animal model used, gene expression 
may variably mirror human disease and should be taken into account in translational studies, e.g. drug 
or vaccine tests. I also showed that the gene expression regulation in the macrophages upon Mtb 
infection is similar in mouse and man. 
Outlook 
This study comparing two profoundly different murine models of TB emphasizes the need to 
identify the best-fit animal model as correlate for a particular human disease. Disco.score as a 
straightforward, robust and simple method is the first step in this direction. It can help us to understand 
which elements of gene expression regulation are widely conserved between man and model organisms; 
which can be used in translational research and are species-specific and give low chances of translation 
to human.  
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For the field of TB research in which I gained deep insights during my doctoral studies I see 
a need of creating a compendium of discordant and concordant gene expression profiles between human 
cohorts and the animal models used to mimic TB. It would vastly help the scientists intending to conduct 
translational research to pick the right model for the specific topic investigated by them, for example 
T-cell response or innate immunity. The first step to create such compendium is to perform reproducible 
experiments and publish the obtained data. As soon as the datasets from broad range of murine and else 
animal models used to study TB is available in the public repositories, they can be compared with the 
human datasets for example with use of disco.score.  
5.2. THE OUTLOOK OF THIS THESIS 
TB remains a challenge for clinicians and researchers despite over 100 years of research since 
Mtb has been identified. Part of this challenge is related to the variability in the outcome of Mtb 
infection. In my doctoral work I looked at the variability in host responses to TB from different angles: 
investigating the differences between individual patients as well as searching for changes in the gene 
expression that explain different outcomes of Mtb infection in various animal models. I have shown 
that the inter-individual variability is strongly related to the extent of IFN signaling in human hosts. The 
variability between different murine models of TB was linked with the discordant expression of T-cell 
co-receptor genes.  
These two results point out the mechanisms of high interest and high complexity which are 
extensively studied in the field of TB. My work brings additional insights into the background of 
phenotypic differences between highly and low susceptible murine models of TB and describes 
correlates of IFN signaling in TB patients. Altogether it is another tiny piece in the big picture of the 
complexity of TB. The described results are shown to be meaningful when seen in the context of other 
studies.  
In my thesis I have developed and proposed methods which can contribute to further animal 
model studies of TB and other diseases as well as to analyze the individual variability of host responses 
to pathogen infection.  
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8. SUPPLEMENTARY MATERIAL 
Supplementary Table 1. Assignment of the genes from the original Li et al. and Chaussabel et al. modules to the new 
IFN type I, IFN type II and IFN type I and II modules  
Original ID and name are derived from (Chaussabel et al., 2008; Li et al., 2014). IFN type is based on the assignment by 
Interferome database (Rusinova et al., 2012). 
Original 
ID 
Original name genes IFN type New module New ID 
LI.M127 type I IFN 
response 
TAP1 I and II Type I and II IFN module 1 LI.M127_IandII 
IFIH1       
IRF7 I and II Type I and II IFN  module 1 LI.M127_IandII 
PARP9 I and II Type I and II IFN  module 1 LI.M127_IandII 
STAT1 I and II Type I and II IFN  module 1 LI.M127_IandII 
PLSCR1 I and II Type I and II IFN  module 1 LI.M127_IandII 
IFITM1 I and II Type I and II IFN  module 1 LI.M127_IandII 
HERC5 I     
DDX60 I and II Type I and II IFN  module 1 LI.M127_IandII 
USP18 I     
RSAD2 I and II Type I and II IFN  module 1 LI.M127_IandII 
IFIT1 I and II Type I and II IFN  module 1 LI.M127_IandII 
LI.M75 Antiviral IFN 
signature 
IFIH1       
ELANE       
SERPING1 I and II Type I and II IFN  module 2 LI.M75_IandII 
IL1B I Type I IFN  module 1 LI.M75_I 
RSAD2 I and II Type I and II IFN  module 2 LI.M75_IandII 
IFIT1 I and II Type I and II IFN  module 2 LI.M75_IandII 
RARA       
DDX58 I Type I IFN  module 1 LI.M75_I 
FCER1A I Type I IFN  module 1 LI.M75_I 
DHX58 I and II Type I and II IFN  module 2 LI.M75_IandII 
PTX3       
CARD9       
OAS1 I and II Type I and II IFN  module 2 LI.M75_IandII 
OAS3 I Type I IFN  module 1 LI.M75_I 
PML I and II Type I and II IFN  module 2 LI.M75_IandII 
ANXA3       
HERC5 I Type I IFN  module 1 LI.M75_I 
DDX60 I and II Type I and II IFN  module 2 LI.M75_IandII 
CXCL10 I Type I IFN  module 1 LI.M75_I 
IRF7 I and II Type I and II IFN  module 2 LI.M75_IandII 
C1QB       
BCL3       
LI.M158.0 IFN alpha 
response (I) 
LHCGR       
COL8A1   
IMPG2   
ITGB4   
MMP12 I 
TNR   
IFNA7   
IFNA4   
SFN   
LAMC2   
ST14   
ADAMTS20   
FGF5   
IFNA10 I 
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IFNA16   
IFNA14   
LI.M158.1 IFN alpha 
response (II) 
LHCGR       
AMER2   
IFNA8   
IFNA2   
IFNA7   
IFNA5   
IFNA4   
IFNA21   
PRL   
ADAMTS20   
IFNA10 I 
IFNA16   
IFNA14   
DC.M5.12   RBCK1 I Type I IFN  module 2 DC.M5.12_I 
TRAFD1 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
TRIM21 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
LOC401433       
RFWD2       
CHM5       
TAP2 I Type I IFN  module 2 DC.M5.12_I 
SP110 I Type I IFN  module 2 DC.M5.12_I 
GADD45B       
IFI16 I Type I IFN  module 2 DC.M5.12_I 
TAP1 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
ZNFX1 I Type I IFN  module 2 DC.M5.12_I 
PHF11 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
ACTA2 I Type I IFN  module 2 DC.M5.12_I 
C1QA I and II Type I and II IFN  module 3 DC.M5.12_IandII 
SP140 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
ABCA1       
TCN2 I nad II Type I and II IFN  module 3 DC.M5.12_IandII 
ZC3HAV1 I Type I IFN  module 2 DC.M5.12_I 
HSH2D I Type I IFN  module 2 DC.M5.12_I 
LOC55420
3 
      
GBP2 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
TRIM5 I Type I IFN  module 2 DC.M5.12_I 
RHBDF2       
TMEM140 I Type I IFN  module 2 DC.M5.12_I 
ADAR I and II Type I and II IFN  module 3 DC.M5.12_IandII 
BTN3A1 II     
PARP10 I nad II Type I and II IFN  module 3 DC.M5.12_IandII 
LGALS9 I Type I IFN  module 2 DC.M5.12_I 
NBN I Type I IFN  module 2 DC.M5.12_I 
TYMP I and II Type I and II IFN  module 3 DC.M5.12_IandII 
SAMD9 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
SRBD1       
NCOA7 I Type I IFN  module 2 DC.M5.12_I 
DRAP1 I Type I IFN  module 2 DC.M5.12_I 
UNC93B1 I Type I IFN  module 2 DC.M5.12_I 
SP100 I Type I IFN  module 2 DC.M5.12_I 
NTNG2 I Type I IFN  module 2 DC.M5.12_I 
DHRS9 II     
TDRD7 I Type I IFN  module 2 DC.M5.12_I 
TRANK1 I Type I IFN  module 2 DC.M5.12_I 
MDK I Type I IFN  module 2 DC.M5.12_I 
NT5C3A I and II Type I and II IFN  module 3 DC.M5.12_IandII 
ASPRV1       
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IRF9 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
REC8       
RNF213 I Type I IFN  module 2 DC.M5.12_I 
ISG20 I nad II Type I and II IFN  module 3 DC.M5.12_IandII 
DYNLT1 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
LHFPL2       
TRIM56 I Type I IFN  module 2 DC.M5.12_I 
TRIM25 I Type I IFN  module 2 DC.M5.12_I 
TRIM38 I Type I IFN  module 2 DC.M5.12_I 
ETV7 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
PSMB9 I and II Type I and II IFN  module 3 DC.M5.12_IandII 
CPT1B       
BST2 I Type I IFN  module 2 DC.M5.12_I 
CASP1 I Type I IFN  module 2 DC.M5.12_I 
NMI I and II Type I and II IFN  module 3 DC.M5.12_IandII 
DC.M1.2 IFN LY6E I and II Type I and II IFN  module 4 DC.M1.2_IandII 
IFIT1 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
OAS1 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
IFIT3 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
OAS3 I Type I IFN  module 3 DC.M1.2_I 
OASL I Type I IFN  module 3 DC.M1.2_I 
LOC129607       
ISG15 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
HERC5 I Type I IFN  module 3 DC.M1.2_I 
MX1 I Type I IFN  module 3 DC.M1.2_I 
BATF2 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
LAMP3 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
IFI44L I and II Type I and II IFN  module 4 DC.M1.2_IandII 
XAF1 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
IFI44 I Type I IFN  module 3 DC.M1.2_I 
OAS2 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
TRIM6       
HES4 I Type I IFN  module 3 DC.M1.2_I 
OTOF I Type I IFN  module 3 DC.M1.2_I 
FLJ20035       
IFITM3 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
CXCL10 I Type I IFN  module 3 DC.M1.2_I 
EPSTI1 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
SERPING1 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
LOC26010       
RSAD2 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
RTP4 I and II Type I and II IFN  module 4 DC.M1.2_IandII 
DC.M3.4 IFN IFIH1       
IRF7 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
PARP14 I Type I IFN  module 4 DC.M3.4_I 
IFIT2 I Type I IFN  module 4 DC.M3.4_I 
IFI35 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
SAMD9L I and II Type I and II IFN  module 5 DC.M3.4_IandII 
STAT1 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
OAS2 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
IFIT5 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
ATF3 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
geneSEPT4 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
HERC6 I Type I IFN  module 4 DC.M3.4_I 
IFITM1 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
TRIM78P   Type I IFN  module 4   
EIF2AK2 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
AIM2 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
MT1A       
MOV10 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
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CCL8 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
HELZ2 I Type I IFN  module 4 DC.M3.4_I 
ZBP1 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
WARS I and II Type I and II IFN  module 5 DC.M3.4_IandII 
LAP3 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
GBP5 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
TNFSF10 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
GBP1       
FBXO6 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
PARP10 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
TRIM22 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
GBP3 I Type I IFN  module 4 DC.M3.4_I 
ZNF684       
CARD17       
GALM I Type I IFN  module 4 DC.M3.4_I 
DHX58 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
CEACAM
1 
      
UBE2L6 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
PML I and II Type I and II IFN  module 5 DC.M3.4_IandII 
APOL6 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
SOCS1 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
LGALS3BP I and II Type I and II IFN  module 5 DC.M3.4_IandII 
SCO2       
DDX58 I Type I IFN  module 4 DC.M3.4_I 
TNFAIP6 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
IDO1 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
MT2A       
GBP6       
STAT2 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
TIMM10       
PARP12 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
PLSCR1 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
PARP9 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
LOC400759       
GBP4 I and II Type I and II IFN  module 5 DC.M3.4_IandII 
 
  
173 
 
Supplementary Table 2 IFN type I signaling genes present in MDS according to Interferome database classification 
1 A2M AAK1 ABCA6 ABCC3 ABCD1 ABCD2 ABCD3 
8 ABCF1 ABCG2 ABHD15 ABHD2 ABHD3 ABL2 ABTB2 
15 ACACA ACAD9 ACO1 ACOT9 ACOX1 ACTA2 ACVR1 
22 ACYP1 ADA ADAM12 ADAMDEC1 ADAP2 ADD3 ADPRH 
29 ADPRHL2 ADRB2 ADSL AFF1 AGO1 AGRN AHR 
36 AKAP10 AKR1C3 ALAD ALDH1A2 ALDH3A2 ALDH5A1 ALKBH1 
43 ALOX5AP AMOTL2 AMPD2 AMT AMY1C ANAPC5 ANGEL2 
50 ANGPT2 ANGPTL4 ANK2 ANK3 ANKFY1 ANKRD12 ANKRD55 
57 ANKS1A ANXA2R AOC1 AP1S2 AP3S2 APEX1 APLNR 
64 APLP2 APOBEC3A APOBEC3B APOBEC3F APOC1 APOC2 APOC4-APOC2 
71 APOE APOM ARAP1 ARAP2 ARF3 ARHGAP19 ARHGAP23 
78 ARHGAP25 ARHGAP27 ARHGAP29 ARHGAP33 ARHGAP35 ARHGEF15 ARHGEF2 
85 ARHGEF3 ARHGEF9 ARID3A ARID5A ARL15 ARL2 ARL2BP 
92 ARL4C ARMCX1 ARRB1 ARRDC2 ARSD ARSE ASAH2 
99 ASAP2 ASB1 ASB14 ASGR1 ASS1 ATF1 ATG10 
106 ATG14 ATG2A ATL3 ATM ATP1B2 ATP2B1 ATP2B4 
113 ATP5B ATP6AP2 ATP6V0A2 ATP6V0B ATP6V1G2-
DDX39B 
ATPAF2 ATRIP 
120 ATRN ATRX ATXN7 AUTS2 AXIN2 AZI2 B3GNT2 
127 BACH1 BAG1 BARD1 BATF3 BAX BBS4 BCKDHA 
134 BCL6 BCL7A BCS1L BICD2 BLNK BLVRA BNIP1 
141 BPGM BRD3 BRD8 BRI3BP BRIP1 BST2 BTG1 
148 BTG2 BUB1 C11orf58 C12orf57 C12orf76 C14orf28 C17orf75 
155 C19orf66 C1GALT1 C1orf27 C21orf91 C2CD2 C2orf27A C4BPA 
162 C4orf33 C4orf46 C6orf48 C9orf66 CACNA1A CACNG1 CACTIN 
169 CALCRL CALML3 CAMK1 CAMK2G CAMSAP2 CAMTA1 CAMTA2 
176 CANX CARD16 CARF CASP1 CASP10 CASP2 CASP4 
183 CASP7 CBFA2T3 CBR1 CBWD1 CBWD2 CBWD3 CBX1 
190 CBX3 CBX5 CCDC62 CCL11 CCL2 CCL20 CCL22 
197 CCL24 CCNA1 CCNE1 CCNG1 CCNG2 CCR1 CCRL2 
204 CD101 CD14 CD163 CD164 CD207 CD2AP CD2BP2 
211 CD68 CD69 CD79B CD80 CD86 CD99 CDC42EP3 
218 CDH18 CDK17 CDK5 CDK5R1 CDK6 CDKL2 CDKN2C 
225 CDKN2D CEBPA CENPF CERK CERS5 CETN3 CFD 
232 CH25H CHAF1A CHN2 CHRNB1 CHRNE CHST15 CHSY1 
239 CITED2 CLDN1 CLDN23 CLEC10A CLEC3B CLEC4C CLECL1 
246 CLMN CLOCK CLUH CMKLR1 CMTR1 CNDP2 CNN2 
253 CNPPD1 COL7A1 COMMD1 COQ10A CORO1B COX7A1 CPD 
260 CPEB4 CPED1 CPM CPNE3 CREB3L2 CREBL2 CROT 
267 CRYAB CSDE1 CSNK1G1 CSRNP1 CSRP2 CST6 CST7 
274 CSTA CSTF1 CSTF3 CTAGE5 CTDNEP1 CTNNAL1 CX3CR1 
281 CXCL1 CXCL10 CXCL12 CXCL16 CXCL2 CXCL3 CXCL5 
288 CXCR2 CXCR4 CXorf21 CYB5R1 CYBRD1 CYP11B1 CYP11B2 
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295 CYP27A1 CYP2J2 CYP3A7 CYTH2 DAPK1 DBF4 DBF4B 
302 DCP2 DDB2 DDIT3 DDO DDX28 DDX39B DDX58 
309 DEDD2 DESI1 DFNA5 DGKG DGKZ DHCR24 DHCR7 
316 DHFR DHRS3 DHX57 DIAPH2 DLG4 DLGAP2 DMTF1 
323 DNAAF1 DNAJB2 DNAJC25 DNAJC25-
GNG10 
DOK1 DOK2 DPH2 
330 DRAP1 DSP DSTYK DTL DTX3L DUSP22 DUSP4 
337 DUSP5 DUT DYNC2LI1 DYSF E2F5 EBNA1BP2 EBP 
344 ECE1 EEF1B2 EEF1E1 EGR1 EHD4 EIF2B2 EIF3C 
351 EIF3D EIF3L EIF4G3 ELF4 ELK4 ELL2 ELMSAN1 
358 ELOVL5 EML3 ENDOD1 ENG ENOSF1 ENTPD1 EPDR1 
365 EPHB2 ERC2 ERCC2 ERF ETS2 ETV6 EVI2A 
372 EVI2B EXO5 EXOC3L1 EXOSC2 EXOSC7 EXOSC9 EXT1 
379 EXT2 EZH1 F3 FADS1 FADS2 FAM102A FAM110A 
386 FAM122C FAM126A FAM13A FAM167A FAM168B FAM177A1 FAM20B 
393 FAM216A FAM46A FAM47E-
STBD1 
FAM49A FAM50B FAM58A FAM72A 
400 FAM72C FAM72D FAM76A FAM84B FARP2 FASN FBRSL1 
407 FBXO46 FBXW2 FCAR FCER1A FCGR2B FCGRT FCHO1 
414 FCRL3 FDFT1 FDPS FDXR FFAR2 FGD2 FGD6 
421 FGF2 FGFBP2 FIG4 FN1 FOLH1 FOS FOXC1 
428 FOXJ1 FOXJ2 FOXO1 FOXO3 FPR3 FRAT2 FRMD3 
435 FRMD4B FUT4 FUT8 FXYD6 FYN FZD1 FZD3 
442 GABARAPL1 GADD45A GAK GAL3ST4 GALM GALNT1 GART 
449 GBE1 GBP3 GCA GCLM GGA2 GGT5 GINS2 
456 GK GK2 GLCE GLRX GLT8D1 GLTP GMDS 
463 GMPR GNA11 GNA12 GNA15 GNAI3 GNAT1 GNB4 
470 GNG10 GNPDA1 GNS GOLM1 GPBAR1 GPD2 GPI 
477 GPN1 GPNMB GPR141 GPR15 GPR161 GPR18 GPR180 
484 GPR183 GPR3 GPR65 GPR68 GPX3 GRAMD4 GRIK2 
491 GRM1 GTF2E2 GTF2H3 GTPBP8 GUCD1 GUCY1A2 GYPA 
498 H1F0 H1FX H2AFV H2BFS HAGH HAVCR2 HCAR2 
505 HCAR3 HDAC5 HDHD2 HDX HEG1 HELB HELZ2 
512 HERC5 HERC6 HES4 HESX1 HGF HINT1 HINT2 
519 HINT3 HIP1 HIPK2 HIRA HIRIP3 HIST1H1E HIST1H2AC 
526 HIST1H2BD HIST1H3I HIST1H4C HIST2H2AA3 HIST2H2AA4 HIST2H2AC HIST2H2BE 
533 HK1 HLA-J HLF HMBS HMGB2 HMGN2P46 HMGN3 
540 HMOX1 HNMT HNRNPA1 HNRNPA1P10 HNRNPM HOMER1 HOXB2 
547 HOXB6 HPSE HRK HSF2 HSH2D HSPA4 ICA1 
554 ICOSLG ID2 IDS IDUA IER3 IER5 IFI16 
561 IFI27 IFI44 IFIT2 IFNA10 IFNA17 IFNGR2 IFRD1 
568 IGF1R IGF2BP3 IGFBP4 IL18 IL1A IL1B IL23A 
575 IL27 IL27RA IL4I1 IL7 IMPA2 IMPDH2 INE1 
582 INHBA INPP5J INSIG1 IPO11 IPO5 IPO9 IRAK2 
589 IRF2 IRF2BP1 IRF4 IRF5 ITGA2B ITGAV ITIH4 
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596 ITPR2 ITSN1 JARID2 JOSD1 JUP KARS KAT7 
603 KBTBD11 KCNC3 KCNG1 KCNMB1 KCNQ3 KCTD14 KCTD20 
610 KDELC2 KDM3A KIAA0040 KIF15 KIF3B KIN KIR2DL1 
617 KLF1 KLF6 KLF7 KLHDC10 KLHL14 KLHL18 KLHL21 
624 KLK13 KLRC1 KLRC2 KLRC3 KMT2D KRT72 KXD1 
631 KYNU LACTB LAIR1 LAMP5 LDHB LEAP2 LETMD1 
638 LGALS2 LGALS9 LGALS9B LGALS9C LIG4 LILRA1 LILRA3 
645 LILRB2 LILRB4 LIMK1 LIMS1 LIMS3 LIN9 LINC00467 
652 LLGL1 LMNB1 LNPEP LPAR1 LPAR6 LPGAT1 LPIN2 
659 LRPPRC LRRC3 LRRFIP1 LTA4H LY6G5B MACF1 MAK 
666 MALT1 MAMLD1 MAN1A1 MAN1A2 MAN2A2 MAOB MAP1B 
673 MAP2K6 MAP3K2 MAP3K3 MAP3K4 MAP3K5 MAP3K9 MAP4K2 
680 MAPK14 MAPKAP1 MAPRE2 MARCKS MARCO MAST1 MAST2 
687 MAST3 MBD1 MBD4 MBNL2 MBNL3 MCAT MCL1 
694 MCM2 MCM5 MDK MDM1 MDM2 MED12 MED22 
701 MEF2D MEFV MFNG MFSD5 MIA3 MIEF1 MIR600HG 
708 MLKL MLXIP MMP12 MNDA MNT MOAP1 MOB3C 
715 MOBP MPHOSPH9 MPPE1 MRPL40 MRPS27 MSL3 MSMO1 
722 MSR1 MT1G MT1X MTDH MTHFD1 MTMR6 MTSS1 
729 MVB12A MVP MX1 MX2 MXD1 MYBPC3 MYC 
736 MYCL MYCN MYOF N4BP1 N4BP3 NADK NAGK 
743 NAP1L5 NAPSA NAPSB NARS NASP NAV3 NBEAL1 
750 NBN NBR1 NCAPD2 NCOA7 NDC80 NDUFS1 NEDD4 
757 NET1 NETO2 NEXN NFAT5 NFATC3 NFE2 NFKBIL1 
764 NFRKB NINJ1 NINJ2 NISCH NME5 NME8 NONO 
771 NOP56 NPAT NPC1 NPC2 NPM1 NPR1 NPRL2 
778 NR1D2 NR4A1 NRG1 NRIP1 NRXN3 NSUN3 NSUN7 
785 NT5C2 NTNG2 NTRK3 NUMA1 NUP210 NUP214 NUP98 
792 NUSAP1 NXF1 NXT2 OAS3 OASL OAT ODC1 
799 ODF3B OGFR OGG1 OLFM1 OLIG2 OPTN OSBPL1A 
806 OSGEPL1 OTOF OTUD1 OXT P2RX1 P2RX7 P2RY10 
813 P2RY13 P2RY14 PABPC1 PABPC4 PALLD PALM2-
AKAP2 
PANK3 
820 PAPD7 PAPSS2 PARD6A PARK7 PARP11 PARP14 PARP2 
827 PATL1 PAX3 PCID2 PCNA PCOLCE2 PDE1C PDGFRA 
834 PDGFRL PDK1 PDSS1 PDXK PEG3 PEX7 PGAP1 
841 PGM1 PHACTR2 PHACTR4 PHF20 PHLDA2 PI4K2A PI4K2B 
848 PIK3AP1 PIK3CB PIK3CD PIK3CG PIK3IP1 PIM1 PIN4 
855 PINK1-AS PITPNC1 PIWIL4 PLA2G15 PLAA PLAGL1 PLD2 
862 PLEKHA1 PLEKHB2 PLEKHN1 PLGRKT PLK2 PLN PLSCR4 
869 PLXNA2 PLXNB2 PMAIP1 PMEPA1 PMS1 PNISR PNPT1 
876 POLG2 POLI POLK POLR2C POLR2J POLR2J2 POLR2J3 
883 POLR2J4 POP7 PPBP PPDPF PPFIBP2 PPIA PPM1F 
890 PPM1H PPM1K PPP1CC PPP2R2A PRADC1 PRAM1 PRC1 
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897 PRDM2 PRF1 PRIM1 PRIMPOL PRKACB PRKAG2 PRKAR2A 
904 PRKCE PRKD2 PRKDC PRPF8 PRPS2 PRPSAP1 PSD3 
911 PSIP1 PSMA2 PSMA4 PSMC3IP PTGES PTGFRN PTK2 
918 PTP4A1 PTP4A2 PTPN13 PTPN22 PTPN4 PTPRCAP PTPRK 
925 PTPRO PURA PYGL QPCT QSOX2 RAB11FIP2 RAB22A 
932 RAB27A RAB32 RAB37 RAB38 RAB40A RAB40AL RAB40C 
939 RAB5B RAB8A RAB8B RABGGTB RAD9A RAI14 RALB 
946 RALBP1 RANGAP1 RAP2B RARB RASA4 RASA4CP RASAL1 
953 RASGRP3 RASSF1 RASSF2 RB1 RBCK1 RBL2 RBM11 
960 RBM3 RBM43 RBM4B RBM8A RBMS1 RBMS3 RBMX 
967 RBMY1HP RBMY1J RECK REL RELA REM1 RFT1 
974 RGL1 RGL2 RGP1 RGS1 RGS2 RHBDD2 RHOB 
981 RHOF RICTOR RIF1 RILPL2 RIN2 RIN3 RIPK1 
988 RIPK2 RLIM RMND5A RNASE1 RNASET2 RNF113A RNF144A 
995 RNF170 RNF213 RNF41 RNF44 RNMT RNU7-1 RP2 
1002 RPL11 RPL13 RPL13A RPL19 RPL22 RPL23 RPL3 
1009 RPL30 RPL34 RPL4 RPL5 RPLP0P6 RPP40 RPRD2 
1016 RPS27L RPS4Y1 RPS6KA2 RPS8 RRM2 RRP8 RSBN1 
1023 RSL1D1 RTCB RTN3 RUNX3 RWDD1 S100A4 S100A8 
1030 S100A9 SAG SAMD4A SAMHD1 SAR1B SART1 SART3 
1037 SAT1 SBNO2 SCAPER SCARB2 SCIMP SCRN3 SEC24D 
1044 SECTM1 SELL SEMA3C SEMA4F SEMA7A SEPHS1 SEPHS2 
1051 SEPT2 SERPINF2 SERTAD2 SETDB2 SFT2D2 SGMS2 SH2B2 
1058 SH2D3C SH3BP5 SHISA5 SHMT2 SIGLEC1 SIGLEC7 SLA 
1065 SLAMF8 SLC10A1 SLC11A1 SLC16A1 SLC16A5 SLC18B1 SLC19A1 
1072 SLC22A13 SLC22A5 SLC24A4 SLC25A20 SLC25A24 SLC25A25 SLC25A36 
1079 SLC25A39 SLC30A1 SLC31A2 SLC35D2 SLC36A1 SLC38A5 SLC39A8 
1086 SLC43A2 SLC48A1 SLC4A7 SLC5A3 SLC7A1 SLC7A6 SLC8A1 
1093 SLC9B2 SLFN12 SLFN13 SLFN5 SMAD3 SMAD6 SMCHD1 
1100 SMG7 SMO SNAP23 SNAPC4 SNHG1 SNRNP200 SNRPN 
1107 SNX29P2 SNX32 SOCS2 SOCS7 SOS1 SOS2 SOWAHC 
1114 SOX4 SP100 SP110 SP140L SPAG7 SPATS2L SPCS3 
1121 SPEN SPI1 SPOCK2 SPTA1 SPTBN1 SPTLC2 SPTSSA 
1128 SQLE SREBF2 SRGAP2 SRGAP2B SRGAP2C SRPK1 SRPX2 
1135 SSH1 SSSCA1 SSTR2 ST3GAL1 ST3GAL5 ST3GAL6 STAG3L3 
1142 STAM STAP1 STARD13 STARD4 STARD7 STK17A STK3 
1149 STK38L STOM STOML1 STRBP STX17 STX3 SUN2 
1156 SUPT7L SUPV3L1 SV2A SWAP70 SYNE1 SYNGR3 TACSTD2 
1163 TAF10 TAOK2 TAP2 TARBP1 TAS2R5 TBCEL TBL1XR1 
1170 TBR1 TBX6 TBXAS1 TCF7L2 TCFL5 TCP1 TDRD7 
1177 TFAP4 TFEB TFEC TFF2 TFF3 TGFA TGFBR1 
1184 TGFBR2 TGM1 TGM5 TGOLN2 THAP11 THBS1 THPO 
1191 THUMPD3 TIGD5 TIMP3 TIPARP TIPIN TKT TKTL1 
1198 TLK2 TLR3 TLR4 TLR6 TMBIM1 TMEM106A TMEM110 
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1205 TMEM110-
MUSTN1 
TMEM120B TMEM123 TMEM126B TMEM135 TMEM140 TMEM141 
1212 TMEM186 TMEM19 TMEM223 TMEM242 TMEM243 TMEM30A TMEM55A 
1219 TMEM62 TMEM97 TMOD2 TMX4 TNFRSF1B TNFSF18 TNFSF9 
1226 TNK2 TOB1 TOMM20 TOP1MT TOP2B TOX TP53 
1233 TPCN1 TPP1 TPST2 TRA2A TRABD TRAF1 TRAF3IP3 
1240 TRAIP TRANK1 TREM1 TRIAP1 TRIB2 TRIL TRIM14 
1247 TRIM25 TRIM26 TRIM34 TRIM38 TRIM5 TRIM56 TRIM6-TRIM34 
1254 TRIM65 TRIP10 TRIP4 TRIP6 TRPS1 TSPAN13 TSPO 
1261 TSPYL5 TTC21A TTC28 TTC39B TTC7B TTLL4 TTN 
1268 TUFT1 TXNDC12 TYMS UBA7 UBAC1 UBASH3B UBE2G1 
1275 UBE2S UBE2W UBE4B UBL4A UBQLNL UBXN2A UBXN7 
1282 UCP3 UEVLD UNC93B1 UQCC1 USP15 USP18 USP22 
1289 USP25 USP4 USP41 USP6 USP6NL UTRN VASH1 
1296 VCAN VCY1B VEGFA VENTX VPREB3 VPS9D1 VRK2 
1303 VTN WBP1L WDFY1 WDR25 WDR74 WIPF1 WISP1 
1310 WNK1 XIAP YPEL3 YY1 ZAP70 ZBED1 ZBTB18 
1317 ZBTB48 ZC3HAV1 ZCCHC2 ZFAND2A ZFP36 ZFP36L2 ZFP69B 
1324 ZFYVE26 ZNF101 ZNF107 ZNF146 ZNF211 ZNF23 ZNF248 
1331 ZNF264 ZNF267 ZNF280B ZNF318 ZNF324 ZNF350 ZNF443 
1338 ZNF446 ZNF512 ZNF516 ZNF543 ZNF552 ZNF618 ZNF626 
1345 ZNF652 ZNF688 ZNF702P ZNF75D ZNF780A ZNF780B ZNF814 
1352 ZNF85 ZNFX1 ZWINT 
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Supplementary Table 3 IFN type II signaling genes present in MDS according to Interferome database classification 
1 AADAT AATK ABCC2 ABHD6 ABLIM1 ACAT2 ACBD5 
8 ACHE ACOT1 ACOT7 ACSS2 ACTG1 ACTN1 ACVR1B 
15 ADAM11 ADAM9 ADCY1 ADO ADORA2A AFAP1L1 AK2 
22 AK8 AKR1B1 AKR7A2P1 ALCAM ALDH1A1 ALDH2 ALOX5 
29 ALPI AMDHD1 AMELX AMELY ANKRD11 ANLN ANO9 
36 ANTXR1 ANXA2P3 AP1B1 AP5B1 APBB1IP APCS APOL2 
43 APOO AR ARID5B ARMC9 ARNTL2 ARSB ASAP1 
50 ASPHD1 ASPHD2 ASPM ATG4C ATP1A1 ATP5F1 ATP6V0A1 
57 ATP6V0D2 ATP6V1H ATP8B4 AURKA AVPI1 B3GNT5 B3GNT8 
64 BAG3 BAMBI BASP1 BCAP31 BCAR3 BCAT1 BCL11A 
71 BHLHE22 BHLHE40 BIN1 BMP6 BOLA3 BRSK1 BTBD11 
78 BTN3A1 C10orf95 C11orf45 C11orf96 C18orf8 C19orf12 C1orf112 
85 C1orf61 C1QB C1QC C1QTNF1 C1R C1RL C1S 
92 C2 C3orf58 C4orf3 C4orf32 C6orf223 C6orf47 CA2 
99 CA9 CABLES1 CACNA2D3 CADM1 CALCA CALCOCO2 CALM3 
106 CALML4 CAMKK1 CAMP CASK CASP5 CBX4 CCDC115 
113 CCL18 CCL3L1 CCL3L3 CCL5 CCM2L CCNA2 CCNB1 
120 CCNB2 CCND1 CCND2 CCNE2 CCNO CD109 CD1A 
127 CD209 CD274 CD276 CD300LB CD47 CD58 CD72 
134 CDC20 CDC45 CDCA5 CDK18 CDKN3 CDR2 CDYL2 
141 CEBPD CELF1 CENPU CENPW CEP135 CEP19 CEP55 
148 CES1 CETP CFP CHD2 CHDH CHI3L2 CHRNA6 
155 CHST7 CIITA CIT CKAP2 CKAP2L CLDN12 CLDND1 
162 CLEC12A CLEC7A CLIP4 CLPS CLPTM1 CLSPN CMC4 
169 CMTM3 CNIH3 CNIH4 CNRIP1 CNTFR COCH COL4A1 
176 COL8A2 COMMD6 COQ10B CORO2A CR2 CRABP2 CRYBB1 
183 CSF3 CSPG4 CSRNP2 CTDSPL CTNNBIP1 CTNND2 CTSK 
190 CTSO CTSS CTTN CXADR CXorf57 CYB5R3 CYFIP1 
197 CYSLTR1 CYTH4 CYTIP DAPP1 DAXX DBN1 DDA1 
204 DDIT4 DENND4C DEXI DGKD DHRS11 DHRS13 DHRS9 
211 DIRAS1 DISP1 DLGAP5 DNAJB6 DNAJC9 DNASE2B DNM3 
218 DNMT3A DOCK2 DOCK3 DOPEY2 DPEP2 DPYD DPYSL4 
225 DRAM1 DUSP14 DUSP2 DUSP6 E2F2 EAF2 EBI3 
232 ECM1 EDA EDEM1 EDN1 EEPD1 EFR3B EMB 
239 EMILIN2 EPAS1 EPB41L3 EPN2 ERICH1 ETV5 EVL 
246 F13A1 FABP3 FAH FAIM FAM109A FAM117B FAM124A 
253 FAM129A FAM129B FAM135A FAM20A FAM20C FAM213A FAM81A 
260 FANCG FAXDC2 FBXO15 FCAMR FCER1G FEZ2 FGD3 
267 FGD5 FGF13 FGFRL1 FGGY FHL1 FKBP5 FLI1 
274 FLNB FLOT2 FMNL2 FNDC3A FOSL2 FOXN2 FOXN3 
281 FOXRED2 FRMD4A FSCN1 G0S2 GAA GABBR1 GALNT12 
288 GAPT GAS2L3 GAS6 GATA1 GCLC GCSHP5 GEM 
295 GFOD1 GGTA1P GIMAP1 GIMAP2 GIMAP4 GIMAP5 GIMAP7 
302 GIMAP8 GINM1 GJC1 GLCCI1 GLDN GLO1 GLRX5 
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309 GLT1D1 GNB1L GNE GNG2 GOLIM4 GPER1 GPR132 
316 GPR162 GPR31 GPR34 GPR84 GPRC5B GPRIN3 GRAMD1A 
323 GRINA GSTT2 GSTT2B GUCY1B3 GUCY2F GVINP1 GYS1 
330 H2AFY2 HBEGF HCK HCST HDAC4 HDAC6 HEATR6 
337 HERPUD1 HGSNAT HILPDA HIPK1 HIST1H2AM HIST1H2BG HIST1H2BI 
344 HIST1H2BJ HIST1H2BL HIST1H2BM HIST1H3A HIST1H3C HIST1H3J HIST1H4B 
351 HIST2H2AB HIVEP3 HLA-A HLA-DMA HLA-DMB HLA-DOA HLA-DPB1 
358 HLA-DRA HLTF HLX HMG20B HMGCS1 HNRNPDL HOMER3 
365 HOXD3 HPCAL1 HS3ST2 HS3ST3B1 HSD11B1 HSD17B7 HSPA6 
372 HTR7 HYI ICAM3 IDO2 IFT172 IGF1 IL10RB 
379 IL12RB1 IL13RA1 IL18BP IL1R2 IL32 IL4R ILDR1 
386 INPP4A IQCE IRS2 ISLR2 ITGB1BP1 ITGB7 ITPKC 
393 JAK3 JAKMIP2 KAT2A KCNA1 KCNAB2 KCNH1 KCNJ10 
400 KCNK13 KCNMA1 KCNQ1 KCTD17 KIAA1147 KIF13B KLF4 
407 KLF9 KLK3 KLRG1 KPNA2 KRBA1 KREMEN1 LAMA3 
414 LASP1 LAT LDB3 LFNG LGALSL LIG1 LILRB5 
421 LIMA1 LIMK2 LINC00324 LITAF LMNA LONP1 LPAR2 
428 LRG1 LRP12 LRRC38 LRRCC1 LRRFIP2 LRRK2 LSM3 
435 LXN LYPD5 LYRM9 MAD2L1 MAD2L1BP MAFB MAFF 
442 MANBAL MAP2K3 MAP3K8 MAP7 MAPK13 MARCH1 MARCH3 
449 MATK ME1 ME3 MELK METTL1 METTL7A MFSD12 
456 MFSD3 MGLL MGST1 MIA MICAL1 MICAL2 MICALL2 
463 MIR22HG MIS18BP1 MKL2 MLLT6 MLPH MMD MME 
470 MMP10 MMP25 MORN2 MOXD1 MPEG1 MPP1 MPZL2 
477 MR1 MRC1 MREG MRPL12 MRPL49 MSANTD3 MSC 
484 MSRB2 MTCP1 MTFP1 MTHFS MTUS1 MUCL1 MVB12B 
491 MYH11 MYL5 MYLIP MYO1D MYO1G MYOC MZT2A 
498 NAA16 NAF1 NCAPG NCF4 NDP NDRG1 NDUFAF2 
505 NEDD4L NEIL1 NEK6 NF1 NFIA NFKB1 NFKB2 
512 NFKBIA NFKBIB NME4 NNMT NOVA1 NPM3 NR2F6 
519 NRIP3 NUMB NUP85 OLFML3 OPRL1 OSBPL9 OSMR 
526 OSTC P2RY8 PACS2 PAG1 PAPLN PAPOLG PARP3 
533 PASK PAWR PBDC1 PBX3 PCBP2 PDE3B PDE9A 
540 PDGFB PDIA4 PDIA6 PEA15 PEAK1 PEMT PFKFB3 
547 PFN1P6 PGD PGS1 PHIP PHLDA3 PIGQ PIK3C2B 
554 PIM3 PLA1A PLAC8 PLAGL2 PLAT PLAUR PLCXD1 
561 PLEKHG2 PLEKHG3 PLTP PM20D2 PMFBP1 PNKD PNMT 
568 POMT2 PPA1 PPIAL4C PPIAL4D PPIAL4G PPIC PPP1R14B 
575 PPP2R5B PPTC7 PRELID1 PRKAR2B PROCR PRR13 PRUNE2 
582 PSEN2 PSMA5 PSMA6 PSMB10 PSTPIP2 PTEN PTGER2 
589 PTGIR PTGR1 PTPN7 PTPRE QPRT RAB12 RAB21 
596 RAB30 RAB3IL1 RAB42 RAP2A RAP2C RAPGEF1 RARA 
603 RARRES1 RASL10A RBBP9 RBFA RBP1 RBP7 RCN3 
610 RDH10 RDH11 RELB RFTN1 RFX1 RFX2 RFX5 
617 RGS10 RGS12 RHBDF1 RHOBTB2 RHOBTB3 RILPL1 RIMBP3 
624 RIMBP3C RIMS3 RND1 RNF114 RNF141 RNF149 RNF24 
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631 RPGRIP1 RRAD RTN4R SACS SAMD8 SAR1A SAV1 
638 SCP2 SDC1 SDC3 SEMA4B SEMA4D SEPT11 SEPT8 
645 SERPINB3 SERPINB4 SERPINF1 SESN2 SGPP2 SH2D4A SH3BGRL3 
652 SH3PXD2A SH3PXD2B SH3RF1 SH3RF3 SHC3 SIX1 SLAMF6 
659 SLAMF9 SLC25A10 SLC25A37 SLC26A11 SLC27A3 SLC28A3 SLC35E3 
666 SLC39A10 SLC39A14 SLC3A1 SLC40A1 SLC43A3 SLC45A3 SLC46A1 
673 SLC50A1 SLC5A4 SLC6A6 SLC7A8 SLC8A3 SLC9A1 SLCO4A1 
680 SLCO5A1 SLPI SMAD7 SMARCA1 SMARCD3 SMCO4 SNX10 
687 SNX21 SNX27 SOCS3 SPATA13 SPECC1L-
ADORA2A 
SPEG SPHK1 
694 SPHK2 SPN SPRED1 SPRY2 SRC SRSF12 SRXN1 
701 SSH2 ST20-
MTHFS 
ST6GALNAC6 STAB1 STARD8 STAT4 STEAP3 
708 STIP1 STK32C STMN1 STX10 SV2B SYNE3 TAF13 
715 TAF1A TANC1 TAPBPL TBC1D1 TBC1D12 TBC1D2B TBC1D4 
722 TBC1D9 TBCD TCF4 TCTEX1D2 TDRD9 TEAD4 TEX2 
729 TEX33 TFB2M TGFB3 THADA THBD TIAM2 TIMP1 
736 TJP2 TLE4 TLR8 TM4SF19 TMC8 TMCC2 TMED3 
743 TMED7-
TICAM2 
TMEM106C TMEM14C TMEM165 TMEM170A TMEM217 TMEM43 
750 TMEM50A TMEM80 TMEM86A TMEM8B TMSB15A TNFAIP2 TNFRSF12A 
757 TNFRSF21 TNIP2 TNIP3 TNKS TOP2A TP53INP2 TPM2 
764 TPM3 TRADD TRAF3IP2 TREM2 TRIP13 TRPC4AP TRPV2 
771 TSC22D1 TSFM TSPAN14 TTC8 TTC9C TUBB4B TUBB6 
778 TULP4 TUT1 TXNIP TXNRD1 TXNRD3 UBE2C UBE2E3 
785 UBFD1 UBTD1 UBXN11 UCHL3 UFSP2 UGCG UHRF1 
792 UNG UNKL UTS2 VASN VAT1 VCP VCPIP1 
799 VPS26B VWF WFDC2 WTAP XPNPEP1 YBX3 ZBED3 
806 ZBED6CL ZBTB17 ZBTB7A ZMIZ2 ZMYM6 ZNF219 ZNF366 
813 ZNF573 ZNF79 ZNRF3 ZYX 
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Supplementary Table 4 INF I and II inducible genes identified by Interferome v2.0 database 
1 ABCC5 ABCG1 ACOX2 ACP2 ADAR ADK ADM 
8 ADORA2B AHNAK AIM2 AK4 ALDOC AMPD3 ANKRD22 
15 APOBEC3G APOL1 APOL3 APOL6 AQP9 ARAP3 ASCL2 
22 ATF3 ATOX1 ATP10A AXL B4GALT5 BAK1 BATF 
29 BATF2 BAZ1A BCL2L13 BIRC3 
BLOC1S5-
TXNDC5 BLZF1 BRCA2 
36 BRMS1L BTG3 BTN3A2 BTN3A3 C15orf48 C1QA C20orf27 
43 C5orf56 CAMK1G CASP3 CCL19 CCL23 CCL4 CCL7 
50 CCL8 CCR2 CCR7 CD163L1 CD180 CD1D CD302 
57 CD36 CD38 CD40 CD44 CD52 CD74 CD83 
64 CD9 CD93 CDA CDK1 CDKN1A CENPM CFB 
71 CFH CFLAR CHST2 CLEC5A CMTM7 CNP COLEC12 
78 CREBRF CREM CSF2RA CSF2RB CSTB CTSC CTSL 
85 CXCL11 CXCL13 CXCL9 CYB561A3 CYP27B1 CYSTM1 CYTL1 
92 DAB2 DBI DBP DCSTAMP DDX60 DENND5A DHX58 
99 DNAJA1 DNASE2 DSE DUSP1 DUSP10 DYNLT1 DYRK2 
106 EIF2AK2 EIF4EBP2 EMP1 ENPP2 EPSTI1 ETV7 EZR 
113 FABP4 FAM105A FAM26F FAM53B FAM60A FAS FBP1 
120 FBXO6 FCGR1A FCGR1B FCN1 FGFR2 FGL2 FGR 
127 FPR2 FZD2 FZD5 GATM GBP1P1 GBP2 GBP4 
134 GBP5 GCH1 GCNT1 GCSH GDF15 GIMAP6 GLS 
141 GM2A GPC4 GPD1L GPR155 GRIN3A GSDMD GSN 
148 GTF2B GTPBP1 GTPBP2 GUCY1A3 HAPLN3 HCP5 HHEX 
155 HIVEP2 HK3 HLA-C HLA-F HMMR HPN HTRA1 
162 HVCN1 IDO1 IFI35 IFI44L IFI6 IFIT1 IFIT3 
169 IFIT5 IFITM1 IFITM2 IFITM3 IL16 IL1RN IL2RA 
176 IL3RA IL7R INF2 IQCK IRAK3 IRF1 IRF7 
183 IRF9 ISG15 ISG20 ITGAE ITGB5 ITPKB IVNS1ABP 
190 JADE2 JAK2 KCNJ2 KCTD12 KIAA0513 KLHDC7B KRT85 
197 LAG3 LAMP3 LAP3 LCP2 LDLR LDLRAD4 LEPROTL1 
204 LGALS3BP LGMN LILRA5 LMO4 LPCAT1 LPL LY6E 
211 LY9 LYN LYRM1 LYSMD2 MAD2L2 MAF MARCKSL1 
218 MASTL MB21D1 MCM6 MCOLN2 MEF2C MEGF9 MERTK 
225 MICB MITF MLEC MLXIPL MMP7 MMP9 MOV10 
232 MS4A4A MS4A6A MT1E MT1F MT1M MTHFD2 MUC1 
239 MXD4 MYD88 NABP1 NACC2 NAMPT NAP1L1 NAPA 
246 NCF1C NCR1 NEURL3 NFE2L3 NFIL3 NMI NOD1 
253 NOD2 NOTCH1 NQO1 NR1H3 NR4A3 NRGN NRP1 
260 NT5C3A NUB1 NUPR1 OAS1 OAS2 OIP5 P2RY6 
267 PAM PANX1 PAPSS1 PARP10 PARP12 PARP9 PC 
274 PCED1B PCGF5 PDE4B PDLIM7 PDPN PFKFB4 PFKP 
281 PHF11 PHLDA1 PID1 PILRA PLA2G16 PLA2G7 PLIN2 
288 PLSCR1 PLXDC2 PML PMP22 PNP PNRC1 POLB 
295 PON2 PPARG PPFIBP1 PPIF PRDM1 PRKCA PRNP 
302 PSMB8 PSMB9 PSME1 PSME2 PTGS1 PTPN1 PTPN2 
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309 RAC2 RAD51AP1 RAPH1 RARRES3 RASGRP1 RBBP6 RCSD1 
316 RHOH RNF144B RNF19B RPL15 RPS6KA1 RSAD2 RTN1 
323 RTP4 RXRA SAMD9 SAMD9L SAMM50 SAMSN1 SAP30 
330 SASH1 SCG5 SCN1B SCPEP1 SDC2 SECISBP2L SEL1L3 
337 SEMA4A SEPT4 SERPINA1 SERPINB1 SERPINB9 SERPING1 SLAMF7 
344 SLC16A10 SLC25A28 SLC2A1 SLC41A2 SLC9A7 SMPD3 SOCS1 
351 SOD2 SORL1 SP140 SPARC SPOCD1 SPP1 SPRY1 
358 SPSB1 ST6GALNAC4 ST8SIA4 STAMBPL1 STAT1 STAT2 STAT3 
365 STRN STX11 TAGAP TANK TAP1 TBC1D10C TBC1D22B 
372 TBK1 TCN2 TCP11L1 TDRD3 TG TGM2 TK1 
379 TLR5 TLR7 TMEM158 TNF TNFAIP3 TNFAIP6 TNFRSF11A 
386 TNFSF10 TNFSF13B TNFSF14 TNIP1 TNNI2 TOP1 TOR1B 
393 TPST1 TRAFD1 TRIM21 TRIM22 TRIM69 TRPM2 TSC22D3 
400 TUBGCP4 TYMP UBE2D1 UBE2L6 UCP2 ULK2 UPP1 
407 UTS2R VAMP5 VPS41 VSIG10L VSIG4 VWA5A WARS 
414 WWP1 XAF1 XRN1 YEATS2 YPEL2 ZBP1 ZBTB16 
421 ZCCHC14 ZHX3 ZMIZ1 na na na na 
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Supplementary Table 5 Module enrichment in the genes sorted by weights in PC1, PC2 and PC8 of gene expression 
set of the MDS 
ID Title AUC adj.P.Val 
Enrichment in PC1 
LI.M7.0 enriched in T cells (I) 0.935812 1.41E-29 
LI.M7.1 T cell activation (I) 0.909565 1.42E-20 
LI.M7.2 enriched in NK cells (I) 0.829489 3.07E-12 
LI.M7.4 T cell activation (III) 0.972746 5.92E-10 
LI.M18 T cell differentiation via ITK and PKC 0.975338 8.45E-10 
LI.S0 T cell surface signature 0.842331 1.61E-08 
LI.M7.3 T cell activation (II) 0.834783 1.79E-08 
LI.M106.0 nuclear pore complex 0.951424 3.82E-08 
LI.M14 T cell differentiation 0.942652 1.02E-07 
LI.M5.1 T cell activation and signaling 0.801434 1.23E-07 
LI.M212 purine nucleotide biosynthesis 0.93928 1.63E-07 
LI.M245 translation initiation factor 3 complex 0.9521 2.73E-07 
LI.M61.2 enriched in NK cells (receptor activation) 0.8859 1.04E-06 
LI.M157 enriched in NK cells (III) 0.925799 1.57E-06 
LI.M19 T cell differentiation (Th2) 0.865283 4.87E-06 
LI.M117 cell adhesion (GO) 0.702055 5.69E-06 
LI.M181 nucleotide metabolism 0.93683 5.90E-06 
LI.M61.0 enriched in NK cells (II) 0.850627 7.51E-06 
LI.M235 mitochondrial cluster 0.900809 1.14E-05 
LI.M143 nuclear pore, transport; mRNA splicing, processing 0.936675 2.27E-05 
LI.M47.0 enriched in B cells (I) 0.809911 5.00E-05 
LI.M204.0 chaperonin mediated protein folding (I) 0.85285 5.78E-05 
LI.M65 IL2, IL7, TCR network 0.803117 6.17E-05 
LI.M169 mitosis (TF motif CCAATNNSNNNGCG) 0.870433 0.000156 
LI.M106.1 nuclear pore complex (mitosis) 0.883762 0.000185 
LI.M223 enriched in T cells (II) 0.926972 0.000309 
LI.M4.8 cell division - E2F transcription network 0.828515 0.000311 
LI.M103 cell cycle (III) 0.729376 0.000446 
LI.M4.4 mitotic cell cycle - DNA replication 0.788318 0.000766 
LI.S7 CD4 T cell surface signature Th2-stimulated 0.786311 0.001363 
LI.M126 double positive thymocytes 0.788578 0.001363 
LI.M47.1 enriched in B cells (II) 0.766986 0.001531 
LI.M182 enriched in DNA interacting proteins 0.792062 0.001531 
LI.M10.0 E2F1 targets (Q3) 0.709764 0.002685 
LI.M204.1 chaperonin mediated protein folding (II) 0.816658 0.004354 
LI.M179 enriched for TF motif PAX3 0.880389 0.005378 
LI.M22.0 mismatch repair (I) 0.753984 0.005429 
LI.M130 enriched in G-protein coupled receptors 0.833819 0.005429 
LI.M5.0 regulation of antigen presentation and immune response 0.498417 0.006667 
LI.M4.1 cell cycle (I) 0.670012 0.007241 
LI.M45 leukocyte activation and migration 0.694664 0.007241 
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LI.M69 enriched in B cells (VI) 0.803069 0.007529 
LI.M12 CD28 costimulation 0.770624 0.008251 
LI.M60 lymphocyte generic cluster 0.75206 0.009 
LI.M156.0 plasma cells & B cells, immunoglobulins 0.808926 0.009 
LI.M47.4 enriched in B cells (V) 0.756107 0.009309 
LI.M10.1 E2F1 targets (Q4) 0.780227 0.009863 
LI.M76 DNA repair 0.736904 0.010472 
LI.M230 cell cycle, mitotic phase 0.741561 0.012543 
LI.M44 T cell signaling and costimulation 0.668879 0.014104 
LI.M22.1 mismatch repair (II) 0.778028 0.019561 
LI.M4.11 mitotic cell cycle in stimulated CD4 T cells 0.777793 0.01989 
LI.M156.1 plasma cells, immunoglobulins 0.860013 0.023462 
LI.M250 spliceosome 0.762262 0.034335 
LI.M37.3 cell division 0.837723 0.034443 
Enrichment in PC2 
LI.M11.0 enriched in monocytes (II) 0.806343 2.06E-19 
LI.M37.0 immune activation - generic cluster 0.679038 1.07E-12 
LI.M4.0 cell cycle and transcription 0.712427 1.53E-11 
LI.M237 golgi membrane (II) 0.962035 1.53E-11 
LI.S4 Monocyte surface signature 0.793659 6.04E-09 
LI.M213 regulation of transcription, transcription factors 0.895308 2.52E-08 
LI.M101 phosphatidylinositol signaling system 0.944165 1.06E-07 
LI.M129 inositol phosphate metabolism 0.931895 2.11E-07 
LI.M144 cell cycle, ATP binding 0.950882 2.53E-07 
LI.M118.0 enriched in monocytes (IV) 0.78088 2.59E-07 
LI.M16 TLR and inflammatory signaling 0.842178 9.29E-07 
LI.M37.1 enriched in neutrophils (I) 0.815243 1.03E-06 
LI.M147 intracellular transport 0.873479 1.23E-05 
LI.M73 enriched in monocytes (III) 0.893751 0.001746 
LI.M5.0 regulation of antigen presentation and immune response 0.634725 0.001862 
LI.M64 enriched in activated dendritic cells/monocytes 0.852277 0.002614 
LI.M169 mitosis (TF motif CCAATNNSNNNGCG) 0.823067 0.00416 
LI.M165 enriched in activated dendritic cells (II) 0.744301 0.00416 
LI.M113 golgi membrane (I) 0.88044 0.005106 
LI.M11.1 blood coagulation 0.801502 0.005845 
LI.M138 enriched for ubiquitination 0.87511 0.006183 
LI.M22.0 mismatch repair (I) 0.767709 0.006303 
LI.M4.3 myeloid cell enriched receptors and transporters 0.768503 0.009813 
LI.M179 enriched for TF motif PAX3 0.860471 0.012319 
LI.M3 regulation of signal transduction 0.679308 0.014948 
LI.M4.13 cell junction (GO) 0.865614 0.015924 
LI.M132 recruitment of neutrophils 0.871681 0.015924 
LI.M25 TLR8-BAFF network 0.831208 0.019401 
LI.M53 inflammasome receptors and signaling 0.787681 0.019401 
LI.M81 enriched in myeloid cells and monocytes 0.620112 0.019401 
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LI.M226 proteasome 0.805515 0.027548 
LI.M163 enriched in neutrophils (II) 0.811818 0.027548 
LI.M230 cell cycle, mitotic phase 0.7676 0.029278 
LI.M40 complement and other receptors in DCs 0.75148 0.029278 
LI.M191 transmembrane transport (II) 0.658033 0.030142 
LI.M114.1 glycerophospholipid metabolism 0.784245 0.032203 
LI.S11 Activated (LPS) dendritic cell surface signature 0.676177 0.032203 
LI.M86.0 chemokines and inflammatory molecules in myeloid cells 0.713533 0.034613 
LI.M118.1 enriched in monocytes (surface) 0.776815 0.03509 
LI.M56 suppression of MAPK signaling 0.813592 0.04503 
LI.M127 type I IFN response 0.825481 0.048774 
Enrichment in PC8 
LI.M4.0 cell cycle and transcription 0.646351 2.05E-16 
LI.M4.1 cell cycle (I) 0.782294 2.05E-16 
LI.M127 type I IFN response 0.996512 1.72E-15 
LI.M75 antiviral IFN signature 0.802929 2.42E-15 
LI.M150 innate antiviral response 0.910664 3.28E-14 
LI.M165 enriched in activated dendritic cells (II) 0.692141 2.21E-13 
LI.M111.1 viral sensing & immunity; IRF2 targets network (II) 0.992409 8.48E-13 
LI.M67 activated dendritic cells 0.961194 1.26E-11 
LI.M146 MHC-TLR7-TLR8 cluster 0.908728 5.35E-09 
LI.M111.0 viral sensing & immunity; IRF2 targets network (I) 0.66489 5.05E-08 
LI.M7.2 enriched in NK cells (I) 0.76298 7.27E-08 
LI.M4.5 mitotic cell cycle in stimulated CD4 T cells 0.808153 2.16E-07 
LI.M4.4 mitotic cell cycle - DNA replication 0.837511 1.58E-06 
LI.M103 cell cycle (III) 0.745543 1.69E-06 
LI.M13 innate activation by cytosolic DNA sensing 0.8076 3.35E-06 
LI.S1 NK cell surface signature 0.687714 8.49E-06 
LI.M68 RIG-1 like receptor signaling 0.764642 3.15E-05 
LI.M10.0 E2F1 targets (Q3) 0.758543 8.27E-05 
LI.M4.7 mitotic cell cycle 0.873012 0.000104 
LI.M4.2 PLK1 signaling events 0.78707 0.000105 
LI.M46 cell division stimulated CD4+ T cells 0.759223 0.000105 
LI.M7.3 T cell activation (II) 0.735883 0.000148 
LI.M200 antigen processing and presentation 0.94937 0.000414 
LI.M22.0 mismatch repair (I) 0.755343 0.00054 
LI.M4.8 cell division - E2F transcription network 0.789056 0.000608 
LI.M4.6 cell division in stimulated CD4 T cells 0.754704 0.000908 
LI.S11 Activated (LPS) dendritic cell surface signature 0.634705 0.000922 
LI.M119 enriched in activated dendritic cells (I) 0.820204 0.000939 
LI.M6 mitotic cell division 0.777184 0.001085 
LI.M8 E2F transcription factor network 0.811219 0.001153 
LI.M27.1 chemokine cluster (II) 0.700175 0.001249 
LI.M35.0 signaling in T cells (I) 0.741508 0.001711 
LI.M61.0 enriched in NK cells (II) 0.745482 0.001711 
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LI.M10.1 E2F1 targets (Q4) 0.777504 0.001711 
LI.M86.1 proinflammatory dendritic cell, myeloid cell response 0.686548 0.00184 
LI.M71 enriched in antigen presentation (I) 0.713108 0.002373 
LI.M157 enriched in NK cells (III) 0.822109 0.002373 
LI.M112.0 complement activation (I) 0.687387 0.00395 
LI.M15 Ran mediated mitosis 0.809206 0.004188 
LI.M7.0 enriched in T cells (I) 0.637452 0.004679 
LI.M95.0 enriched in antigen presentation (II) 0.696265 0.005101 
LI.M27.0 chemokine cluster (I) 0.649879 0.005872 
LI.M61.1 enriched in NK cells (KIR cluster) 0.952797 0.006633 
LI.M4.11 mitotic cell cycle in stimulated CD4 T cells 0.815779 0.007165 
LI.S5 DC surface signature 0.57073 0.009301 
LI.M49 transcription regulation in cell development 0.632027 0.010549 
LI.M4.10 cell cycle (II) 0.778996 0.017228 
LI.M35.1 signaling in T cells (II) 0.706575 0.017815 
LI.M76 DNA repair 0.693131 0.01828 
LI.M4.12 C-MYC transcriptional network 0.715134 0.018418 
LI.M5.0 regulation of antigen presentation and immune response 0.561311 0.01851 
LI.M7.1 T cell activation (I) 0.62737 0.018856 
LI.M4.9 mitotic cell cycle in stimulated CD4 T cells 0.749141 0.020322 
LI.M130 enriched in G-protein coupled receptors 0.794312 0.023019 
LI.M38 chemokines and receptors 0.706293 0.024886 
LI.M86.0 chemokines and inflammatory molecules in myeloid cells 0.568602 0.028193 
LI.M22.1 mismatch repair (II) 0.694001 0.028193 
LI.S10 Resting dendritic cell surface signature 0.550361 0.029807 
LI.M20 AP-1 transcription factor network 0.627408 0.033011 
LI.S3 Plasma cell surface signature 0.665601 0.033898 
LI.M73 enriched in monocytes (III) 0.64378 0.034145 
LI.M122 enriched for cell migration 0.720921 0.038456 
LI.M61.2 enriched in NK cells (receptor activation) 0.683523 0.042002 
LI.M95.1 enriched in antigen presentation (III) 0.594848 0.04938 
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Supplementary Table 6 Module enrichment in the genes sorted by weights in PC2 and PC6 of gene expression set of 
TB patients 
ID Title AUC adj.P.Val 
Enrichment in PC2 
LI.M7.0 enriched in T cells (I) 0.866599 1.18E-13 
LI.M7.1 T cell activation (I) 0.79087 9.02E-07 
LI.M171 heme biosynthesis (I) 0.961933 2.04E-06 
LI.M245 translation initiation factor 3 complex 0.8971 1.18E-05 
LI.M222 heme biosynthesis (II) 0.921906 1.70E-05 
LI.M7.2 enriched in NK cells (I) 0.772867 3.27E-05 
LI.S0 T cell surface signature 0.76349 0.000118 
LI.M7.3 T cell activation (II) 0.726406 0.000238 
LI.M61.2 enriched in NK cells (receptor activation) 0.901331 0.000654 
LI.M173 erythrocyte differentiation 0.806322 0.000997 
LI.M18 T cell differentiation via ITK and PKC 0.883852 0.001108 
LI.M61.0 enriched in NK cells (II) 0.836805 0.001281 
LI.M7.4 T cell activation (III) 0.872297 0.002163 
LI.M5.1 T cell activation and signaling 0.685075 0.003272 
LI.M14 T cell differentiation 0.836531 0.003272 
LI.M19 T cell differentiation (Th2) 0.728054 0.003627 
LI.M212 purine nucleotide biosynthesis 0.777762 0.008759 
LI.M238 respiratory electron transport chain (mitochondrion) 0.725251 0.010242 
LI.M126 double positive thymocytes 0.727144 0.016192 
LI.M117 cell adhesion (GO) 0.615905 0.020669 
LI.M234 transcription elongation, RNA polymerase II 0.698233 0.036267 
LI.M157 enriched in NK cells (III) 0.72714 0.036267 
LI.M167 enriched in cell cycle 0.685136 0.049391 
Enrichment in PC6 
LI.M14 T cell differentiation 0.891986 0.002228 
LI.M147 intracellular transport 0.804421 0.004291 
LI.M7.4 T cell activation (III) 0.740942 0.013856 
LI.M117 cell adhesion (GO) 0.724468 0.020221 
LI.M144 cell cycle, ATP binding 0.688033 0.030775 
LI.M18 T cell differentiation via ITK and PKC 0.750013 0.031709 
LI.M109 receptors, cell migration 0.729665 0.042816 
LI.M7.0 enriched in T cells (I) 0.609577 0.042816 
LI.M11.0 enriched in monocytes (II) 0.585239 0.046486 
LI.M230 cell cycle, mitotic phase 0.825074 0.047172 
 
 
